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Abstract 
 
The worldwide increase in antibiotic resistant bacteria has been identified as a 
major concern to the continued provision of healthcare. The lack of new 
antibiotic discoveries and the diminishing number effective against multi-drug 
resistant bacteria has increased efforts to identify new natural antimicrobials 
and to use synthetic biology to engineer artificial ones. Lantibiotics, a class of 
ribosomally synthesized antimicrobial peptides, with a broad spectrum of 
activity, have been identified as potential candidates to combat such bacteria. 
However no clinical lantibiotic products currently exist, owing to low product 
titres and lack of a suitable manufacturing process. 
 
Initial studies on the lantibiotic gallidermin have managed to increase product 
titre by modifying the producer strain, Stapylococcus gallinarum Tϋ3928, to 
synthesize the biologically inactive precursor, pregallidermin. This helps 
overcome product auto-toxicity and may be a generic route to enhancing the 
production of novel engineered lantibiotics.  
 
This thesis investigates the scalability of a pregallidermin production process to 
determine whether it could serve as a production platform for novel lantibiotics. 
Initially, fed-batch cultures were performed in 7.5 L stirred tank bioreactors to 
characterise the parameters necessary for achieving high cell density. These 
identified aeration, agitation and nutrient feed rates as important parameters to 
optimal product formation. The fed-batch culture was repeated at pilot scale (30 
L) under the same process conditions, yielding 0.7 g.L-1 of pregallidermin. 
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A scalable downstream process was also developed and evaluated. The overall 
process flowsheet comprised of pregallidermin capture on the hydrophobic resin 
Amberlite XAD-7, followed by cation exchange chromatography to purify the 
pregallidermin. This was then trypsinised to release the required gallidermin. 
The final purity of gallidermin was 70 % (w/w) with an overall process yield of 
13.5 %. Using this downstream process sequence 1.9 g (0.09 g.L-1) of 
pregallidermin was isolated from the 30 L fermentation. Confirmation of the 
identity of the purified pregallidermin and gallidermin was obtained by HPLC 
and mass spectrometry. 
 
Microscale methods were developed to optimise the downstream process and 
determine product physico-chemical properties with a view to informing process 
design. These determined that higher purity gallidermin recovery was possible 
with the optimisation of the XAD-7 adsorption/desorption. Optimal conditions for 
pregallidermin adsorption, resin wash and pregallidermin elution from resin 
were determined using the microscale methods. A redesign of the downstream 
process based on optimised pregallidermin capture increased overall recovery 
of mature gallidermin 3-fold to 0.3 g.L-1. 
 
In summary, this work has demonstrated a novel process for lantibiotic 
production and purification at pilot scale. The process is sufficiently generic that 
it could serve as a manufacturing platform for production of next generation 
engineered lantibiotics. It has also demonstrated the utility of microscale 
methods in optimising the production process. 
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1. Introduction  
1.1.1 Need for new antibiotics 
 
The emergence of antimicrobial resistance over the past few decades has been 
declared a global crisis. A report commissioned by the UK government predicts 
that over the intervening years until 2050, antibiotic resistance will have caused 
300 million premature deaths and caused $100 trillion in losses to the global 
economy (O’Neill, 2014). The overuse of antibiotics within global health systems 
has resulted in the emergence of these antibiotic resistant microorganisms 
(Wenzel et al., 2012; Okeke et al., 1999; Yoneyama & Katsumata, 2006). These 
cover a wide range of illnesses, from mutated strains of tuberculosis to a deadly 
version of Staphylococcus aureus  (methicillin resistant S.aureus or commonly 
abbreviated as MRSA) that has been responsible for many deaths in western 
hospitals. However, it has been noted that the use of antibiotics is not being 
scaled back; rather with the economic emergence of much of the developing 
world, consumption is expected to increase (Reardon, 2014). This would lead to 
an increase in bacterial mutations which would in turn leave more of the present 
selection of antibiotics ineffective. The resultant impact on human health could 
be devastating, thus it becomes imperative that modern medicines keep pace 
with the changing bacteria. 
 
There are also other very compelling reasons for the pursuit of new antibiotic 
treatments, chief among which is the economic impact of not being able to 
tackle infectious diseases. A well publicised example is MRSA, which has $8 
billion in annual treatment costs in the US alone (Smith & Hillman, 2008) and is 
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responsible for nearly 20,000 deaths every year (Joo & Otto, 2015). If a single 
infection can have such a massive economic impact, the cost of a whole range 
of untreatable infections for the global economy would be dire.  Research 
shows that large scale infection not only has enormous treatment cost, but also 
causes a negative impact on GDP growth rates (O'Neil, 2014; Gallup & Sachs, 
2001). The added burden on global healthcare systems would be enormous.  
 
Thus the search for alternative antibiotics becomes crucial in the fight against 
infectious disease and for the advancement of human socio-economic 
development. This is where the new field of synthetic biology offers a golden 
opportunity, as it allows for the generation of artificial antibiotics. The ability to 
selectively modify biological molecules and give them desirable properties has 
the potential to provide solutions to infectious disease (Field et al., 2015). The 
added benefit of being able to grow these artificial antibiotics within biological 
host organisms, specifically designed for purpose, potentially offers a cheap 
manufacturing pathway, that makes synthetic biology a vital tool in the battle 
against drug resistant infection (Heinmann & Panke, 2006). 
 
1.1.2 Synthetic Biology based solutions 
 
Synthetic biology promises to deliver a large variety of new products and find 
many applications in both existing and future technologies (Zhang et al., 2016; 
Ferber, 2004). The most high-profile application is within healthcare and 
biopharmaceuticals, with synthetic biology promising custom drugs that are 
capable of treating an ever increasing plethora of diseases. These include 
applications such as smart-drugs, capable of tracking down certain types of 
disease vectors and cancers based on chemical signal recognition ‘built-in’ to 
Haroon D.S. Khan  Chapter 1 
 
19 
 
the biological products (Andrianantoandro et al., 2006). They also find 
numerous potential applications as diagnostic devices, with researchers already 
having developed cells capable of changing colour and glowing.  
 
Another very high profile application is found in the production of Biofuels (Patel 
et al., 2017). Synthetic biology techniques would allow the ‘fabrication’ of host 
organisms developed specifically to feed on certain material and produce fuel 
for industry and transport (Keasling & Chou, 2008). Similarly there is huge 
potential for using synthetic biology to replace existing chemical production 
methods, specifically the production of optically pure enantiomers which remain 
a challenge for the purely chemical techniques (Lye et al., 2002). Most industrial 
applications for synthetic biology utilize the concept of biological organisms as a 
factory (Ferber, 2004) and will rely on the ability of researchers to have 
complete control of the biological systems applied to any process. 
 
There are numerous other possible applications, such as in food production and 
use in agriculture. Researchers have also looked at creating biological 
computers by utilizing whole sets of biological systems in smart feedback loops 
(Benner & Sismour, 2005; Ferber, 2004). Biological toxin detection systems for 
the environment have also been suggested. 
 
The list of potential synthetic biology applications is seemingly endless; 
however it is dependent on a complete understanding of biological systems. 
The possible rewards are great, as has been demonstrated by the use of 
synthetic biological techniques in some existing systems (Andrianantoandro et 
al., 2006). However, there must be adequate resources made available for 
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rigorous testing and research if effective and completely safe applications are to 
be found. Furthermore, the development of the tools for synthetic biology 
remain in the initial stages (Kuthning et al., 2016), with greater effort required to 
obtain a comprehensive understanding of biological processes before their 
modification to the necessary degree becomes cost effective and less 
challenging ( Benner and Sismour, 2005). 
 
1.2 Synthetic Biology for novel antibiotic 
development 
 
1.2.1 Principles of Synthetic Biology 
 
Synthetic biology is the name given to a multidisciplinary field that combines 
current knowledge in the fields of the biological sciences with techniques and 
methodologies developed for engineering (Garcia-Ojalvo et al., 2016; 
Andrianantoandro et al., 2006; Heinemann & Panke, 2006). It can be difficult to 
use a standard definition for synthetic biology, with the definition varying based 
on the expertise of the individuals involved. To the molecular biologist, the field 
deals with the modification (in some cases artificial fabrication) of cellular 
microorganisms. The chemist would say synthetic biology involves designing 
synthetic systems that replicate the behaviour of biological systems. The 
computer scientist calls it the use of artificial intelligence and simulations to 
better understand biological systems, while to the engineer it involves utilizing 
biological components to build new ‘devices’ in order to achieve desirable 
outcomes (Benner & Sismour, 2005). 
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Regardless of how it is defined, the overarching aim of synthetic biology is the 
ability to utilize living microorganisms as ‘factories’ for the production of novel 
products or compounds that are too difficult to manufacture by chemical 
synthesis (Garcia et al., 2016; Ferber, 2004). In many cases, chemical 
synthesis of compounds, such as proteins or antibiotic molecules requires a 
large number of expensive manufacturing stages, making them prohibitively 
expensive (Lye et al., 2003). Living cells on the other hand can utilize their 
complex cellular machinery in order to perform the synthesis within themselves, 
greatly reducing the overall stages required within the production process and 
effectively reducing the chemical synthesis stages to a limited number of steps 
(Khosla & Keasling, 2003). Thus there is great hope that the use of synthetic 
biology will allow the production of a large number of valuable compounds 
cheaply and in a much more environment-friendly manner. 
 
The economic and environmental benefits of synthetic biology make it 
advantageous in comparison to certain chemical processes. However it is not 
currently possible to replace these production methods with biological ones. 
This is due to the limited understanding of the all complexities associated with 
the living cell (Smanski et al., 2016). Engineering non-biological systems is 
made considerably easier based on a full understanding of all the component 
parts, mainly because the system components are man-made. In comparison 
biological systems are far more complex, with many cellular interactions yet to 
be deciphered (Benner & Sismour, 2005). 
 
Living cells will usually never be found individually, acting instead in concert 
with a mass of other cells, in either tissues or organs to respond to various 
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stimuli. This gives rise to great difficulty when attempting to utilize the wild-type 
of the cells for specific purposes; they usually will not grow very well under such 
circumstances (Andrianantoandro et al., 2006). This is where the biological 
knowledge gathered from fields such as genetic engineering, metabolic 
engineering and molecular biology can be utilized to modify and adapt the wild-
type cells to a synthetic environment. Process engineering techniques can then 
be utilized to scale-up the processes to full scale production facilities 
. 
The development of novel organisms by genetic manipulation and metabolic 
engineering procedures is work conducted at the microlitre or millilitre scales. In 
order to produce commercially useful quantities of product, it becomes vital that 
the same organisms can be cultured at large scale. This translation from the 
lab-bench to pilot scale to commercial scale culture remains a significant 
challenge (Chubukov et al., 2016). 
 
The development of viable scale up strategies involves detailed process 
characterisation in order to identify the key stress factors and process 
parameters influencing cell growth and product yield. However, it is notable that 
there is no common generally applicable scale-up strategy, with the most 
commonly prescribed scale-up techniques  suggesting that engineering 
characteristics such as impeller tip speed, superficial gas velocity, mixing time, 
volumetric mass transfer coefficient  or power per unit volume should remain 
constant (Junker, 2004).  
 
It has been suggested that using the power to volume ratio and the oxygen 
mass transfer coefficient, kLa, is the dominant scale up strategy in the industry 
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(Nuebauer & Junne, 2016). Studies conducted at UCL by Islam et al., (2007) 
and Gill et al., (2008) demonstrated that cultures grown at different scales under 
conditions of matched kLa values had a greater degree of reproducibility than 
those grown under a matched power to volume ratio (P/Vg). Thus, it is 
suggested that for highly aerobic fermentations, maintaining the kLa may be an 
effective strategy for bench-scale to pilot scale translation.  
    
Recent work by Voulgaris et al., (2016) utilized a scale-up strategy where the 
fermentation of a modified Escheria coli was translated from 1 L scale to 20 L 
scale by maintaining the dissolved oxygen levels (DOT). This strategy coupled 
with the maintenance of the substrate feed rate at the various scales may be 
relevant to the current research involving Staphylococcus 
gallinarum∆gdmP::aphIII. 
 
It is hoped that with greater understanding of the various component processes 
in biological systems, it will eventually become possible to develop totally new 
organisms from scratch, using an existing cell as a chassis for the efficient large 
scale production of novel, economically important compounds or creating 
completely new ‘artificial’ living organisms that have been designed to do the 
same job (Smanski et al., 2016; Garcia-Ojalvo et al., 2016; Heinemann & Panke 
2006).   
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Figure 0.1.1 The various component disciplines of Synthetic Biology an interdisciplinary field, 
adapted from (www.esf.org) 
 
1.2.2 Stapylococcus gallinarum Tϋ3928 and the 
modified Stapylococcus gallinarum∆gdmP::aphIII  
 
Staphylococcus gallinarum Tϋ3928 was first identified in the early 1980s 
(Devriese et al., 1983) with Gallidermin, the lantibiotic it produces, first 
described by Günther Jung’s group at the University of Tϋbingen in 1988 
(Kellner et al., 1988). In nature the organism can be found living on chicken 
crests. The species displays novobiocin resistance and a wide range of positive 
carbohydrate reactions. 
 
Early research with the organism to understand the lantibiotic product 
machinery involved site-directed mutagenesis on the lantibiotic structural genes 
allowing the creation of modified variants of Gallidermin, identifying the 
organism as a good candidate for target oriented peptide engineering 
(Ottenwälder et al., 1995). It was determined that the mode of action of 
lantibiotic compounds resulted in auto-toxicity to the producer strains (Sahl et 
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al., 1998), meaning that lantibiotic yield from fermentations involving 
S.gallinarum Tϋ3928 are low (Fiedler et al., 1999; Hille et al., 2001). 
 
In order to overcome this limit on lantibiotic yield, Valsesia et al., (2007) created 
a mutant strain of S.gallinarum Tϋ3928 called Staphylococcus 
gallinarum∆gdmP::aphIII (Stapylococcus gallinarum Δp), that lacked an 
extracellular protease (referred to as GdmP) responsible for activating the 
inactive lantibiotic precursor peptide into the active lantibiotic. The mutant was 
an insertional-deletion, with genes for Kanamycin resistance inserted in place of 
the deleted GdmP expressing genes. Later work by Medaglia (2009) with 
S.gallinarum Δp showed that the inactive gallidermin precursor, pregallidermin 
(PGDM) produced was almost 30 times less toxic to S.gallinarum Tϋ3928 than 
activated gallidermin (GDM).  
 
The well characterised genetic machinery of S.gallinarum Tϋ3928 and the 
relative ease with which it could be modified in order to produce novel GDM and 
PGDM variants was the reason behind its choosing as the test bed organism in 
this research. Additionally, it enabled the testing of lantibiotic precursor peptide 
production at scale.    
 
1.2.3 Creation of ‘chassis’ organisms 
 
The ability to use synthetic biology for the modification of organisms in order to 
achieve desired compounds is of huge potential benefit to the biotech industry. 
However, it may not be efficient to utilise large amounts of resource on 
engineering countless different organisms, an approach which may also be 
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limited by the complexity of existing biological systems (Heinemann & Panke, 
2006). 
 
A solution to this problem may be to use synthetic biology approaches to 
express the targeted genes in selected ‘chasis’ organisms that have been well 
studied and characterised, in order to improve production of the desired 
compound and obtain higher yields (Patel et al., 2017). In the case of PGDM 
production, Valsesia (2009) demonstrated this to be possible by transferring the 
pregallidermin gene cluster to a Staphylococcus aureus mutant, resulting in a 
1.3 fold higher yield of PGDM than in S.gallinarum Δp under equivalent 
conditions. 
 
Chassis organisms could be created by removing portions of their genome in 
order to reduce their complexity (Andrianantoandro et al., 2006). Recently, the 
first such organism was constructed using this methodology that has a genome 
smaller than that of the smallest known natural bacterium (Hutchinson et al., 
2016). 
    
 1.2.4 Advantages and limitations of developing 
novel organisms 
 
The creation of novel organisms specifically to serve as factories for biological 
compounds could provide several advantages over native producer strains. 
Firstly, the novel organisms could be created from existing strains that are very 
well researched and have been used in industry for a long time, allowing 
production to be optimised efficiently by using rational or semi-rational host 
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engineering strategies. Secondly, organisms could be engineered to be more 
genetically stable, consistently producing the desired compounds to the 
required standards. Finally, the creation of novel chassis organisms could allow 
the production of products from organisms that are currently not possible or 
difficult to culture e.g. rare terrestrial or marine organisms (Zhang et al., 2016). 
 
However, it is unlikely that an organism can be created which is able to express 
metabolites from all available biosynthetic pathways, especially considering that 
one of the key strategies to create such organisms is to minimise its genome 
(Juhas, 2016). In comparison to native producer strains, synthetic organisms 
are unlikely to possess all the cellular factors necessary for production of the 
desired compound, meaning they will have to be introduced, which could result 
in incompatible regulatory systems. Additionally, the creation of organisms by 
minimizing their genome may not yield organisms that operate with precision 
and reliability (Andrianantoandro et al., 2006). Neither is it necessary that an 
organism with a minimum genome would allow production to be optimised 
efficiently. 
 
1.2.5 Application of Synthetic Biology to Natural 
Product Synthesis 
 
Products produced by living organisms tend to be more environmentally friendly 
or ‘natural’ (Zhang et al., 2016). This is mainly due to the removal of large 
numbers of processing steps required in chemical synthesis of the same 
product  (Ross et al., 2010), often using corrosive and hazardous chemical 
substances. The complex mining and refining processes providing raw 
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materials for chemical synthesis serve to increase the cost and environmental 
footprint of many substances that are vital to the global economy. In essence 
this makes them more artificial and less ‘natural’ than those produced by 
biological systems. 
 
The scope of synthetic biology to produce large numbers of natural products is 
vast (Smanski et al., 2016; Baker et al., 2006). It is hoped that a short to 
medium-term application can be the replacement of complex chemical 
manufacturing processes by highly optimized biological ones that are less 
resource intensive. The potential exists for highly modified living cells to 
produce numerous substances for all manner of applications such as 
pharmaceuticals, fuel, diagnostics and purification technologies (Ferber, 2004).  
 
An added advantage of synthetic biology is the fact that the production systems 
are living cells, part of biological systems; hence the products should be safer 
for use in living organisms than comparable products based on chemical 
synthesis, indeed a few microbial strains of interest are commensal organisms 
(Joo & Otto, 2015). However, this adds another layer of complexity to 
developing biological technologies as keeping the modified organisms healthy 
and in ‘production mode’ requires stringent monitoring of the cellular 
environments (Andrianantoandro et al., 2006). Development of more robust 
variants of the host organisms, capable of surviving harsher environmental 
conditions will aid in the process of bringing more synthetic biological processes 
to market (Baker et al., 2006). 
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It is of note that although much of the research described will find future 
applications, synthetic biology is already in use to produce many valuable 
compounds. Much of global penicillin production is based on engineered 
organisms, as is most of the biosynthetic ‘human’ insulin. These technologies 
made the specific substances much cheaper and production more easily 
scalable than conventional production methods; as an example, prior to 
producing human insulin biosynthetically, it was taken from pigs, a method ill 
suited to provide sustained long term global supplies. 
 
1.3 Lantibiotics 
 
1.3.1 Basic Structure 
 
Lantibiotics are a class of antibiotic peptides named after the lanthionine 
residues that they contain. The lanthionine residues in these compounds, which 
are formed very rarely in nature, form ring structures through thioether bonding 
(Van Heel et al., 2013). Lantibiotics usually also contain a methyl-substituted 
lanthionine derivative, (2S, 3S, 6R)-3-methyllanthione (figure.1.2) and typically 
(though not always) will contain the unsaturated amino acids 2, 3 
Didehydroalanine (Dha) and (Z)-2,3-didehydrobutyrine (Dhb) (Chatterjee et al., 
2005; Jung & Sahl, 1991; Kuipers et al., 1996). 
 
 
 
 
 
 
 
A                                                 B 
 
 
Figure 1.2 Structure of (A) Lanthionine and (B) Methyllanthionine residues 
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The molecules will also contain other structures that are introduced due to post-
translational modification (Montalbán-López et al., 2015); D-alanine, 2-
oxybutyrate, lactate and pyruvate are just a few of those found (Kuipers et al., 
1996) . It is of note that almost one-third of all amino acid residues present 
within the original peptide molecules undergo post-translational modifications 
during biosynthesis to form the final lantibiotic. 
 
Lantibiotic peptides are very small (<5 kDa) (de Freire Bastos et al., 2014) and 
about 5 nm long (Kuipers et al., 1996). The thioether rings in lantibiotics are 
believed to be responsible for their antimicrobial properties. It is also believed 
that the same thioether rings allow for recognition of the peptides during 
biosynthesis, allowing for appropriate immune responses and the prevention of 
proteolytic degradation (Bellancini, 2015; Chatterjee et al., 2005).  
 
1.3.2 Properties of Lantibiotics 
 
There are a number of basic properties that are common to Lantibiotics. These 
properties are responsible for the antimicrobial and antibiotic function of the 
peptides. Indeed alteration in them will often result in the loss of activity (Zhou 
et al., 2015; Cotter et al., 2005; Rollema et al., 1995). 
 
Thiol Bridge Formation: All lantibiotic molecules will form thiol and thioether 
ring structures due to the presence of lanthionine and methylanthionine 
residues (Tabor, 2011). The ring structures represent the unifying motif within 
all lantibiotic molecules and are important for microbial activity as well as 
structural stability (Nagao et al., 2006). 
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Presence of Dha/Dhb residues: Most lantibiotics possess either of the 
unsaturated and dehydrated amino acid residues Dha or Dhb (Tabor, 2011; 
Cotter et al., 2005). In the molecules that do possess these residues, it has 
been found that they are essential for activity e.g. in the Type A (I) lantibiotic 
Nisin, it has been found that the modification of the Dha residue at position 5 
leads to a loss of antimicrobial activity (Chan et al., 1996). 
 
 Presence of a Hinge region: All lantibiotic molecules contain a hinge region; 
any region flexible or rigid that connects the thioether ring domain to the other 
domains of the lantibiotic (Chatterjee et al., 2005). It has been shown that 
changes to the hinge region can have negative effects for the antimicrobial 
activity of the peptides (Zhou et al., 2015). 
 
 Presence of a Charge: All type-A lantibiotics are cationic (Nagao et al., 2006). 
Type-B lantibiotics have not been found to posses any charge. In type-A 
lantibiotics the charge influences solubility of the peptides and is believed to 
contribute to their pore forming abilities and bactericidal activity (Van Staden, 
2015; Cotter et al., 2005). 
 
Binding to Lipid II in microbes: Most lantibiotics have been found to bind to 
lipid II in the microbial cell wall (Islam et al., 2012; Cotter et al., 2005). Lipid II is 
an essential intermediate in cell wall biosynthesis, the lantibiotic Nisin uses Lipid 
II as a docking molecule and subsequently forms pores in the cellular 
membrane (Nagao et al., 2006).  
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1.3.3 Structural grouping of Lantibiotics 
 
Over 100 different Lantibiotics are known, all with varying structures, size and 
mode of action (Ongey & Neubauer, 2016). Originally these were classified as 
either Type A or Type B dependant on the topology of their ring structures and 
biological activities (Jung & Sahl, 1991), though new classification schemes 
have been proposed based on an analysis of their biosynthetic pathways, the 
original scheme is still in general use (Suárez et al., 2013;Tabor, 2011). The 
classification of the different types is described in the following sections. 
 
1.3.4 Type A Lantibiotics 
 
Type-A lantibiotics form elongated screw shaped structures and are 
amphipathic when in solution (Al-Mahrous & Upton, 2011). They range in length 
from 20 to 34 amino acid residues and have a net positive charge. Their 
bacterial action was initially thought to be based on pore formation to cause 
permeabilization of the cell membranes; however recent advances have shown 
that a number of lantibiotics interfere with peptidoglycan biosynthesis by binding 
to Lipid II, this behaviour is not limited to Type-A only (Kuipers et al.,1996). 
  
Type-A Lantibiotics can be further divided into Type A (I) and Type A (II) based 
on the number of post-translational enzymes involved in the creation of their 
Lanthionine residues, and a third type, two-component lantibiotics in which two 
structurally different peptides act synergistically to kill the target organism (Islam 
et al., 2012). Type A (I) lantibiotics have their lanthionine residues formed by the 
action of two distinct enzymes, named LanB and LanC. Type A (II) lantibiotics 
have theirs formed by a single enzyme, LanM (Gomes et al., 2017).  
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Type A lantibiotics are generally flexible molecules with a hinge region between 
their C and N-terminal rings, however there are some molecules within Type A 
(I) that show some inflexibility in water (Pep5) (Kuipers et al.,1996). The 
prototype lantibiotic for Type A (I) is Nisin (Figure 1.3A), one of the most 
extensively studied Lantibiotics, due to its use in food preservation. The 
prototype lantibiotic within Type A (II) is Lacticin 481 (fig 1.3B). 
 
1.3.5 Gallidermin 
 
Gallidermin is a natural variant of Epidermin, produced by Staphylococcus 
gallinarum Tϋ3928. The only difference between the peptides is the interchange 
of a Leucine residue in Gallidermin for an Isoleucine residue in Epidermin 
(Kellner et al., 1988).  
 
Gallidermin has characteristic lanthionine rings between residues 3 and 7, plus 
a hinge region from residues 12 to 15. The average length of the peptide is 30 å 
and the average diameter ranges between 8 to 10 å, giving the peptide a screw 
shape. It is an amphiphillic, screw shaped peptide with a lipophillic C-terminus 
and a hydrophilic N-terminus (Kuipers et al., 1996).   
 
Gallidermin possesses the same putative lipid II binding motif as nisin; however, 
it is considerably shorter (22 amino acids in gallidermin, compared to 34 in 
nisin). It has been demonstrated that pore formation in the bacterial cell 
membrane by gallidermin depends on membrane thickness, and that it is the 
interaction with lipids I and II rather than pore formation that contributes to its 
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bactericidal activity. The superior activity of gallidermin over nisin in a cell wall 
biosynthesis assay may explain its high killing potency (Bonelli et al., 2006).  
 
It has been demonstrated that nisin and gallidermin not only bind to lipid II but 
also to the lipid intermediates lipid III (undecaprenol-pyrophosphate-N- 
acetylglucosamine) and lipid IV (undecaprenol-pyrophosphate- N-
acetylglucosamine-N-acetyl-mannosamine) of the wall teichoic acid (WTA) 
biosynthesis pathway. The specific interaction with the WTA precursors 
promoted pore formation in artificial lipid bilayers (Saising et al., 2012). 
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Figure 1.3 The structure of (A) Nisin (amino acid residues and thioether rings), (B) Lacticin 481 
and (C) Gallidermin, adapted from (Willey and Donk, 2007) 
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1.3.6 Type B Lantibiotics 
 
Type B lantibiotics are globular in shape and from 19-20 amino acid residues 
long.  They possess no net charge or a negative charge (Islam et al., 2012), 
unlike Type A, but they are flexible molecules with a hinge region.  Originally, 
their mode of activity was thought to be the inhibition of specific enzymes 
involved in cell wall biosynthesis however, they were later shown to also interact 
with lipid II (Brötz et al., 1998).  The representative lantibiotic for Type B is 
Mersacidin, illustrated in figure 1.4 A. 
 
Actagardine is a Type B lantibiotic with a rigid and compact globular shape. The 
molecule has no net charge and contains three short β-sheets at the C-terminal 
end which provide stability (Zimmermann & Jung, 1997). The N-terminal ring is 
between residues 1-6 and the intertwined C-terminal rings are located between 
residues 7-12, 9-17 and 14-1910. 
 
However, Actagardine (figure 1.4B) has a single negative charge in solution at 
neutral pH. It is also notable for containing an oxidized C-terminal melan 
residue (Kuipers et al., 1996). 
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Figure 1.4 The structure of type B lantibiotics (A) Mersacidin and (B) Actagardine (amino acids 
and thioether ring structures), adapted from (Willey and Donk, 2007). 
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1.3.7 Mode of Action 
 
Lantibiotics have been shown to display a broad spectrum of antimicrobial 
activity owing to the structural diversity of the different types (Willey & Donk, 
2007). Type A lantibiotics, which are positively charged, flexible elongated 
structures, have been shown to possess a dual mode of antibacterial action. 
They are capable of disrupting the bacterial cytoplasmic membranes by forming 
non-targeted pores  (Zhou et al., 2015) at micromolar concentrations; 
additionally when available in nanomolar concentrations they are also capable 
of blocking bacterial cell wall synthesis by binding to lipid II in the cell wall, 
preventing its incorporation into the peptidoglycan layer (Figure 1.5B) (Hechard 
et al., 2002). The specific targeting of lipid II is promising from the perspective of 
developing a clinical product, as lipid II is only involved in bacterial cell 
synthesis, meaning lantibiotic compounds would show low cytotoxicity to animal 
cells. Additionally the bacterial cell walls usually possess a small amount of lipid 
II, which has a high turnover rate during peptidoglycan biosynthesis. 
Consequently lipid II represents an ideal target for antibiotic action (Breukink & 
Kruijff, 2006). 
 
It is notable that when the lantibiotic nisin bound to lipid II in the bacterial cell 
cytoplasmic membrane, the pores formed had larger diameters and increased 
stability in comparison to pores formed when lipid II was absent (Wiedemann et 
al., 2004). However the lantibiotic gallidermin, a Type A lantibiotic that also 
possesses the dual antibacterial mode of action, is considerably shorter than 
Nisin and thus the non-targeted pore formation depends on the membrane 
composition (Wenzel et al., 2012; Bonelli et al., 2006). However, gallidermin 
was still found to be very effective at killing bacterial cells based on the halt to 
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bacterial cell wall biosynthesis (Brotz et al., 1998 b).The type B lantibiotics kill 
bacterial cells through their interaction with lipid II, which inhibits bacterial cell 
wall synthesis, however unlike type A, type B lantibiotics do not form pores in 
the cytoplasmic membrane (Brotz et al., 1998). Thus, type A lantibiotics kill 
bacterial cells quicker than type B (Guder et al., 2000). 
  
1.3.8 Regulation of Biosynthesis: Quorum Sensing 
 
All bacterial strains that produce lantibiotics have regulatory mechanisms for 
their production. Most of these mechanisms are based on quorum-sensing 
systems, which enable the bacteria to act in a coordinated manner (Ali et al., 
2017; Kleerbezem, 2004). The quorum-sensing mechanisms involve the 
production of peptide pheromones that accumulate during bacterial growth. 
Once a specific threshold concentration of peptides is reached, they trigger a 
signal transduction pathway that leads to target gene expression. The signal 
transduction pathway is based on two-component regulatory systems (Willey & 
van der Donk, 2007), which are mediated by the interaction of the peptide 
pheromone with its cognate receptor, a membrane-bound histidine kinase 
sensor protein (LanK for lantibiotics), which results in the phosphorylation of an 
aspartic acid residue of a response regulator (LanR in lantibiotics). This 
activates the transcription of target genes (Valsesia, 2008).  
 
An autoregulation mechanism was demonstrated for nisin production by L. 
lactis, in which the lantibiotic has been shown to act as a peptide pheromone 
(Kuipers et al., 1995). 
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1.3.9 Lantibiotic auto-toxicity 
 
Lantibiotics are a class of peptide antibiotics synthesized by a number of gram-
positive bacteria, which show a broad spectrum of bactericidal activity against 
other gram-positive bactreia (Götz et al., 2014; Willey & van der Donk, 2007). 
As such, any bacterial strain that produces antimicrobial compounds that are 
active against closely related strains must also protect itself against its product 
compounds (Chatterjee et al., 2005).  
 
In the case of lantibiotics, this immunity can be conferred by a specific immunity 
protein (LanI) and by specialized ATP binding cassette (ABC) transporter 
proteins, which are encoded by the LanFEG genes e.g. for the lantibiotic Pep5; 
a single PepI peptide appears to bind at the membrane-cell wall interface, 
thereby masking the Pep5 target molecule. In comparison NisI, which is 
anchored to the outer face of the membrane by a lipoprotein signal sequence, 
intercepts the nisin to reduce its concentration in the immediate local 
environment. Although in many cases, LanI cannot confer full resistance and it 
functions cooperatively with the ABC transporters (Willey & van der Donk, 2007; 
Chatterjee et al., 2005). 
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Figure 1.5  The modes of action of Type A and Type B lantibiotics with A) a type A lantibiotic 
(Nisin depicted by the black peptide chain) forming wedge like pores in the cell phospholipid 
layer at micromolar concentrations, B) a type A lantibiotic (depicted by Nisin) using lipid II as a 
docking molecule to form target mediated pores at nanomolar concentrations and C) a type B 
lantibiotic ( Mersacidin) blocking cell wall synthesis by halting the incorporation of lipid II into 
peptidoglycan (Type A lantibiotics also possess this attribute). Adapted from (Hechard et al., 
2002)  
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1.3.10 Therapeutic potential 
 
The only lantibiotic that currently has wide commercial application is Nisin, with 
its application in the food industry to prevent spoilage (Cotter and Ross, 2005) 
although it has not been used therapeutically (Field et al., 2015). However, 
lantibiotics have been identified as having the potential to treat variety infections 
caused by Clostridium difficile, Staphylococci, Enterococci, and Streptococci. 
(van Heel et al., 2011; Hancock & Sahl, 2006). 
 
At the present time though, the most important application for lantibiotics would 
be there potential in the treatment of antibiotic resistant bacteria e.g. the type B 
lantibiotic Mersacidin has shown promise in the treatment of MRSA nasal 
colonization (Kruszewska et al., 2004). Nisin was found to be active against 
vancomycin resistant enterococci, multidrug resistant strains of Staphylococcus 
aureus and Streptococcus  pneumoniae (Severina et al., 1998). Additionally 
nisin has shown potential in the treatment of C.difficile, by preventing the 
germination of clostridial spores, displaying killing kinetics similar to vancomycin 
when tested in vitro (Kerr et al., 1997). Other potential therapeutic uses for 
lantibiotics could be in the treatment of cancer, in combating viruses, treatment 
of inflammation and pain relief (Gomes et al., 2017). 
 
 
There has also been some research focused on the topical application of 
lantibiotics to treat skin infections. Gallidermin has been proposed as a 
candidate for the treatment of eczema, cellulitis, impetigo and acne (Valsesia, 
2008); with Lacticin 3147 showing similar scope (Allgaier et al., 1991). 
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Lantibiotics, specifically Nisin, are also being considered for the potential 
treatment of H.pylori (Al-Mahrous & Upton, 2011; Jerris, 1995), due to their 
stability under acidic conditions (Rollema et al., 1995; Delves-Broughton et al., 
1996). Mutacin 1140 has been investigated for the treatment of dental caries 
caused by Streptococcus mutans (Hillman, 2002); with duramycin in trials to 
potentially clear mucus secretion associated with cystic fibrosis and other 
airway diseases (Willey et al., 2007). 
 
The large number of structurally diverse lantibiotics indicates a wide spectrum 
of antibacterial activity; however with the continued advances in synthetic 
biology, it has become possible to alter existing lantibiotics to produce artificial 
variants by combining components of different peptides to produce novel hybrid 
antibiotics (van Heel et al., 2013), some of which display higher activity against 
targeted bacteria than the original peptides (Arnusch et al., 2008). 
 
1.4 Lantibiotic Synthesis 
 
1.4.1 Biosynthesis of Lantibiotics 
 
The lantibiotics are a class of ribosomally synthesised peptides that are 
produced by a complex process that includes formation of a precursor, post-
translational modification followed by N-terminal leader sequence cleavage and 
secretion (Gomes et al., 2017; van Kraaij et al., 1999). 
 
The highly modified nature of the lantibiotics means that the percentage of 
residues undergoing modification ranges from 24% to 58% (Valsesia, 2008). 
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These post-translational modifications are enzymatically initiated; with the 
majority involving Serine (Ser) and Threonine (Thr), the hydroxyl amino acids, 
and Cysteine (Cys), the sulfhydryl. 
 
Initially, the Ser and Thr residues are dehydrated to form Dha and Dhb, which 
are then subjected to a nucelophilic attack by the thiol group of a Cys residue to 
form the characteristic thioether lanthionine (Lan) and 3-methyllanthionine 
(MeLan) bridges as shown in figure 1.6 (Valsesia, 2008). However it is notable 
that there are usually more dehydrated amino acids than Cys residues, which 
results in lantibiotics usually containing unmodified dehydrated amino acid 
residues.   
 
The lantibiotics gallidermin and epidermin have been shown to undergo an 
additional modification, with enzymatic cyclization occurring at the C-terminus, 
the terminal C residue is first oxidized and then decarboxylated before the 
nucleophilic assault on the dehydrated residues, forming 2-aminovinyl-D-
cysteine (Kupke et al., 1995).  
 
These post-translationally modified residues give rise to certain structural 
properties of lantibiotics, such as enhanced temperature stability (Hurst, 1991), 
stability under oxidizing conditions (Sahl et al., 1995), increased acid tolerance 
and resistance to proteolytic degradation.   
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Figure 1.6 The mechanism of lanthionine (Lan) and methyllantionine (MeLan) formation in 
lantibiotics with A) the enzymatic dehydration of Ser and Thr, to Dha and Dhb, followed by B) 
nucleophillic attack from the thiol group on the Cys residue to form the thioether bridge,  
adapted from (Valsesia, 2008).  
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1.4.2 Precursor Production 
 
Prior to achieving the final active form, lantibiotics are produced as biologically 
inactive precursor peptides (Gomes et al., 2017; van der Meer et al., 1993). 
These carry a ‘leader peptide’ an N-terminal extension, and a C-terminal 
propeptide moiety that undergoes post-translation modifications (Weil et al., 
1990).The C-terminal moiety is activated after the post-translational 
modifications by removal of the leader peptide via proteolytic cleavage. 
 
The leader peptide is thought to stabilise the precursor peptide during 
translation, ensures it stays biologically inactive, preserves its specific 
conformation during processing and assists with the precursor translocation by 
specific transport systems (Ongey & Neubauer, 2016; van Heel et al., 2013; de 
Vuyst & Vandamme, 1994). 
 
The biological inactivity of the precursor lantibiotics, as opposed to the auto-
toxicity and self-regulation of the activated lantibiotics, has been identified as a 
potential solution to achieving high product titres in fermentation. Indeed, work 
by (Valsesia et al., 2007) utilises synthetic biology to remove the gene encoding 
for the extracellular protease that activates the lantibiotic gallidermin by 
proteolytic cleavage of the leader peptide. The result was a fully post-
translationally modified lantibiotic precursor. 
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1.5 Production of Lantibiotics 
1.5.1 Upstream Processes 
 
Nisin was the first and so far continues to be the sole lantibiotic used 
commercially, mainly used in the food industry to prevent spoilage, it has been 
known since the early 20th century (Field et al., 2015; Jack et al., 1995). Nisin, 
accorded GRAS (generally recognised as safe) status by the American FDA 
(Food and Drug Administration), has been produced industrially since 1953 
(Parente & Ricciardi, 1999). However, there are no lantibiotics produced 
commercially for therapeutic use in humans (Ongey & Neubauer, 2016). 
 
The current industrial production method for nisin involves treating pasteurized 
milk, which has an added yeast extract, with a protease. This is then used as a 
substrate in batch fermentations at a controlled temperature and pH. The broth 
is then subjected to concentration step and a spray drying step to obtain the 
nisin. The resulting powder is standardized with common salt (NaCl) to 1x106 IU 
g-1. Any further purification is expensive and hence not commercially viable for 
the food industry (Parente & Ricciardi, 1999). 
 
There are no comparable large scale commercial production processes for 
other lantibiotics. However, due to their potential for treatment of human 
ailments, since 1988 many lab scale studies have been conducted in order to 
develop high yielding processes for these molecules (Chatterjee et al., 2005; 
Kempf et al., 1999). In the case of gallidermin, a lantibiotic of interest to this 
project, most bench scale studies have been conducted using a batch or fed-
batch fermentation (Valsesia et al., 2007; Medaglia, 2009; Valsesia, 2008), with 
a large number of studies focussing on the effect of the feeding regime  . 
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In the case of Gallidermin, early literature points towards the optimal medium 
containing yeast extract with an added calcium source, the role of the calcium 
however remains unclear (Kempf et al., 1999). However, later in later work by 
Medaglia (2009), maltose appears to be the most favourable carbon source, it is 
also the feed material used within most fed-batch productions for Gallidermin.  
 
In studies for the production of other lantibiotics, simple batch fermentations and 
some continuous culture experimentation has been utilized (Arias et al., 2013; 
Kempf et al., 1999), however self-regulation by the host cells (Kleerebezem, 
2004) means that the yield of the desired lantibiotic is usually limited to a few 
hundred milligram per litre of fermentation culture. In effect product-host 
regulation presents the greatest difficulty in increasing yields from all production 
processes (Valsesia et al., 2007). 
 
In order to get around the problem of cellular self-regulation, (Medaglia, 2009), 
researched modification of a host organism, S.gallinarum Tϋ3928, for the 
production of the inactive precursor, rather than the activated Gallidermin.  The 
modified host, renamed S.gallinarum ΔP, was found to produce inactivated 
pregallidermin (PGDM) with yields of greater than 1 g.L-1 in optimised media. 
The conditions utilized for the fermentations were similar to previous fed-batch 
cultures by Kempf et al., (1999) that were pulsed with a maltose feed; however 
an additional step in order to obtain the active gallidermin from the precursor 
becomes necessary. A trypsinization step is sufficient for separation of the 
precursor leader peptide from the active molecule. 
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It appears logical to use the two step approach in order to circumvent the 
difficulties associated with product inhibition in the wild type organisms. It is 
plausible that with further work on cellular product expression and the eventual 
development of a defined medium (Medaglia, 2009), highly optimized 
production processes would become possible, resulting in the greater product 
titres required to make large scale manufacture economically viable.  There is 
thus great scope for research into the various engineering parameters in pursuit 
of producing optimal process conditions. 
 
1.5.2 Downstream Process Sequences 
 
One of the main reasons for the lack of commercially produced lantibiotics, with 
the exception of Nisin, is the difficulty in obtaining sufficient quantities of active 
product (Medaglia, 2009). The primary problem has been low product titres, 
which when scaled up, would result in volumetrically large processes, 
increasing plant capital and operating costs. There remains a lack of high yield 
and well characterised processes for the production of lantibiotics (Ongey & 
Neubauer, 2016).  
 
Laboratory scale research on lantibiotics shows preference for downstream 
purification processes involving multiple chromatography steps, in some cases 
preceded by a precipitation step as a primary extraction method. (Section 1.5.3) 
 
The downstream process sequence shown in figure 1.7 A represents the most 
common scheme found in literature, although there has been research into 
modifications to the process such as a single step immuno-affinity separation 
procedure, pH dependant host absorption or a sequence involving butanol 
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extraction. These methodologies nonetheless suffer from the same problems of 
scale as mentioned previously due to the limited productivity achievable of the 
lantibiotic molecule in its active form (Field et al., 2015). 
 
However, part of this project will attempt the development of an optimized 
downstream process, for the inactive gallidermin precursor pregallidermin , due 
to its’ ability to obtain much higher lantibiotic titres in culture (Valsesia et al., 
2007). The ability to achieve high titres from an optimized pregallidermin 
production process should allow for a significant reduction in plant investment 
based on smaller process volumes. Fed-batch methods having been 
established as the preferred choice for organism growth (Medaglia, 2009; 
Valsesia, 2008; Valsesia et al., 2007; Kempf et al., 1999; Kempf et al., 1999b). 
High titre strains potentially allow for higher productivity per litre and allow for 
smaller equipment sizing, regardless of the downstream processing path 
chosen. 
 
The possible downstream processing sequences for Gallidermin production 
using pregallidermin are illustrated in figure 1.7 B (Medaglia, 2009). The choice 
is heavily dependent on the economics of each process sequence. The optimal 
sequence would be the least cost intensive, yet allow for high productivity, 
purification and product yield. Thus the choice becomes dependant on the 
reaction of the downstream process to the physical properties of the product.   
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Figure 1.7 Downstream processing sequences with A) common production process for 
lantibiotics in literature and B) production using the pregallidermin precursor molecule. Adapted 
from (Medaglia, 2009) 
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1.5.3 Isolation and purification 
 
The most common method utilized in order to isolate Lantibiotic molecules in 
recent literature is resin based absorption chromatography, usually with 
Amberlite resins (Arias et al., 2013; Valsesia et al., 2007; Fiedler et al., 1988). 
Further downstream purification to achieve the final product is then performed 
using ion-exchange chromatography, utilizing the cationic properties of Type A1 
lantibiotics (Barbour et al., 2013; Furmanek et al., 1999; Kellner et al., 1988).  
 
Alternatively, the isolation of Lantibiotics and bacteriocins (protein products of 
bacteria) has also been performed previously using ammonium sulphate 
precipitation from solution (Parente & Ricciardi, 1999). The method appears to 
have been popular as a generic purification strategy for bacteriocins and is not 
specific to lantibiotics; however it has also been used for the isolation of Nisin 
and Staphylococcin T (a natural variant of Gallidermin) (Furmanek et al., 1999). 
However, further downstream purification after using the precipitation method 
still relies on two chromatographic separation stages; hence logically the 
preferred method would rely on fewer purification stages and therefore reduce 
the expense of the overall process. 
  
There are also reports in literature of a primary separation process utilizing 
butanol extraction (liquid-liquid extraction) (Piva & Headon, 1994); however as 
non-polar solvents seem to denature and inactivate the product, there is a 
greater loss of activity. It is worth noting that there is further scope for research 
into the use of liquid-liquid extraction as an economically viable purification 
technique by utilising developments such as micelles (Lye, 1994).  
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Lantibiotics have also been shown to adsorb to the host cells at high pH, 
opening the possibility of utilizing host adsorption as a means of primary 
separation (Yang et al., 1992). Thus a pH dependant extraction is a possible 
exploration avenue; however the method has been tested with wild-type 
lantibiotics and none of the synthetic strains, hence further research is required 
into the behaviour of the precursor molecules. 
 
Another development in lantibiotic separation technology is the use of immuno-
affinity chromatography as a single stage purification process to produce the 
purified final product direct from the fermentation broth. The method reportedly 
achieves greater yields in comparison to multi-stage extraction and purification 
processes (Suárez et al., 1997). However, as research has so far focussed on 
the wild type, ‘active’ molecule, it is intuitive that overall process yield is still low 
due to product toxicity. The method also requires research time and resource 
allocation to determining suitable antibodies for the chromatography. While it 
remains an expensive method to perform small scale purification attributable to 
the cost of antibodies, it is possible that large scale production facilities based 
on single-step extraction and purification may become viable. 
 
The most common final purification technique is an ion-exchange 
chromatography (AlKhatib et al., 2014; Kellner et al., 1988; Ottenwälder et al., 
1995), based on the cationic nature of type A1 lantibiotics, however reverse-
phase HPLC at preparative scale has also been utilized; primarily using silica 
based C-18 columns. The reverse-phase HPLC has been shown to achieve 
purities of greater than 95% (Parente & Ricciardi, 1999). 
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It is interesting to note that although there are numerous methods in use in lab 
and research scale, they may not necessarily be economically viable at 
production scale. A need exists for much more research into the downstream 
processing methodologies best suited and optimized for any synthetic biology 
product, enabling Lantibiotic availability at quantities necessary for clinical use. 
 
1.5.4 Identification & Analytics 
 
There is a general consensus use of reversed-phase HPLC as the preferred 
method of peptide purification in the literature (Ross et al., 2010; van Kraaij et 
al., 1999; Kuipers et al., 1996). It provides good resolution of the sample without 
needing large amounts of it. The analytical HPLC methods also utilize silica 
based columns, most notably C18; however other columns have also been 
utilized (Valsesia et al., 2007; Wescombe & Tagg, 2003). The method is almost 
exclusively a gradient elution, utilizing a weak buffer, usually TFA based, and 
Acetonitrile (or an Acetonitrile based solution) as the mobile phase. 
 
A whole host of techniques have been utilized for peptide sequencing of 
lantibiotics with the primary method of choice being Edman degradation (Kellner 
et al., 1988; Kuipers et al., 1996; Zimmermann & Jung, 1997). It is noticeable 
that because of the difficulty posed to the method by the thioether bridges and 
dehydrated residues, chemical and enzymatic fragmentation needs to be 
performed first in order to form detectable residues (Ottenwälder et al., 1995).  
 
The other analytical methods utilized include GC-MS analysis, MALDI-TOF and 
various NMR based analyses (Barbour et al., 2013; Kuipers et al., 1996). These 
are used mainly for identification of the peptides and confirming their presence. 
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1.5.5 The impact of lantibiotic physical properties 
on Downstream Processing 
 
The physical and chemical properties of the product determine the preferred 
strategy for purification, processing, and practical applications (Rollema et al., 
1995). It is thus important to understand the interactions the intended product 
will have with the production media, the purification setup and the extraction 
techniques. Some of the potential relationships are shown in Table 1.1. 
 
It would be illogical to perform a tryptic digest initially if it is found that the 
product has low stability in its final form. Similarly if the product is determined to 
show varying solubility in different solvents, it would be much more logical to 
utilize a liquid-liquid extraction process compared to expensive chromatography 
procedures. A detailed understanding of all physical and chemical properties of 
the intended product is thus a necessary prerequisite for the translation of any 
new research work to large-scale production (Chubukov et al., 2016). 
 
It therefore becomes critical to establish a robust and reliable analysis method 
to determine the physical-chemical properties of lantibiotics to aid in 
downstream process development and selection, on an optimized cost-benefit 
basis.  
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Table 1.1 Relationship of physical properties to downstream processing 
 
Physical properties Impact on DSP 
Solubility Choice of extraction and purification method 
pH stability Choice of reagents and buffer solutions 
Temperature stability Heating/Cooling needs 
Reactivity Downtimes, scheduling and reagent choices 
Viscosity Choice of equipment based on shear 
Size Impacts filtration and purification 
Biological Activity Choice of assays and strains 
 
 
1.5.6 Challenges imposed by synthetic biology on 
Downstream Processing 
 
It is suggested that synthetic biology has the potential to enhance the antibiotic 
pipeline by providing new drugs for treating infection (Chubokov et al., 2016; 
Elander, 2003). It also enables medicine and pharmaceuticals to keep pace with 
rapidly evolving microorganisms that have acquired resistance to a large 
number of existing drugs (Yoneyama & Katsumata, 2006).  
 
However there are major challenges imposed by synthetic biology, in terms of 
finding the ideal candidate drugs and treatments that fulfil all requirements of 
efficacy, safety, scalability, affordability and ease of processing (Zhang et al., 
2016). Even though synthetic biology provides the necessary tools that allow for 
modification and customization, the complexity of living organisms and DNA 
means that inducing an organism into making a particular molecular product 
remains extremely resource intensive and difficult (Benner & Sismour, 2005; 
Heinemann & Panke, 2006). It is expected that with further research, greater 
understanding will result in enhanced abilities to develop ‘scratch built’ 
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organisms, however that aim requires the cataloguing of the vast number of 
possible combinations that result in the production of useful compounds and 
determine certain product behaviour. 
  
In the present circumstances, until global biological expertise and knowledge 
reaches the aforementioned level, the production of biological products that 
display desirable modification and characteristics will continue to require the 
‘sieving’ of a vast number of mutant variants. This process itself creates 
challenges for the biotech industry in the requirement of high throughput-
screening and analysis techniques, with novel high throughput screening 
methods under development (Walser et al., 2009). Unless faster methodologies 
and analysis techniques are utilized, they could potentially become a bottleneck 
in the application and utilization of synthetic biology (Ongey & Neubauer 2016). 
 
Thus the advance of synthetic biology means that the ability to rapidly 
characterize and define the physical and chemical properties of novel 
compounds becomes crucial. The success of any product both commercial and 
medical depends on how rapidly it can come to market and how many of the 
desired characteristics it possesses. Inability to do so would potentially make 
the synthetic drug discovery process both extremely time consuming and costly. 
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1.6  Microscale Approaches to Downstream 
Process design 
1.6.1 Microscale Methods 
The global biotechnology industry has been promoting the use of microscale 
methodologies and technology as part of ultra scale down (USD) studies. This 
includes both the use of microwells and microfluidics in the pursuit of process 
development (Rayat et al., 2016). Microscale technologies allow testing and 
experimentation to be performed without the need for much material, a critical 
advantage in allowing for high throughput screening of new molecules (Lye et 
al., 2003; Titchener-Hooker et al., 2008). 
 
In the search for new and better drugs and treatments, it is expected that with 
the aid of synthetic biology, vast libraries of compounds will be produced, each 
variant possessing some of the characteristics needed for the purpose. 
Determining which candidate would be the optimal choice requires the rapid 
screening of the candidate in order to determine the assimilation of the 
modifications. This has become more easily achievable with the spread of 
microscale technology. The ability to sort through vast libraries of cells within 
greatly reduced timeframes offer the potential benefit of bringing drugs to 
market much faster or identifying potential failures before having to expend any 
more resources (Titchener-Hooker et al., 2008). Thus it is unsurprising that the 
potential benefits have encouraged its uptake in the drug discovery process. 
 
In the same way as microscale technologies have aided drug discovery, they 
have the potential to aid early process development. Much work has been done 
Haroon D.S. Khan  Chapter 1 
 
59 
 
at UCL on mimicking process unit operations at microscale, with the focus on 
fermentation and bioreactors (Titchener-Hooker et al., 2008). The ability to 
conduct process development studies at microscale has recently been referred 
to as micro biochemical engineering and the reproduction of a unit operation at 
microscale has been referred to as an ultra scale down (USD) study. The 
challenge with conducting USD studies has been the complexity faced when 
comparing large-scale with microscale environments, with the cellular behaviour 
changing dramatically. Research has been conducted into the best ways to 
ensure that key coefficients can be maintained, such as KLA and the oxygen 
transfer rate (OTR) (Lye et al., 2003; Micheletti et al., 2006). Ensuring this 
allows comparisons to be made based on normalized data. 
 
In comparison to fermentation, there remains lots of scope for the application of 
microscale technology to downstream processing. There are investigations in 
the literature about the availability of microscale methods for downstream 
processes such as chromatography, centrifugation and filtration (Voulgaris et 
al., 2016; Titchener-Hooker et al., 2008). However, much work still needs to be 
done in order to fully compare the performance of microscale downstream 
processing with its full-scale equivalents. 
 
The ability to use microscale methods would greatly aid process development of 
new drug candidates. It could potentially allow process development to take 
place immediately after drug discovery, allowing for reduced risk and greater 
focus when setting up actual pilot scale production for clinical trials (Micheletti & 
Lye, 2006).  
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1.6.2 Rapid characterization, identification and 
analysis 
Microscale techniques allow for rapid identification and analysis of drug 
candidates by using minimal quantities and high throughput methods in order to 
screen vast libraries of compounds (Micheletti & Lye, 2006). They could also 
allow the rapid analysis of their physical and chemical properties in order to aid 
process development immediately after drug discovery, substantially reducing 
the time taken for experimentation and providing scale data that could be 
incorporated into models for simulating pilot scale facilities. This would allow 
more focus on key unit operations, while reducing risk. The use of microfluidic 
devices enables parallel microscale studies to be conducted, increasing 
throughput substantially (Davies et al., 2014). 
 
An advantage of microscale techniques is that with the use of standardized 
microplates and microwells, automation of the liquid handling and plate 
movement would allow for extremely high throughput systems (Nealon et al., 
2005). These when programmed to carry out tasks, could be left to conduct the 
analysis without the requirement for supervision allowing for minimum 
manpower requirements. The TECAN® automated platform is an example of 
such a technology that can be integrated with microwell methods (Lye et al., 
2003; Micheletti et al., 2006). 
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1.6.3 Economic Benefits 
The economic benefits are incurred by a combination of reduced times to 
market and reduction of risk in the drug development process. The reduced 
resource requirements for initial testing and reducing the number of pilot-scale 
production to those drug candidates with the highest chances of success also 
provide great savings in resources (Lye et al., 2002; Micheletti & Lye, 2006;  
Titchener-Hooker et al., 2008).  
 
The ability to screen vast libraries in a cost effective manner also implies more 
resources can be diverted to new research. Another advantage of microscale 
technology is that by making initial research cheaper, the cost of failure is 
considerably reduced, as a more directed effort would allow the optimum 
allocation of resources, eliminating the waste associated with trial and error 
strategies during pilot scale development. 
 
1.7 Current status of the Bioprocessing aspects  
 
Despite recognising the potential of lantibiotic compounds in treating disease 
(Smith & Hillman, 2008; Valsesia, 2008); it is notable that there is currently no 
lantibiotic in human clinical use.  
 
One of the contributing factors for these antibiotics having not been translated 
into commercial products is the lack of a well defined large scale manufacturing 
process (Ongey & Neubauer, 2016). The development of manufacturing routes 
for lantibiotics and modified lantibiotics is still in the early stages. As described 
in Section 1.3.10 most published work focuses on characterizing lantibiotics 
with useful antimicrobial properties and creating novel variants rather than 
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attempting their production at anything beyond laboratory scale. While attempts 
have been made to modify organisms to increase lantibiotic yield during 
fermentation (Kuipers et al., 1996; Valsesia et al., 2007), there currently exists 
no fermentation process with well defined operational parameters that provides 
a platform for reproducible antibiotic production in bioreactors. Neither is there 
any published work on the reproducible production at pilot or manufacturing 
scale, of antibiotics that have been modified using synthetic biology. 
 
Likewise, while there are numerous publications on the isolation and purification 
of selected lantibiotics for analytical purposes, no published work currently 
exists on the preparative or manufacturing scale downstream processing of this 
class of molecules. A variety of methods such as ion exchange 
chromatography, immuno-affinity chromatography, hydrophobic interaction 
resins, product precipitation and adsorption onto the producer organisms by pH 
variation have been proposed as described in Section 1.5.3. However none of 
these methods have been tested beyond laboratory scale and have tended to 
be studied as isolated steps rather than within a whole downstream processing 
sequence. The one strong indication from the available literature is a general 
preference for the use of hydrophobic interaction resins, with 
adsorption/desorption used as a primary capture step (Valsesia et al., 2007; 
Fiedler et al., 1988; Arias et al., 2013; Medaglia, 2009). 
 
The work by Giovanni Medaglia (2009) in the Bioprocess laboratory, at the 
department for Biosystems Science and Engineering, ETH Zurich using 
S.gallinarum Δp is the closest attempt at designing a complete process for 
lantibiotic production that could be attempted at pilot scale. The research is 
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based on prior work by Valsesia et al. (2007) and Fiedler et al. (1999) on the 
S.gallinarum Tϋ3928 cell strain and seeks to optimise the production of 
lantibiotic by performing high cell density cultures and identifying possible DSP 
strategies for the capture and purification of PGDM. A search of the literature 
did not reveal any similar attempts at developing a complete bioprocess for 
lantibiotic production at scale since then. 
 
Additionally, while the properties of a number of lantibiotics have been 
characterized, there is a lack of basic knowledge about the physico-chemical 
properties of lantibiotics that would influence their behaviour in downstream 
process environments (Table 1.1). Investigations have been reported on the 
stability and solubility of Nisin (Rollema et al., 1995) which are factors which 
would influence process design. Similar data on other lantibiotics is lacking and 
methods to rapidly acquire this data for libraries of engineered novel lantibiotics 
would greatly enhance downstream process synthesis and design. 
 
1.8 Novelty of the work performed 
  
The past two decades have seen a lot of research focused on the development 
of novel lantibiotics by studying the producer organisms and understanding the 
molecular mechanisms of production (Sandiford, 2014). This has allowed a 
wealth of knowledge to be gained on the genetic sequences and enzymes 
involved in the synthesis of these antimicrobial peptides, which has led to 
development of tools that allow them to be modified on the genetic level, 
creating libraries of novel compounds. 
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However, over the same time period, very few studies have attempted to 
characterise a production process that would allow large amounts of these 
compounds to be obtained for clinical use. Work on individual bioprocess unit 
operations (Suarez et al., 1997; Kempf et al., 1999; Fiedler et al., 1988) has 
been performed but so far only Medaglia (2009) has attempted to identify a 
complete process by which clinically significant amounts could be produced.  
 
This work has built heavily on the work of Medaglia (2009) as a foundation to 
identify a complete process that could potentially provide a platform for research 
into the large scale production of novel lantibiotics. However, unlike the 
previous work, it attempts to characterise the microenvironment of the 
S.gallinarum Δp fermentation and demonstrate reproducibility between batches. 
It is also the first work to perform a 30 L scale fermentation using S.gallinarum 
Δp to produce the gallidermin precursor peptide, pregallidermin. 
 
Fiedler et al. (1988) and Medaglia (2009) identified and outlined potential DSP 
sequences that could be utilized for the isolation and purification of gallidermin 
and pregallidermin respectively. However, those studies were conducted at 
bench scale. This is the first work to utilise pilot scale DSP operations to attempt 
the purification of a lantibiotic precursor.  This is also the first work that attempts 
to combine the pilot scale fermentation, DSP operations and microscale 
optimisation studies into a complete pilot scale platform process. This platform 
process can be used to obtain information than can aid the biotechnologist in 
process design for lantibiotic producing organisms. 
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1.9 Aims and Objectives   
 
The absence of a well defined manufacturing process to allow production of 
modified lantibiotics at scale and generic rules for their downstream process 
remains a barrier to their further development. The aim of this thesis is to 
systematically analyse options for lantibiotic production at pilot/manufacturing 
scale and to develop microscale methods for acquiring the physic-chemical 
property data that will aid downstream process synthesis. The approach will be 
illustrated using the S. gallinarum Δp cell line; a modification of the S.gallinarum 
tü 3928 cell line, that produces pregallidermin, the inactive precursor to the 
lantibiotic gallidermin (Valsesia, 2008). Production of the pre-lantibiotics is a 
novel approach that overcomes the auto-toxicity of the lantibiotic to the 
producing organism but requires an additional downstream processing step, 
trypsination, for removal of the leader-peptide on the actual lantibiotic molecule 
(Chapter 1.4.2). The specific objectives of this research are: 
 
 To systematically characterise the fermentation parameters that allow 
reproducible fermentations and maximisation of antibiotic production. 
These parameters will be used to identify the conditions needed to 
achieve optimal antibiotic production and the reproduction of these 
results at pilot scale. This study is reported in Chapter 3. 
 
 To systematically develop a whole downstream process sequence for the 
removal of cell mass, followed by the capture and purification of PGDM 
that is applicable at pilot and manufacturing at scale. This study will aim 
to identify generic rules for the design of lantibiotic purification processes 
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and the necessary physico-chemical property data required to inform 
downstream process design. This work is described in Chapter 4. 
 
 To develop microscale methods that can be used to rapidly acquire 
physico-chemical property data on lantibiotic molecules that will help 
inform early stage downstream process design.  Additionally, the 
microscale data will be used to optimise a process identified in Chapter 
4. Stability studies will also demonstrate the potential of these methods 
to allow informed choices on DSP design, with the process redesigned in 
light of the data from the microscale analysis. This work is described in 
Chapter 5. 
 
Chapter 2, which follows immediately after this section, details the experimental 
materials and methods used throughout this thesis along with the relevant 
analytical techniques.  
 
Chapter 6 will summarise the novel insights gained from this research and 
attempt to derive a set of conclusions based on the results, additionally it will 
outline avenues of future work.  
 
Finally, Chapter 7 will consider practical applications for the knowledge 
obtained. The chapter is included as part of the requirements for award of the 
UCL EngD. It will provide a concise argument for the platform process 
developed to be used in the design and future production of libraries of novel 
lantibiotic compounds.  
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2. Materials and Methods 
 
2.1 Materials 
 
All consumables and reagents were procured from Sigma-Aldrich (Dorset, 
United Kingdom), unless otherwise stated, and were of the highest purity 
available. A list of all chemicals used is given in Appendix 1. All solutions were 
made up with RO water or higher purity Milli-Q water (Merck Millipore, 
Darmstadt, Germany). 
 
All materials and lab-ware were sterilised by autoclaving at 121ºC for 20 
minutes where possible. All transfer of cells, plating and preparation of glycerol 
stock was performed under sterile conditions in a Class II biological safety 
cabinet to prevent any contamination of stocks and samples. Where it was not 
possible to sterilise by autoclaving i.e. in the case of antibiotic preparation, 
materials were filter sterilised using 0.2 μm Sartorius (Göttingen, Germany) 
syringe filters.  
 
2.1.1 Organism  
 
The modified bacterial strain Staphylococcus gallinarum∆gdmP::aphIII 
(S.gallinarum Δp) was a kind gift provided for use in this research by Professor 
Sven Panke’s group at the Biprocess Laboratory of ETH Zurich in Basle, 
Switzerland. 
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 S.gallinarum Δp is a modification of the wild-type S.gallinarum tü 3928 
producing the lantibiotic precursor pregallidermin (PGDM), rather than the wild-
type active gallidermin. The strains were received from ETH Zurich plated onto 
agar slopes. 
 
The organism was created by Valseia et al. (2007) in order to increase the yield 
of lantibiotics from culture by negating the effect of auto-toxicity towards the 
host strain displayed by gallidermin (Sahl et al., 1998). The wild-type 
S.gallinarum tü 3928 was modified by developing a new plasmid vector that 
knocked-out the genetic sequence for the extracellular protease GdmP 
(responsible from cleaving the leader peptide for the lantibiotic precursor 
molecule) and replaced it with the sequence for resistance to the antibiotic 
Kanamycin. The wild-type S.gallinarum tü 3928 is not naturally resistant to 
Kanamycin, allowing the antibiotic to be used to ensure selectivity for the 
mutant strain in culture. 
 
2.1.2 Preparation of glycerol stocks 
 
Glycerol stocks were prepared by initially plating the strains on process media 
with the addition of 2 % (w/v) agar. The antibiotics Kanamycin, 20 μg.mL-1, and 
Tetracycline, 10 μg.mL-1, were added to the agar solution before it had solidified 
and subsequently poured into Petri dishes. The antibiotics were separately filter 
sterilised through a 0.2 um syringe filter before use. The plates were then 
sealed using Para-film (Bemis, Wisconsin, United States) and incubated 
overnight at 37 ºC.  
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50 mL Falcon tubes were filled with 10 mL of fresh media and the antibiotics 
were added. From the agar plates, single colonies of the bacterial strains were 
inoculated into the Falcon tubes, which were then placed into Kühner orbital 
shakers (Basel, Switzerland) at 37 ºC and 250 rpm overnight. 0.5 mL of the 
bacterial culture was then pipetted aseptically into 1.5 mL Eppendorf tubes 
along with 0.5 mL of glycerol, which were then vortexed and stored at -80ºC. 
 
2.1.3 Fermentation media and feed for fed-batch 
fermentations 
 
All fermentations performed in the course of this research utilised the same 
yeast extract based complex media for bacterial growth. The media, referred to 
as Medium 21B by Medaglia (2009) in the initial process development studies 
conducted at ETH Zurich, was a solution of 50 g.L-1 yeast extract and 20 g.L-1 
sodium chloride per litre dissolved in RO water (the original recipe did not 
specifically require the use of RO water due to the complex nature of the 
ingredients, however as the original plan had called for the research to be 
conducted across multiple labs in various locations, RO water was utilized to 
maintain consistency between all media and feed solutions). 
 
The two feed solutions were simply made by dissolving either maltose or yeast 
extract in water and then sterilising by autoclaving for 20 minutes at 120°C.  
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Table 2.1 Composition of media and feed solutions used in the various fermentations 
 
Operation 
Fermentation media 
components 
Feed composition 
 
Yeast 
Extract 
Sodium 
Chloride 
Maltose Feed 
Yeast-
Extract Feed 
Scale 
Shake Flask 50 gL
-1
   20 gL
-1
   None   None   0.5L 
STR Batch   50 gL
-1
   20 gL
-1
   None   None   7.5L 
STR Fed-
Batch   
50 gL
-1
   20 gL
-1
   500 gL
-1
   None   7.5L 
STR Fed-
Batch   
50 gL
-1
   20 gL
-1
   500 gL
-1
   300 gL
-1
   7.5L 
STR Fed-
Batch   
50 gL
-1
   20 gL
-1
   500 gL
-1
   300 gL
-1
   30.0L 
STR Fed-
Batch   
50 gL
-1
   20 gL
-1
   600 gL
-1
   200 gL
-1
   30.0L 
 
 
2.2 Fermentation of S. gallinarum Δp 
 
2.2.1 Shake flask fermentation of S.gallinarum Δp 
 
Fermentation media for cell culture of S. gallinarum Δp was prepared by 
dissolving 50 g of yeast extract and 20 g of sodium chloride per litre of RO 
(reverse osmosis) water as described in Section 2.1.3. The media was sterilised 
by autoclaving at 121 ºC for 20 minutes, and then allowed to cool before use. 
 
A pre-culture was prepared by pipetting 10 mL of media into 50 mL falcon 
tubes. Antibiotics used to ensure selectivity of the strain were 20 μg.mL-1 
Kanamycin and 10 μg.mL-1 Tetracycline. The pre-culture was inoculated with 
100 μL of S.gallinarum Δp frozen glycerol stock and left overnight in a Kühner 
(basel, Switzerland) orbital shaker at 37 °C and 250 rpm. 
 
Haroon D.S. Khan  Chapter 2 
 
71 
 
Sterile 500 mL conical flasks were filled with 90 mL of fermentation media and 
fresh Kanamycin and Tetracycline was pipetted into them. The conical flasks 
were inoculated with 10 mL of S. gallinarum Δp pre-culture, the tops were 
sealed with cotton wool and aluminium foil and then placed in a Kühner orbital 
shaker at 37 ºC and 250 rpm. A 1 mL sample of culture was taken every hour, 
with OD being measured at 600nm to monitor cell growth (Section 2.5.1) and 
then analysed by HPLC (Section 2.5.3) to quantify the amount of pregallidermin 
(PGDM) present.   
 
2.2.2 7.5L fermentation of S.gallinarum Δp: batch 
mode 
 
 
Batch fermentations were performed using 7.5 L BioFlo 110 bioreactors (New 
Brunswick Scientific Company, Edison, NJ, USA). The bioreactor had a top-
driven impeller shaft with two six-bladed Rushton turbine impellers, capable of 
agitation between 200 rpm and 1200 rpm (Figure 2.1). The bioreactor working 
volume was 5 L. 
 
The pH probe was calibrated by initial immersion in a buffer at pH 4, followed by 
a buffer at pH 7. The probe was tested by immersing in a solution of known pH, 
with the reading confirmed using a bench-top Mettler-Toledo (Leicester, UK) pH 
probe. The DOT probe (Mettler-Toledo Ltd, Leicester, UK) was calibrated at 0 
% air saturation by placing in a stream of pure nitrogen outside the vessel, 
followed by calibration at 100 % air saturation by leaving the probe exposed to 
air for at least 30 minutes. The exit gas port from the bioreactor was connected 
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to a Prima-Pro process mass spectrometer (Thermo Scientific, Waltham, MA, 
USA). 
 
The BioFlo reactors allow for the automatic control of pH, temperature, DOT 
and antifoam (polypropylene glycol, PPG) addition. Process media was 
prepared (as described in Section 2.1.3) and filled into the bioreactor up to 5 L. 
The media was sterilised by autoclaving the whole bioreactor for 20 minutes at 
121 ºC in a Getinge H-Series autoclave (Getinge, Sweden). The temperature of 
the media was adjusted to 37 ºC and the pH adjusted to 6.5 using 20 % (v/v) 
ammonium hydroxide solution and 20 % (v/v) phosphoric acid. Airflow was set 
to 1 vvm (vessel volume per litre per minute) and impeller speed set to a 
minimum of 250 rpm and a maximum of 1200 rpm. DOT (dissolved oxygen 
tension) was set at a minimum of 30 %. A cascade system was operated by 
which vessel agitation would automatically increase in response to drops in 
DOT due to cellular growth. PPG addition was done via syringe injection 
through a septum as opposed to automated control. The antibiotics Kanamycin 
20 μg.mL-1 and Tetracycline 10 μg.mL-1 were added prior to inoculation to 
ensure microbial selectivity. 
 
Inoculation was performed with 10% (v/v) cell culture solution (prepared as 
described in section 2.1.2). Growth of the cells was charted by taking OD 
readings of samples at 600nm (section 2.5.1) and PGDM expression analysed 
by HPLC (section 2.5.3).   
 
Antifoam used in the culture was autoclaved at 121ºC for 20 minutes. All 
connectors used for the addition of substances were sterilised by wiping with 70 
% (v/v) ethanol solution. 
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2.2.3 7.5L fermentation of S.gallinarum Δp: fed-
batch mode 
 
Fed-batch cultures were performed in the same 7.5 L New Brunswick BioFlo 
bioreactors as used for batch cultures in Section 2.2.2. For fed-batch cultures 
these were initially filled with 1.8 L of media. One litre each of the feed solutions 
(500 g.L-1 maltose and 300 g.L-1 yeast extract solution) were attached to the 
bioreactor using sterile connectors and tubing, with the whole system being 
sterilised by autoclaving at 121 ºC for a minimum of 20 minutes. The system 
temperature was then adjusted to 37 ºC, pH adjusted to 6.5 using 20 % (v/v) 
ammonium hydroxide and 20 % (v/v) phosphoric acid and DOT set to 30 % with 
cascade control of agitation between 250 rpm and 1200 rpm. The vessels 
containing the feed solutions were placed on weighing scales to record feed 
rates over time with flow rates adjusted using Watson-Marlow 101 U/R 
peristaltic pumps (Wilmington, MA, USA). Automatic antifoam control was set 
up for the fed-batch cultures by setting the control system to activate PPG 
addition if liquid level hit the foam detection probe tip. The antibiotics 
Kanamycin 20 μg.mL-1 and Tetracycline 10 μg.mL-1 were added prior to 
inoculation. 
 
Inoculation was performed using a 10 % (v/v) cell culture solution, placed 
overnight in a 1 L conical flask at 37 ºC and 250 rpm in an orbital shaker, grown 
direct from frozen glycerol stock as described in Section 2.1.2. Cellular growth 
was determined by taking the OD at 600 nm of cell culture samples (Section 
2.5.1), with HPLC analysis used to determine PGDM expression (Section 
2.5.3).  
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Feeding of the 500 g.L-1 maltose solution was initiated at 2 hours post 
inoculation, with feeding of the 300 g.L-1 yeast extract solution initiated at 4 
hours post inoculation in fed-batch fermentations where a two feed setup was 
used.  
 
Aeration was initially set at 1 vvm; however it was manually adjusted to allow for 
the changing volume of the bioreactor broth. Where the DOT fell below the 
minimum 30 % at maximum impeller agitation rate and maximum possible 
aeration rate, pure oxygen was blended into the vessel air supply to a maximum 
of 100 % (v/v) to increase DOT back to the set point. The exit gas port from the 
bioreactor was connected to a Prima PRO process mass spectrometer (Thermo 
Scientific, Waltham, MA, USA). 
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A  
 
 
 
 
B 
 
 
 
Figure 2.1 The Dimensions of the BioFlo 110 7.5 L bioreactor, with A) showing the vertical 
cross-section and B) showing the horizontal cross-section.  X= the impeller shaft; Y= impeller 
blade; Z= baffle.  All measurements are displayed in millimetres (mm). 
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2.2.4 30L Fed-Batch fermentation of S.gallinarum 
Δp  
 
Fed-batch fermentations were performed at 30 L scale using a Sartorius 
Biostat® CPlus bioreactor (Göttingen, Germany). The reactor had a height to 
diameter aspect ratio of 3:1, with a total internal volume of 42 L and a working 
volume of 30 L. The reactor has a top-driven impeller shaft with three 6-bladed 
impellers, allowing agitation up to 1000 rpm. The pH and DOT probes were 
calibrated as described in Section 2.2.2 and the bioreactor off-gas was 
connected to the Prima Pro process mass spectrometer (Thermo Scientific, 
Waltham, MA, USA) for analysis. 
 
The Biostat® CPlus allows for the control of temperature, pH, antifoam addition 
and DOT control via aeration, agitation and gas blending (with O2). Additionally, 
the bioreactor can be programmed to perform exponential feeding via 
automated control of the flowrates of attached peristaltic pumps. 
 
The feed solutions of either 500 or 600 g.L-1 maltose solution, 300 or 200 g.L-1 
yeast extract solution and the antifoam PPG were sterilised by autoclaving at 
121 °C for 20 minutes and then attached to the bioreactor. Aqueous ammonium 
hydroxide 20 % (v/v) and phosphoric acid 20 % (v/v) were connected to the 
bioreactor prior to process media filling. 9 L of process media was filled into the 
bioreactor, which was sterilized in-situ by steam injection into the vessel jacket 
raising temperature to 121 ºC for a minimum of 20 minutes. The antibiotics 
Kanamycin 20 μg.mL-1 and Tetracycline 10 μg.mL-1 were added to the sterile 
media pre-inoculation. The temperature was controlled at 37 °C, pH at 6.5 and 
DOT set to a minimum of 30 %. 
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Inoculation was preformed with a 1 L cell culture, grown in a 3 L conical flask 
overnight at 37 °C and 250 rpm, in a Kühner orbital shaker, direct from frozen 
glycerol stock. Off-gas was analysed for OUR and CER using the process mass 
spectrometer. 
 
 
The flowrate of feed solutions was adjusted using Watson Marlow 101 U/R 
peristaltic pumps (Wilmington, MA, USA). 
 
 Maltose feed was started at 3 hours post-inoculation and yeast extract feed 
was started 6 hours post-inoculation. When pump reached maximum flow rate, 
the feed rate was maintained at this level until fermentation end.  
 
Aeration was begun with 1 vvm, however it was manually adjusted to account 
for the changing volume of the reactor, due to feed addition and to maintain 
DOT at a minimum 30 %. 
 
2.2.5 Fermentation substrate feed strategies 
 
At 7.5L scale substrate was fed into the fermentation using either an 
exponential feed regimen or a step-up regimen; both these feed profiles are 
illustrated in Figure 2.2.  
 
For the ‘exponential’ regimen, it was not possible to use the Watson-Marlow 
101 U/R (Wilmington, MA, USA) pumps as the BioFlo 110 bioreactors do not 
possess an interface that allows external pumps to be controlled. Instead, the 
BioFlo’s built-in pumps were utilised and programmed with an exponential 
profile.  
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The ‘step-up’ feeding regimen required a manual adjustment of the Watson-
Marlow 101 U/R to allow a step increase in the feed rate in order to ensure the 
substrate did not become growth limiting. This adjustment was performed in 
response to a drop in DOT and subsequent increase in impeller agitation rate, 
which were used as indicators of increased cellular respiration.  
 
 The exponential regime was applied to the feed solutions following the 
equation: 
 
             
    
    
   
  
  
                       (2.1) 
 
 
where feed (t) in L.h-1 is the feed rate for a single feed, μset (h
-1) is the desired 
specific growth rate; Yx/s (g/g
-1) is the biomass yield per unit of maltose fed, X0 is 
cell dry weight (CDW) in g.L-1 i.e. the CDW concentration at the beginning of the 
feed, V0 (L) is the liquid volume in the bioreactor at the start of the feed, S0 (g.L
-
1) is the concentration of the substrate in the feed solution and t (h) is the time 
elapsed since feed start (Medaglia, 2009). 
 
In comparison the 30L Sartorius Biostat® CPlus bioreactor (Göttingen, 
Germany) allows the flow rate of external pumps to be controlled from the main 
user interface, hence the flow rates of the Watson Marlow 101 U/R peristaltic 
pumps (Wilmington, MA, USA) was controlled by the bioreactor where an 
exponential feed regime was applied.   
 
In the case of the ‘step-up’ feed regimen, the flow rate of the pumps was 
manually adjusted in response to changes in DOT and impeller agitation rate. 
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A 
 
 
B 
 
 
Figure 2.2 The two substrate feed profiles used for the fermentation studies, with A) depicting 
an exponential feed regime in which an attempt is made to map the feed rate onto the microbial 
growth curve and B) showing a ‘step-up’ feed profile, with step changes in the feed rate to 
ensure the substrate is maintained in excess and does not become growth limiting.   
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2.2.6 Anti-foaming agent utilised    
 
Polypropylene Glycol (PPG) from Sigma-Aldrich (Dorset, UK) was added either 
manually or using an automated control system as the anti-foaming agent in all 
Stirred-tank bioreactions. 
 
2.2.7 Measurement and calculation of off-gas data  
 
The Prima PRO (Thermo Scientific, Waltham, MA, USA) process Mass 
Spectrometer (MS) is connected to the bioreactor air inlet port and the off-gas 
port for both the 7.5L scale and 30L scale bioreactors. This allows the 
instrument to measure the composition of the air being bubbled into the 
fermentation and the air flowing out. Detection of these quantitative changes 
allow the MS software to determine the bioreactor OUR and CER, which can 
then be used to calculate the Respiratory Quotient (RQ). The RQ can be used 
as an indicator of the substrate being utilised, with different RQ values 
corresponding to cellular metabolism on different substrates (Winkler, 1990; 
Arifin et al., 2014). 
 
The calculation of these variables may be done by the use of the following 
equations: 
     
 
 
                            (2.2) 
Where (O2)in, (O2)out are the oxygen concentrations, and Fin and Fout are the gas 
flow rates at inlet and outlet respectively. 
     
 
 
                             (2.3) 
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Where (CO2)in, (CO2)out are the carbon dioxide concentrations at the inlet and  
outlet respectively. 
    
   
   
       (2.4) 
In this research, the calculation of the variables for the bioreactor studies 
(where possible) conducted at 7.5L and 30L scale were performed using the 
Prima PRO process MS software. 
 
2.3 Purification of Pregallidermin 
 
The purification sequence established for the novel PGDM product comprised 
the following stages: centrifugation, adsorption/desorption, ion exchange 
chromatography, salt removal by adsorption desorption and lyophilisation. 
These are described in detail in the following sections. 
 
2.3.1 Small Scale centrifugation 
 
Small scale centrifugation was performed using an Eppendorf 5810 bench top 
centrifuge (Hamburg, Germany). Cell culture broth was pipetted into 1.5 mL 
Eppendorf tubes and spun at 14,000 rpm for 5 minutes, at a temperature of 4 
°C. The supernatant was pipetted into another 1.5mL Eppendorf tube and re-
centrifuged for another 5 minutes to ensure the adequate removal of cells for 
supernatant analysis. 
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2.3.2 Large Scale Centrifugation 
 
Large scale centrifugation was performed using a Beckman-Coulter Avanti® 
centrifuge (Brea, CA, USA). Cell culture broth was filled into 500 mL centrifuge 
flasks and spun at 10,000 rpm for 30 minutes at a temperature of 4 °C. The 
supernatant was decanted into fresh 500mL flasks and the centrifugation 
repeated for another 30 minutes. The supernatant was then pooled in Duran 
flasks and stored in the refrigerator at 4 ºC for storage and further processing.  
 
2.3.3 Adsorption using XAD-7 
 
The hydrophobic resin, Amberlite® XAD-7, (Sigma-Aldrich, Dorset, UK) was 
prepared for adsorption by first washing with pure methanol for 60 minutes. The 
methanol was then replaced with MilliQ water and the beads washed for 
another 60 minutes. The water was then removed by vacuum filtration and 20 g 
of beads measured out into 500 mL conical flasks. 100 mL of clarified 
fermentation broth was poured into the flasks, which were then placed into a 
Kuhner (Basel, Switzerland) orbital shaker at 25°C and 200rpm for 60 minutes.  
The supernatant was removed by vacuum filtration with the adsorbed amount of 
PGDM determined by HPLC (Section 2.5.3) of the fermentation broth, pre and 
post adsorption. 
 
For prep-scale adsorption of material, 40 g of washed and vacuum filtered XAD-
7 was filled into a 3 L conical flask with 1 L of clarified fermentation broth. The 
conical flask was placed into an orbital shaker at 250 rpm and 25 °C for 120 
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minutes. Adsorption was determined by comparison of the HPLC (Section 
2.5.3) chromatograms prior to and post adsorption. 
 
2.3.4 Desorption 
 
Prior to desorption the XAD-7 beads from section 2.3.3 were washed with 0.5 L 
of MilliQ water followed by a 0.02 M phosphate buffer solution at pH 6. The 
wash liquids were examined for PGDM by HPLC analysis Section 2.5.3 and the 
yeast extract released by the beads was monitored by measuring the change in 
colour intensity of the wash buffer using a UV spectrophotometer (section 
2.5.1). Desorption was performed in two batches using a 100 mL solution of 
60%/40% (v/v) Methanol/0.05 M sulphuric acid, placed in an orbital shaker at 
250 rpm and 25 °C for 90 minutes. The amount and purity of desorbed PGDM 
was determined by HPLC (Section 2.5.3) before the batches were pooled and 
methanol evaporated in a rotary evaporator in preparation for ion exchange 
chromatography (Section 2.3.5).  
 
2.3.5 Ion Exchange Chromatography 
 
 
Ion exchange chromatography was performed using a GE Healthcare (Little 
Chalfont, UK) Sepharose SP FF and SP HP 1mL Hitrap® column on a GE 
Healthcare ÄKTA Purifier (Little Chalfont, UK) liquid chromatography system. 
Mobile phases for the chromatography were 0.02 M acetate buffer at pH 4.5 as 
the load and wash buffer, with 0.02 M acetate buffer at pH 4.5 with 2 M sodium 
chloride serving as the elution buffer. PGDM from 2 mL of desorbed eluent 
(Section 2.3.4) was purified using gradient elution from 0 % elution buffer to 15 
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% elution buffer. The eluted liquid was captured in 1 mL fractions and analysed 
for PGDM by HPLC (Section 2.5.3).  
 
Scale up was performed using GE Healthcare SP HP, a strong cation exchange 
resin. An XK-16 (GE Healthcare, Little Chalfont, and UK) column was packed 
with 15 mL of resin, with packing quality tested by the symmetry of the peak 
produced by a 1 % (v/v) acetone solution.on the chromatogram. Operational 
flowrate was maintained at 6 mL.min-1. The purified PGDM was analysed using 
HPLC and then all fractions pooled for removal of sodium acetate and sodium 
chloride components by XAD-7.     
2.3.6 Adsorption/Desorption 
 
 
The PGDM containing Ion exchange fractions were pooled and 50 mL, product 
rich solution, poured into 250 mL conical flasks containing 2 g of washed 
Amberlite® XAD-7 resin (as mentioned in Section 2.3.4). Adsorption was 
performed by shaking the flasks at 250 rpm and 25 °C, for 60 minutes. The 
resin was then washed with 0.05 M buffer at pH 7 until no more yeast extract 
components were released (Section 2.3.4). 
 
Desorption was performed using a 100 mL solution of 60% MeOH and 40%  
distilled water, at 25°C shaken at 250 rpm, in two batches of 50 mL each. The 
batches were pooled together with the Methanol removed using a rotary 
evaporator in preparation for lyophilisation.  
 
HPLC analysis was used to determine yield and purity of the desorbed PGDM 
(section 2.5.3). 
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2.3.7 Lyophilization  
 
Lyophilisation of the PGDM solution obtained from Section 2.3.6 was performed 
by placing 5 mL samples in pre-weighed flasks in a VirTis® (SP Scientific, 
Ipswich, UK) freeze dryer over 24 hours. Once liquid removal was complete, 
samples of the powder were weighed and analysed by HPLC (section 2.5.3).   
 
2.4 Trypsinization of PGDM 
 
PGDM (1 mg.mL-1) was trypsinised (Chapter 1.5.1) using 10 μL of 1 mg.mL-1 
porcine trypsin buffered at pH 7 using a 0.02 M phosphate buffer, a PGDM to 
trypsin ratio of 100:1 (w/w), at 25 °C. Samples were taken every 60 seconds, 
with the trypsin denatured using 10 μL of concentrated 10 M sulphuric acid to 
halt the conversion, and analysed by HPLC to confirm the presence of the 
mature gallidermin. 
 
Confirmation of the identity of gallidermin and leader sequences was 
undertaken by Mass Spectrometry (MALDI-MS) as described in Section 2.5.4. 
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2.5 Analytical Techniques 
 
2.5.1 UV-VIS spectroscopy  
 
The growth kinetics of the S.gallinarum variants (Section 2.1.1) during 
fermentation were determined by UV-VIS spectroscopy at 600 nm, using a 
Genesys UV-VIS spectrophotometer (Waltham, MA, USA). 1 mL samples of 
fermentation broth were pipetted into cuvettes for analysis. Dilutions with RO 
water were performed for high concentration fermentation samples that showed 
absorbance values beyond the accuracy range specified for the 
spectrophotometer (0 to 1 absorbance units (OD) at 600 nm).  
 
The amount of yeast extract removed from XAD-7 resin beads during 
desorption (section 2.3.4) was also determined by measuring the UV-
absorbance of 1 mL samples of wash buffer at 600 nm.   
2.5.2 Biomass quantification 
 
UV-VIS analysed samples of fermentation broth were filtered using pre-weighed 
membrane filters (Sartorius, Göttingen, Germany) and then dried overnight in 
an oven at 60 °C. The filters with the dry cell mass were reweighed and a 
calibration curve was determined using triplicate samples of each concentration.  
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2.5.3 Quantification of antibiotic concentration and 
purity 
 
Gallidermin and PGDM were quantified and identified in broth by analysis on an 
Agilent 1200-series high performance liquid chromatography system (Agilent 
Technologies, Santa Clara, CA, USA). The system was equipped with a 
degasser, quaternary pump, automatic injector and a diode array detector 
(DAD) capable of detecting multiple wavelengths of visible and ultra-violet light. 
 
The column utilized for the separation was a Nucleosil 100 C-18 column with 
5μm pore size (125 x 4 mm) and a guard column (Hewlett-Packard, Dortmund, 
Germany). Sample Injection volume was maintained at 10 μL and temperature 
was maintained at 25°C. The wavelength for detection was 204 nm. All samples 
were run in triplicate. 
 
The mobile phases were composed of 0.1% (v/v) H3PO4 (solvent A) and 
Acetonitrile (solvent B), which followed a linear gradient from 0 to 40% solvent B 
in 10 minutes. Stripping, regeneration and re-equilibration of column to start 
conditions were achieved in another 7 minutes.  
 
Identifications were performed by comparing the retention time of samples of 
PGDM/GDM against the retention time of a sample of commercially purchased 
pure gallidermin (Enzo-Life Sciences, Farmingdale, NY, USA). Quantification 
was performed by comparison against calibration curves made using the pure 
commercially sourced materials (Appendix 2). 
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Product purity was determined by comparing the total product peak area in 
mAU, on the HPLC chromatogram, with the total area in mAU of all the 
component peaks in the analysed sample (including product peak). The purity is 
thus expressed as a percentage of the sample. The purity is calculated using 
the equation: 
            
     
    
       (2.5) 
Where Purity is the PGDM or GDM purity in %, AProd is the total area of the 
product peak/peaks in mAU and ATot is the total area of all sample peaks in 
mAU. 
  
It is noteworthy, that when calculating the purity of pregallidermin, the area of 
the peaks of both PGDM variant 1 and PGDM variant 2 have to be added. 
 
 
2.5.4 Mass Spectrometry for product identification 
 
Mass Spectrometry of the samples was performed by the UCL Chemistry Mass 
Spectrometry service using MALDI-TOF analysis on a Micromass Maldi micro 
MX system (Waters Corporation, Milford, MA, USA). Purified PGDM dissolved 
in water and gallidermin from the trypsinization in Section 2.4 were diluted with 
RO water to a concentration of 0.1 mg.mL-1 and provided for analysis. The 
mass spectra obtained were compared against mass spectra of commercially 
sourced gallidermin and literature to confirm product identity by molar mass.   
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2.6 Microscale Methods for product analysis 
 
Microscale methods for the analysis of PGDM and gallidermin properties were 
initially established using a 24 microwell Eppendorf Thermomixer Comfort® 
(Hamburg, Germany), with enclosing lid. The thermo-mixer allowed for control 
of temperature and agitation. 1.5 mL eppendorf tubes were utilized to contain 
the antibiotic solutions with the plate lid providing an additional barrier to liquid 
evaporation, control experiments conducted with the setup showed negligible 
evaporation, allowing it to be ignored. All samples were analysed using HPLC 
as described in Section 2.5.3. 
 
 
 
2.6.1 Temperature stability studies 
 
The temperature stability of PGDM and GDM was determined by pipetting a 1 
g.L-1 antibiotic solution, buffered at pH 6, 7 or 8 using a 0.02 M phosphate 
buffer, into a 1.5 mL eppendorf tube and placing onto a thermo-mixer at 25 °C 
and 37 °C. Samples from the microwells were analysed via HPLC as described 
in Section 2.5.3 to determine changes in concentration of antibiotics over time. 
 
 
 
2.6.2 pH stability studies 
 
The pH stability of the antibiotics was determined by pipetting 1 mL of 1 g.L-1 
antibiotic solution at pH 6, 7 and 8 into 1.5 mL Eppendorf tubes and placing 
them within the thermo-mixer. The samples were adjusted to pH 6 using 0.02 M 
acetate buffer and pH 7 and 8 using 0.02 M phosphate buffer. Experiments 
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were carried out at 25 ºC and 37 °C, with mixer shaking set at 1200 rpm.  
Samples were analysed by HPLC (Section 2.5.3). 
 
2.6.3 Stability at varying ionic strength 
 
The impact of antibiotic concentration on degradation kinetics was determined 
by pipetting 1 g.L-1 of antibiotic solution; buffered at ph 6, 7, and 8, with ionic 
strengths of 0.02 M, 0.04 M and 0.06 M, into 1.5 mL eppendorf tubes and 
placing into a thermo-mixer agitated at 1200 rpm. Experiments were carried out 
at temperatures of 25 ºC and 37 ºC with samples taken at regular intervals 
analysed by HPLC over time.  
 
2.7 Microscale methods for optimisation of 
product capture 
 
Microscale methods for optimisation of DSP sequences were performed using a 
24 well Eppendorf Thermomixer Comfort® (Hamburg, Germany) with enclosing 
lid. The methods were used to optimise the PGDM primary capture step, 
product capture by Amberlite XAD-7. 1.5 mL Eppendorf tubes filled with 20 mg 
of XAD-7 resin were utilized for each experiment. One clarified fermentation 
broth was filled into the tubes; the temperature was set at 25 ºC and agitation 
rate to 1200 rpm. The quantity of adsorbed and desorbed PGDM was 
determined by HPLC as described in section 2.5.3. The optimisation 
experiments are described in the following sections.  
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2.7.1 Optimisation of product capture on XAD-7 
 
1 mL each of clarified fermentation broth adjusted to a pH of 5, 6, 7, 8, and 9, 
was pipetted into 1.5 mL eppendorf tubes. 20 mg of Amberlite XAD-7 resin was 
added to the broth in each Eppendorf tube and shaken on the thermo-mixer at 
25°C and 1200 rpm for 90 minutes. Samples of broth were pipetted into HPLC 
vials and analysed to determine antibiotic uptake (Section 2.5.3). 
 
The Eppendorf tubes were then centrifuged at 10,000 rpm, decanted to remove 
supernatant and refilled with 1 mL of wash buffer at pH 5, 6, 7, 8 and 9. The 
resin wash was repeated 3 times, before elution was performed using a 60 % 
(v/v) Methanol/0.05 M sulphuric acid elution buffer. HPLC analysis as described 
in Secition 2.5.3 was performed on all samples for each wash step and the 
PGDM elution step. In wash analysis by HPLC, where there was no detectable 
PGDM present, a sum of the total area for all impurity peaks ( in milli-
absorbance units, mAU) on the chromatogram was used as a representation of 
the amount of impurity released by the resin during wash of an individual 
sample. A comparison between the total HPLC chromatogram impurity peak 
area, for the various samples, was used to determine impurity removal 
efficiency of the wash buffer in the individual eppendorf tube. 
    
2.7.2 Optimisation of product elution from XAD-7 
 
1 mL of clarified fermentation broth, adjusted to pH 6, was pipetted into 1.5 mL 
eppendorf tubes. The tubes were filled with 20 mg of XAD-7 resin each and 
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adsorption of PGDM was performed by shaking at 25 ºC and 1200 rpm as 
described in Section 2.7. 
 
The beads were then washed with 0.06 M phosphate buffer at pH 7. Once 
washing was complete, the eppendorf tubes were spun at 10,000 rpm, 
decanted and refilled with the elution liquid composed of Methanol and a 
sulphuric acid (H2SO4) solution co-solvent. Methanol concentration was 
adjusted from 0 % (v/v) to 100 % (v/v). The ionic strength of the H2SO4 co-
solvent was adjusted between nil and 0.005 M. Elution was performed in two 
batches with samples analysed using HPLC to determine amount and purity of 
eluted antibiotic (Section 2.5.3). 
 
2.7.3 Optimisation of impurity removal from XAD-7 
 
1 mL of clarified fermentation broth was used for PGDM adsorption onto 20 mg 
of XAD-7 resin as described in Section 2.7.2.   
 
The beads were then washed with a wash buffer composed of 0 to 10 % (v/v) 
Methanol and 0.02 to 0.06 M phosphate buffer at pH 7. After 60 minutes of 
washing, each wash sample was analysed for the presence of PGDM. Where 
PGDM was not present, the sum of the total area of all impurity peaks was used 
as representative of impurity removal from the XAD-7 resin beads (Section 
2.7.1). A comparison of total impurity removal (total impurity peak area in mAU ) 
from each sample was used to determine the optimal resin wash. 
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Elution was then performed using 80% (v/v) Methanol/0.05 M sulphuric acid. 
The purity and concentration of PGDM as determined by HPLC for each 
sample, (Section 2.5.3) was used to confirm the optimal conditions for XAD-7 
impurity removal.      
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3. Optimisation of Pregallidermin 
production by Fed-batch 
fermentation of S.gallinarum Δp 
 
3.1 Introduction and Aims 
 
It is important to realise that in order for any useful benefits to be derived from 
the novel antibiotic candidates under consideration, they must be producible at 
scale. Scale production of compounds using biological organisms relies on 
fermentative culture in bioreactors. Large scale bioreactors have environments 
that differ substantially from lab-scale environments, with completely different 
engineering parameters and mass transfer methods. Thus for large scale 
production of any novel compound, the choice of chasis organism and its 
interaction with the bioreactor environment becomes crucial in the compounds 
commercial viability (Zhang et al., 2016). 
 
The ability to develop platform processes, that can be used to produce the 
novel compounds at scale thus become an important component in developing 
the ability to rapidly deal with outbreaks of novel or multidrug resistant bacteria. 
To develop such platform processes would require an understanding of the 
behaviour of the chosen chasis organisms under pilot-scale and large scale 
fermentation conditions. 
 
Thus in order to optimise the production of a candidate antibiotic compound, it is 
vital that the various environmental interactions and engineering parameters at 
which the organism thrives and yields the most antibiotic are studied. In the 
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following research a genetically modified organism Staphylococcus 
gallinarum∆gdmP::aphIII, a knock-out mutant (Valsesia et al., 2007), which 
produces the novel antibiotic compound pregallidermin is investigated for the 
optimisation of antibiotic production with respect to the crucial engineering 
parameters in scale fermentation.  
 
As described in Section 1.9, the aim of this Chapter is to establish a 
reproducible and scalable fermentation process for the production of PGDM by 
S.gallinarum Δp. The focus is on production of PGDM rather than gallidermin 
directly because the gallidermin displays host cell auto-toxicity, which limits 
achievable titres in culture (Section 1.3.9). The specific objectives are as 
follows: 
  
 To characterise PGDM production in batch and fed-batch cultures of 
S.gallinarum Δp in laboratory scale (7.5 L) stirred tank bioreactors (STR). 
 
 To examine the impact of different feeding regimes and aeration control 
strategies on the efficiency of PGDM production. 
 
 To establish the scale-up of the fed-batch PGDM fermentation process to 
a small pilot-scale (30 L) fermenter 
 
 
 To compare PGDM production at various scales to determine critical 
parameters for fermentation scale-up. PGDM was identified and 
quantified using HPLC and MS, outlined in section 2.5.3 and 2.5.4. 
Product identity confirmed by spectra in Figure 4.5. 
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3.2 Overview of fermentation development 
strategy 
The research presented in this Chapter aims to understand the impact of 
various engineering parameters on the cellular growth of S.gallinarum Δp and 
production of the novel antibiotic PGDM. The data acquired is intended to 
illuminate the scalability and reproducibility of S.gallinarum Δp fermentations 
and provide material for study in subsequent parts of this thesis. 
 
The approach to fermentation development and the different scales of fermenter 
used is summarised in Figure 3.1. Initial experiments were perfomed in shake 
flasks to determine cellular batch growth kinetics. Subsequently studies were 
performed in laboratory scale fermenters to examine feed regimes and aeration 
strategies to characterise their impact on growth. Finally, attempts are made to 
replicate cell growth and PGDM production at 30 L scale, with a view to 
analysing the importance of the characterised parameters on scale up. Table 
3.1 summarises the main findings from all the stirred bioreactor studies. These 
will be described in further detail in the following sections. 
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Figure 3.1 Overview of the types of fermentation performed as outlined in Section 2.2. 
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3.3 Shake Flask culture 
 
In order to understand the initial growth parameters of the S.gallinarum Δp, 
shake flask cultures with a 10 % inoculum were performed. The 1:9 ratio for 
pre-culture and media were kept uniform for all fermentations. After inoculation, 
1 mL samples were taken every hour in order to map the batch growth kinetics. 
Figure 3.2 illustrates the growth of S.gallinarum Δp.   
 
From the growth curves it is visible that S.gallinarum Δp is a rapidly growing 
organism, obtaining maximum biomass in about 11 hours of growth. To 
determine the fastest period of growth for the organism, it is useful to convert 
cellular growth to a logarithmic scale.  Figure 3.3 illustrates the logarithmic 
growth of the organism. The period of fastest growth (the exponential growth 
phase) of the organism is found to be between 1- 4 hours after inoculation. The 
fastest specific growth rate achieved by the organism is 1 h-1.  
 
The total increase in cell biomass as demonstrated by the data is 4 orders of 
magnitude within the experimental time. In order to achieve higher cell 
densities, it would be important to prolong the exponential phase as much as 
possible, as the lantibiotic gallidermin displays primary metabolite kinetics, and 
hence maximum biomass would lead to maximum lantibiotic yield (Medaglia, 
2009).  
 
Shake flask studies on S.Gallinarum Δp have previously been performed by 
both Valsesia (2008) and Medaglia (2009). In the latter case these studies were 
briefly done for the preparation of inocula and testing of cellular growth in a 
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selection of liquid culture media. However, the shake flask studies performed by 
Valsesia (2008) produced amounts of PGDM detectable by HPLC. Earlier 
experiments in shake flasks by Kempf et al., 2000 with the wild type 
Stapylococcus gallinarum Tϋ3928 had also produced detectable quantities of 
the wild type gallidermin, considering the PGDM is the precursor, it would be 
expected that expression would follow the same profile as the active lantibiotic. 
It is worth noting that this was not the case with   the current work, which was 
unexpected as the secretion of a primary metabolite in solution should match 
cellular growth. 
 
Shake flask cultures are an important tool for the determination of preliminary 
data on bacterial growth characteristics. However in order to the conditions 
necessary to achieve optimal bacterial growth over a sustained period, other 
parameters such as dissolved oxygen, aeration and mixing are required which 
are beyond the scope of the shake flask setup to determine. These are 
examined in the following sections. 
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Figure 3.2 Representative shake flask batch growth kinetic profile of Staphylococcus 
gallinarum Δp. The error bars represent one standard deviation about the mean. (n=3, 
average of 3 fermentations) Experiments performed as described in Section 2.2.1. 
 
 
 
 
 
 
Figure 3.3 Logarithmic growth curve for Staphylococcus gallinarum Δp. The error bars 
represent one standard deviation around the mean. (n=3) 
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3.4 7.5 L STR Fermentation: S.gallinarum Δp 
growth in batch mode 
 
Batch fermentations were performed at 7.5 L scale with a 10 % inoculation 
(Section 2.2.2). The 5 L stirred tank bioreactor allows for the control of a larger 
number of engineering parameters than shake flask fermentations, allowing for 
a greater degree of control to be exerted on the bacterial growth. The attached 
mass spectrometer allowed the off-gas to be analysed for CER (carbon 
evolution rate) and OUR (oxygen uptake rate), allowing for the calculation of the 
respiratory quotient (RQ) in order to relate the two parameters to cellular 
growth.  
 
The results in figure 3.4 show that as the cells grow, an increase in the CER 
and OUR is observed, especially in the exponential growth phase.  The 
agitation rate similarly increases with increasing cellular growth, which is logical 
as growing cells put greater pressure on the oxygen availability, requiring higher 
fluid agitation to ensure greater oxygen distribution and maintain DOT. The 
growth pattern was similar to the shake flask kinetics, with a rapid exponential 
phase lasting about 5 hours. The OUR and CER follow each other quite closely, 
both increasing as the exponential growth progressed. However both drop off 
considerably when biomass increase declines, illustrating the much reduced 
oxygen requirements for cellular maintenance as opposed to growth. The 
corresponding drop in agitation rate from about 700 rpm to roughly 300 rpm 
reinforces this assessment. 
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Figure 3.5 displays the RQ for the duration of the fermentation and as is visible 
the value was approximately 1, which suggests that the cells prefer 
carbohydrate as the main growth substrate. However, it is also visible from 
figure 3.4 A that cellular growth drops-off with no corresponding drop in RQ, 
which suggests that in Medium 21B, growth was limited by a nutrient other than 
carbohydrates.  
 
It is of note that the 21B medium used for the experimental set-up is composed 
of yeast extract, which is a complex combination of autolysed carbohydrates 
and proteins. The reason for the choice is the ease of making the media and 
low-cost of the components, characteristics suitable for platform production 
processes. However the media complexity means that precise composition by 
mass of proteins as opposed to carbohydrates is uncertain. This is significant as 
the RQ indicates carbohydrate to be the preferred growth substrate for the 
organism, suggesting media with higher sugar content may be a better choice. 
The data indicates that 21B media containing 50 g.L-1 of yeast extract results in 
a biomass yield of roughly 12.5 g.L-1. This computes to a biomass conversion 
ratio of roughly 1:4 at a DOT of 40 %.  
 
It is however interesting to note that when the batch process was tested for the 
presence of the lantibiotic pregallidermin (Section 2.5.3), it was found that none 
was present. Considering that pregallidermin has been shown to display 
primary metabolite kinetics (Valsesia et al., 2007), this was unexpected. It has 
been suggested previously that lantibiotic production is initiated by quorum 
sensing (Heinman & Panke, 2006; Kleerbezem, 2004); hence it is possible that 
the cellular biomass concentration is simply not high enough for a quorum to 
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form. Work by Kempf et al. (1999) with the wild-type strain had determined that 
the use of an appropriate feeding strategy was important to maximise the 
production of lantibiotic. Studies by Medaglia (2009) on the use of various 
substrate feeds to S.gallinarum Δp had demonstrated a culture that had not 
been fed any substrate (i.e. essentially a batch culture) produced very little 
detectable PGDM during the exponential growth phase, which later disappeared 
from solution during the stationary phase. It is also notable that Medaglia’s 
(2009) fermentation had a biomass yield of about 20 g.L-1, which is significantly 
higher than the 12.5 g.L-1 generated in this work. This difference may potentially 
be due to differences in aeration and agitation strategy, though this is difficult to 
determine as Medaglia (2009) did not characterise these parameters. 
 
Additionally, Medaglia (2009) showed that PGDM degraded much faster in 
media that had low sugar content; hence it is possible that even if a small 
amount of PGDM was produced, it degraded rapidly.    
 
Also of note is the initial reduction in the OUR and CER after 3 hours of 
fermentation. As the two parameters closely map the growth of S.gallinarum Δp, 
it is suggested that some kind of metabolic shift takes place, possibly from the 
preferred media substrate to the second substrate. An examination of the RQ 
provides no clue as to what happened, experimentation with defined media 
would be suggested to establish the organism’s preference; however such 
experimentation is beyond the scope of this research. 
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A 
 
 
B 
 
 
 
 
Figure 3.4 Batch growth kinetics of Staphylococcus gallinarum Δp at 7.5 L scale. (A) 
Biomass increase with DOT maintained at 40% (B) the corresponding OUR, CER and 
Agitation profiles. Error bars represent one standard deviation around the mean (n=3, 
average of 3 fermentations). Fermentations performed as described in Section 2.2.2. A 
summary of fermentation performance is provided in Table 3.2. 
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Figure 3.5 RQ profile for the 7.5L scale batch fermentation of Staphylococcus gallinarum Δp  
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3.5 7.5 L STR Fermentation: S.gallinarum Δp 
growth in fed-batch mode 
 
The data from the 7.5 L STR in Figure 3.4 illustrates the substrate limitations to 
growth and lantibiotic production in batch mode. It also appears that the 
biomass achieved was insufficient to initiate lantibiotic production. In order to 
achieve a higher biomass and subsequently initiate pregallidermin production, a 
fed-batch mode of operation was pursued with a 500 g.L-1 maltose solution 
chosen as the feed (Section 2.2.3). Maltose offers the highest pregallidermin 
production out of a selection of simple sugars (Medaglia, 2009).   
 
After running a fed-batch culture using a maltose feed only (Figure 3.6), it again 
became apparent that there was a limiting reactant present in the media and 
feed combination. The continued feeding of maltose did not lead to any 
increase in biomass beyond 30 g.L-1, a result consistent with previous studies 
by Medaglia (2009).This lead to the assumption that a nitrogen source (protein) 
or a different medium nutrient had become growth limiting.  As yeast extract is a 
complex combination of proteins, carbohydrates and other simple components, 
a yeast feed of 300 g.L-1 was used as the nitrogen source. This dual feed 
method was applied in order to achieve high lantibiotic production, which 
seemingly necessitates a high cell density culture. 
 
 
 
 
 
 
 
 
Haroon D.S. Khan  Chapter 3 
 
107 
 
3.5.1 Fed-batch – Maltose feed 
 
As shown in Figure 3.6, the use of a maltose feed resulted in a total biomass of 
30 g.L-1, in comparison to 12.5 g.L-1 achieved in batch mode. Engineering 
parameters such as temperature, pH and DOT were maintained at the same 
levels as the batch fermentations. It is important to note that the maltose feed 
resulted in the production of pregallidermin, which indicates a cell density high 
enough to activate quorum sensing. Additionally, it could also suggest that the 
addition of a concentrated maltose feed prevents the pregallidermin from 
degrading in culture (Medaglia, 2009).  
 
It is also notable that the growth kinetics, of the fed-batch culture, were similar 
to batch culture and the provision of extra-nutrients did not prolong the 
exponential growth phase. Similarly increasing the amount of maltose in 
solution further did not result in a corresponding increase in biomass above 30 
g.L-1. Additionally, as in the batch fermentation (Figure 3.5), the RQ for the fed-
batch fermentation (Figure 3.7 B) stayed at approximately 1, indicating that the 
cells continued to use carbohydrate as the principle substrate and providing 
further evidence that some other medium component was limiting growth.  
 
When the biomass achievable in batch mode (12.5 g.L-1) is accounted to the 
fermentation media alone, the new biomass accountable to maltose addition 
alone is determined to be 17.5 g.L-1 from the addition of 70 g.L-1 maltose. The 
resultant biomass to substrate conversion ratio achieved overall is 1:4; however 
it is visible that conversion efficiency was greater at the start of exponential 
phase as opposed to the late exponential phase and stationary phase. Hence it 
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could be assumed that prolonging the exponential phase would result in 
utilization of the carbon source more efficiently. 
 
What does however, become clear from the fed-batch growth of S.gallinarum 
Δp is that achieving high cell density fermentations requires certain key 
variables to be adjusted at an exponential rate. The agitation rate in Figure 3.6 
C, mirrors cellular growth (Figure 3.6 A), with increasing agitation signalling 
growth and decreasing agitation indicating the slowing of cellular growth and the 
beginning of stationary phase for cell maintenance. The cascade system 
involving agitation rate and DOT was adequate to maintain the DOT at 30 %.  
 
It is notable though that the aeration rate must also be increased with the 
cellular growth rate. This was unexpected as it was assumed that maintaining a 
DOT set-point of 30 % would be sufficient to cater to the oxygenation and 
aeration needs of cellular growth. However as is apparent, aeration was 
manually adjusted to mirror the cellular growth in the exponential phase, starting 
at 3 L.h-1 (1 vvm of the starting volume of the culture) and ending at 9 L.h-1, 
triple the initial aeration rate (and roughly 2 vvm of final bioreactor volume).  
 
The feed-regime (Figure 3.7A) also maps the growth of S.gallinarum Δp, 
however the bioreactor utilized for the culture did not possess the ability to 
employ an exponential feed regime. In order to map the growth rate of the 
organism with the feed regime, feeding was started once the dry cell weight 
became 1 g.L-1 and manually adjusted to follow growth by adjusting the feed 
rate every hour in a step-up pattern.  
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The final feed rate broadly follows the equation:     
                      (3.1) 
Where y is the feed rate in g.L-1.h-1and x is the time in hours. 
 
Equation 3.1 seems to indicate a very linear relationship between the feed 
requirements and cellular growth. 
 
Pregallidermin production began once the cellular dry cell mass approached 25 
g.L-1 and continued with the growth in mass (Figure 3.6 A). However, lantibiotic 
production stopped as soon as growth slowed down, demonstrating primary 
metabolite kinetics, and did not restart with an increase in the maltose 
concentration.  
 
The average cellular growth profile of multiple (n=3) fed-batch fermentations 
was consistent with a maltose based fed cultivation performed by Medaglia 
(2009) and Valsesia et al. (2007). However, it is notable that the present work 
produced significantly lower PGDM; a maximum of 0.1 g.L-1 in comparison to 
almost 0.6 g.L-1in both previous studies. This was unexpected and it is unclear 
exactly why this happened. A possible explanation is variability in the aeration 
and agitation regimes, Medaglia (2009) ensured the DOT was maintained 
above 20%, however in both cases details were not provided on the 
adjustments made to achieve this. Thus it is difficult to ascertain the cause of 
the reduced yield without characterisation of these parameters. 
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However, the results were consistent in showing that there is a limit to biomass 
yield based on just maltose addition, and further feeding did not coerce any 
more cellular growth.      
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Figure 3.6 Fed-batch growth kinetics of Staphylococcus gallinarum Δp at 7.5L scale 
using a maltose feed.(A) showing cell growth, the maltose feed and PGDM production. 
(B) DOT and the aeration rate. (C) Agitation, CER and OUR (Off-gas analysis) as 
fermentation progresses. The error bars represent one standard deviation about the 
mean (n= 3, average of 3 fermentations).Fermentations performed as described in 
Section 2.2.3. A summary of fermentation performance is provided in Table 3.1.  
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Figure 3.7 Fed-batch growth of Staphyloccocus gallinarum Δp on 21B medium and 
500g.L-1 maltose feed at 7.5L scale with A) showing the maltose feed rate and feed 
profile applied to the culture and B) showing the RQ.  
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3.5.2 Fed Batch- Maltose and yeast extract feed  
 
The culture of S.gallinarum Δp in fed-batch mode with only maltose as the 
additional carbon source did not reach very high cell densities and subsequently 
did not produce correspondingly high levels of lantibiotic. Yeast-extract (300 g.L-
1) was introduced as a secondary feed with a view to providing a protein source 
and ensuring that growth is not limited by the absence of a nitrogen source or 
any other component in the medium (Section 3.5).   
 
Figure 3.8 illustrates the use of a dual feed fed-batch system (Section 2.2.3), 
which allowed the dry cell mass to reach around 120 g.L-1.  The corresponding 
yield of PGDM from the fermentation was around 350 mg. The provision of a 
protein source in the form of a yeast-extract feed allowed for an extension in the 
exponential growth phase from 3 hours to roughly 6 hours. The results confirm 
the nitrogen substrate limitation placed on a fed-batch system with only maltose 
as an additional carbon source. 
 
The trends from the dual feed setup reconfirm the importance of mirroring the 
cellular growth pattern with the process inputs such as aeration and the feed 
streams. The parameters all map the growth pattern of s.gallinarum Δp in its 
exponential growth phase, indicating that to prolong cellular growth, a dynamic 
bioreactor environment must be provided where any of the carbon source 
(maltose), nitrogen source (yeast-extract protein) and airflow rate cannot be 
limiting to growth. 
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The system generated about 110 g.L-1 of additional biomass (compared to the 
7.5 L batch fermentation, with no added maltose in Section 3.4) using 120 g.L-1 
of maltose. This translates to a yield of biomass on substrate of 0.9 g.g-1 for the 
complete fermentation as opposed to 0.25 g.g-1 in cultures without the presence 
of yeast-extract. PGDM production also tripled, however at quadruple the total 
cell biomass of the single feed fed-batch culture.  
 
The aeration rate was increased to map the growth pattern of S.gallinarum Δp, 
notably this was done even without a corresponding drop in the DOT set-point. 
It appears that to promote high cell density culture with S.gallinarum Δp, the 
aeration becomes a critical factor indicating that the bacteria is highly aerobic. 
The data indicates that a doubling of the airflow rate corresponds to roughly a 
doubling of the biomass during the organisms’ exponential growth phase.   
 
 It is also notable that in order to maintain the DOT set-point, gas blending was 
performed on the air flowing into the bioreactor. The gas-blending operated in a 
cascade mechanism synchronised with the agitation, where any fall in DOT 
upon reaching the maximum agitation rate would initiate pure oxygen to be 
blended into the air supply. The initiation of pure oxygen blending meant that 
the concentration of oxygen exiting the bioreactor in the off-gas was higher than 
in the air inlet, hence at this time the OUR readings became unreliable (this 
occurred at the end of the cellular exponential growth phase, as can be seen by 
the agitation rate flattening and hitting a maximum in figure 3.9 B, as a result 
only the CER readings for these fermentations have been provided). 
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However, it is still possible to compute the fermentation RQ profile by excluding 
the time period with unreliable OUR values (data not shown). The RQ values for 
the dual-feed fed-batch culture are illustrated in Figure 3.9 C. The data 
suggests that the primary substrate for the fermentation was no longer 
carbohydrate, rather as the RQ is roughly between 0.7 - 0.8, it appears that a 
mixture of nutrients is being utilised by the cell. As the culture resulted in a very 
high level of biomass, it would appear to support the suggestion made earlier in 
section 3.5.1 that high cell density cultivations of S.gallinarum Δp require the 
presence of additional nutrients present in the yeast-extract to continue cellular 
growth.      
 
The maltose and yeast extract feeds were manually adjusted (using separate 
Watson-Marlow 101 U/R pumps) in a ‘step-up’ feeding regimen (Figure 3.9 A). 
The maltose feed was started earlier as in Section 3.5.1, when dry cell mass 
approached 1 g.L-1. In comparison, yeast-extract feeding was only started once 
the cells were in early exponential phase and stepped-up hourly until the 
maximum achievable (Figure 3.9 A). The final maltose feed profile broadly 
follows the linear equation:     
                      (3.2) 
Where y is the feed rate in g.L-1.h-1and x is the time in hours. 
 
It is notable from Equation 3.2, that in comparison to the fed-batch culture 
utilising only maltose as the feed in Equation 3.1, the dual-feed system uses 
twice as much maltose per hour. This was likely because the dual feed system 
successfully prolonged the cells exponential growth phase, meaning higher 
substrate requirements for longer. It also provides further evidence that 
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S.gallinarum Δp requires certain additional nutrients, which are present in the 
yeast-extract to maintain cellular growth. Thus, high cell density cultures cannot 
be grown using just an additional carbon source.  
    
It was also notable that during cellular exponential growth phase, on average 
the feed rate of the maltose was roughly 3 times the feed rate of yeast-extract 
(Figure 3.9 A), suggesting that a ratio of 3:1 maltose to yeast extract could 
provide suitable substrate requirements for fast growing cells and thus enable 
an elongation of the exponential growth phase by maintaining a dynamic 
nutrient microenvironment within the bioreactor.  
 
Additionally, the CER closely mapped the production of PGDM (Figure 3.9 B). 
This suggests that PGDM is a normal by-product of cellular respiration for 
S.gallinarum Δp. 
 
 
Kempf et al. (1999) had studied the growth of the wild-type S.gallinarum and 
found that improving the production of lantibiotic required the addition of a 
source of peptides. As the 21B medium component yeast-extract is a mixture of 
proteins and carbohydrates, it is reasonable to suggest that the use of a yeast-
extract feed provides this additional nutrient requirement. Biomass yield for the 
dual-feed approach was comparable to similar studies conducted by Medaglia 
(2009), however as in the case of the maltose-only fed-batch cultivation, the 
yield of PGDM for the present study was significantly lower, 0.35 g.L-1 
compared to 1.2 g.L-1 for the previous study.  
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As in the previous instance, Medaglia (2009) did not characterise the aeration 
strategy and agitation strategy and thus, there it is not possible to compare 
these parameters to spot potential differences. However, a notable difference is 
Medaglia’s (2009) use of an exponential feeding strategy as compared to a step 
change or step-up strategy in the current work. It is suggested that an 
exponential feed strategy better predicts the growth profile of the cells in 
exponential growth phase, and hence is better able to emulate the nutrient 
requirements. Thus, the varying feed-strategies could be the source of the 
difference in product titres.  
 
However, it is notable that a step-up profile is simpler to reproduce than an 
exponential profile, in cases where the bioreactors and pumps cannot be easily 
programmed or lack the capacity to use exponential regimes. Thus, from the 
perspective of developing a platform process, being able to easily reproduce 
results may be of greater importance for the initial lantibiotic production to 
enable optimization studies that allow simultaneous process development. 
 
Another difference between this work and studies by Medaglia (2009) was the 
lack of excessive foaming that was observed by the latter. Foaming in the 
present fermentation was easily controlled by the addition of anti-foam via 
bioreactors automated control system and provided no impediment to the 
continuation of fermentation. 
 
The results also demonstrate that high cellular growth requires all key 
parameters to map each other, creating a dynamic bioreactor environment. 
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Such conditions have previously been demonstrated to increase productivity 
and product quality (Spadiut et al., 2013).    
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Figure 3.8 Fed-batch growth kinetics of Staphylococcus gallinarum Δp at 7.5L scale 
using dual Maltose and yeast extract feed.(A) Biomass and pregallidermin production. 
(B) Cumulative maltose (500g.L
-1
) and yeast extract (300g.L
-1
) feed addition. (C) 
Aeration and DOT (set-point minimum 30%). Error bars represent one standard 
deviation around the mean. (n=2).Fermentations performed as described in Section 
2.2.3. A summary of fermentation performance is provided in Table 3.2.  
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Figure 3.9 Fed-batch growth of Staphylococcus gallinarum Δp at 7.5L scale using dual 
maltose and yeast extract feed with A) showing the feed rates of the 500g.L
-1
 maltose 
feed and 300g.L
-1
 yeast-extract feed B) the agitation rate and CER and C) the RQ. Error 
bars represent one standard deviation around the mean. (n=2). Fermentations 
performed as described in Section 2.2.3. 
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3.6 30 L STR Fermentation: Scale up of 
pregallidermin production 
 
 
In order to produce enough material for subsequent purification studies in 
Chapter 4, the fermentation process was scaled-up to 30 L scale (Section 
2.2.4). Figures 3.10 and Figure 3.11 show the results of the fermentation along 
with the critical parameters outlined in previous fermentations. The dry cell 
weight achieved by the S.gallinarum Δp was 105 g.L-1, while PGDM yield was 
0.7 g.L-1, more than twice the yield at 7.5 L scale. 
 
It is clearly visible that the trends outlined by experiments at 7.5 L scale are 
displayed at 30 L scale, suggesting reproducibility at scale by ensuring that 
parameters such as feed regime and aeration closely map the cellular growth 
pattern. As suggested at 7.5 L scale in Section 3.5.2, the ratio of maltose to 
yeast extract feed solutions was modified to 3:1, with a maltose feed of 600 g.L-
1 and a yeast-extract feed of 200 g.L-1. This change benefits the process by 
making the experimental set-up simpler i.e. by using a constant ratio between 
the feeds; a single pump can be used for both, discarding the necessity of 
having to make manual adjustments to two individual pumps in an effort to 
closely map cellular growth. Instead, a gate clamp can be used on the yeast-
extract feed tube until the beginning of exponential growth phase to ensure the 
feed is pumped into the broth at the correct time.    
 
The step-up feeding regime from Section 3.5.2 was replicated for the culture 
and the exponential growth phase of the cells was successfully elongated to 6 
hours. The importance of maintaining the nutrient balance between maltose and 
yeast-extract was illustrated by the fact that when yeast-extract feed ran out 
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after a total cumulative addition to the broth of  40 g.L-1 (Figure 3.10 B), bacterial 
growth slowed dramatically and entered stationary phase (Figure 3.10 A), the 
addition of extra maltose did not coerce any more increase in biomass. The 30 
L scale fermentation generated an additional 93 g.L-1 of biomass (as compared 
to the batch fermentation in Section 3.4), for the addition of about 110 g.L-1 of 
maltose. This translates to a yield of biomass on substrate of about 0.84 g.g-1 
compared to 0.9 g.g-1 at 7.5 L scale.  
 
Aeration was manually adjusted to map growth patterns, however, when 
aeration was maintained at 16 L.min-1, a sharp drop in the off-gas carbon 
dioxide concentration from 3 % to 2 % was noted. Unfortunately, as the oxygen 
detector malfunctioned shortly into the fermentation, the OUR rates could not be 
obtained, meaning the RQ could not be calculated. However, previous 
fermentations in Section 3.5 had demonstrated that the CER closely mapped 
cellular growth in the exponential phase; hence a drop in this rate suggested a 
potential slowdown in cell growth. 
 
The subsequent increase in aeration to 20 L.min-1 (Figure 3.11 A) caused a 
jump in bacterial growth, suggesting that aeration had become growth limiting at 
that stage, reinforcing the highly aerobic nature of S.gallinarum Δp.  A provision 
was made for gas blending, however at no point did DOT dip significantly 
enough below the set-point to activate the oxygen blending cascade. This was 
unexpected as gas blending had been necessary in all the 7.5 L scale 
fermentations using the dual feed mode of operation.  
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The production of lantibiotic pregallidermin closely mapped the bacterial 
exponential growth phase, with additional expression appearing to halt in the 
stationary phase. It is however notable that PGDM expression starts earlier at 
30 L scale as opposed to 7.5 L scale, at a time of 3 hours post inoculation as 
opposed to 6 hours respectively. This could potentially be explained by the total 
biomass present in culture, meaning the total biomass required to activate 
quorum sensing could be achieved earlier at larger scales. 
 
The minimum agitation rate at 30 L scale was 400 rpm (bioreactor cascade 
setup requirements) and the maximum was 1000 rpm, as opposed to a 
maximum of 1200 rpm at 7.5 L scale. The agitation rate never hit maximum 
(Figure 3.11 B), this could be due to the differences in mass transfer rate 
impacted by vessel geometry and impeller radii, however those parameters are 
beyond the scope of this work to investigate.                                           
 
The application of the aeration and feed strategy developed at 7.5 L scale to a 
30 L fermentation was successfully able to replicate the previous cellular growth 
profile. However, in comparison to the smaller scale fermentation, the 30 L 
culture yielded twice the amount of pregallidermin per litre. This suggests that 
there could be a link between the total overall mass of cells in culture and the 
yield of product. However, this is still significantly lower than that achieved by 
Medaglia (2009) at smaller scale. Possible reasons for the lower yield have 
been suggested in Section 3.5.2.  
 
Pilot scale fermentations for active lantibiotic production have previously been 
conducted by Arias et al. (2013) and Kempf et al. (2000). In both studies, the 
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authors did not characterise the bioreactor microenvironment or the engineering 
parameters used.  
 
However, in the study by Kempf et al. (2000), where fermentations were 
performed in a 20 L pilot scale bioreactor and a simulated 200 L bioreactor, it is 
notable that the highest yield of wild-type gallidermin was 0.33 g.L-1, less than 
half the 0.7 g.L-1 of pregallidermin (which equates to 0.45 g.L-1 of active 
gallidermin) produced in the present study. This suggests that production of 
lantibiotic precursors in fermentation is a viable step in an overall production 
process for active lantibiotics.   
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Figure 3.10 Fed-batch growth kinetics of Staphyloccocus gallinarum Δp at 30L scale 
using dual feed of maltose and yeast extract.(A) Biomass and pregallidermin 
production. (B) Cumulative total maltose (600g.L
-1
) and yeast extract (200g.L
-1
) feed 
added to culture and  (C) showing the feed rates. Fermentation performed as described 
in Section 2.2.4. A summary of fermentation kinetics is provided in Table 3.2 
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Figure 3.11 Fed-batch growth of Staphyloccocus gallinarum Δp at 30L scale using dual 
feed of maltose and yeast extract with A) showing aeration and DOT (set-point 30%) 
and B)showing  Agitation and CER (Determined by the BIOStat C-Plus as a percentage 
of total exit gas). Fermentation performed as described in Section 2.2.4. A summary of 
fermentation kinetics is provided in Table 3.2 
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3.7 Factors influencing the oxidative production 
of PGDM by S.gallinarum Δp 
 
3.7.1 Aeration 
 
The aeration regime of the bacterial culture appeared to have a significant 
impact on growth and lantibiotic production. The growth rate appeared heavily 
linked to aeration strategy, specifically the vessel airflow rate. This was 
unexpected as the maintenance of DOT above the set-point implies that the 
dissolved oxygen concentration of the culture should be sufficient for bacterial 
growth as suggested by Medaglia, (2009). However it was clearly visible that 
even when the DOT was sustained at 30 %, increases in airflow rates led to 
increases in cell biomass. 
 
The DOT or the available dissolved oxygen in the fermenter broth can be linked 
to the KLA, an oxygen mass transfer coefficient through the cellular OUR and 
OTR (Klöckner et al., 2013, Garcia-Ochoa et al., 2010). To achieve cellular 
growth, the available oxygen in solution must exceed the critical level required 
for cellular maintenance. However the introduction of higher input airflow rates 
increases the absolute mass of oxygen made available, notably in this case 
without an impact on DOT, contrary to the expected spike in DOT, it is 
sustained at the set point. This could possibly indicate that the added mass of 
oxygen is being consumed for cellular respiration and the cells require a 
minimum DOT above 30 % to maintain growth rates. Studies using the wild type 
S.gallinarum Tϋ3928 indicate that oxygen saturation during cellular growth 
phase is important to achieve high cellular biomass (Kempf et al., 1997). 
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 It is also possible that in a high cell density environment, the high rates of 
agitation rate required to maintain DOT prevents the cells in culture from 
adequately utilising the oxygen, indeed high rates of agitation have been 
demonstrated to have a negative impact on cellular growth in certain cell 
cultures (Ducros et al., 2009). Thus, it is possible DOT is maintained purely 
because a large amount of the oxygen is unconsumed, requiring an increasing 
mass of oxygen to meet cellular respiration needs. Indeed the drop in carbon 
dioxide evolution noted at the 30 L scale when the input airflow was sustained 
at 16 L.min-1 would seem to indicate that it is the additional oxygen being 
consumed for cellular growth. 
 
In order to gain a better understanding of the impact of airflow rate versus DOT 
on cellular growth, it is useful to examine a study conducted under a constant 
aeration rate. Batch cultures where DOT was sustained purely by changes in 
agitation rate under constant airflow did not achieve high cell densities (Section 
3.4). However it is beyond the scope of this work to perform a detailed analysis 
on the impacts of both these parameters on the mass transfer efficiency in 
solution. 
 
Consistent with previous studies by Medaglia, (2009) and Valsesia et al. (2007) 
involving fermentation of S.gallinarum Δp, the aeration rate was maximised in 
order to ensure high cellular growth. However, contrary to the both previous 
studies, it was found that the aeration rate needed to be increased in concert 
with agitation rates to achieve high cell density cultures, even when no fall in 
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DOT was observed. This suggests a crucial role for aeration strategy in process 
reproducibility. 
3.7.2 Feed 
 
Maximum cellular growth was obtained by emulating cellular growth patterns 
with the dual component feed setup. The high cell density dual feed 
fermentation was performed using a ‘step-up’ feed strategy, with the feed rate 
manually adjusted through the duration of the fermentation. The maltose feed 
rate profile for high cell density fermentation can be described by the linear 
equation: 
                  (3.3) 
Where t is the feed rate in g.L-1.h-1and x is the time in hours. 
 
It must be noted that feeding was only started after 1 g.L-1of cell density had 
been attained; this was used as a signal that cells had started growing steadily 
post inoculation (typical fermenter cell density immediately post inoculation was 
0.3 g.L-1, data not shown). Equation 3.3 indicates that high cell density cultures 
require the feed rate to be doubled every hour, a simple correlation which 
should be easy to calculate and replicate. 
 
However, it is worth mentioning that using a linear feeding regimen means that 
cellular growth patterns can be replicated with less precision, as such regimes 
have a tendency to overfeed in the initial stages when growth is slow and 
underfeed in the latter stages, when growth is high. This also applies to step-up 
feeding regimes, however step-up regimes allow a capacity for adjustment to 
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the feed rate based on observation of other parameters such as agitation rate 
and RQ. This capacity for reacting to changes in fermentation parameters 
means that a step-up feed regime can maintain dynamic conditions in the 
bioreactor (Spadiut et al., 2013).  
 
While using a linear feed is much easier in terms of setting up the system and it 
requires fewer calculations in determining a feed pumping rate, the reduced 
dynamism inherent in the strategy may prevent it from achieving high cell 
density cultures and as a consequence reduce the lantibiotic yield. Data from 
the fermentations performed in Sections 3.5 through Section 3.6 demonstrate 
the importance of all fermentation parameters mapping the growth profile of the 
organism in its exponential phase, which a linear feed would be incapable of 
doing.  
 
In comparison, an exponential feed was suggested by Medaglia, (2009) as the 
optimal feed strategy to achieve high cell density cultures with a high yield of 
pregallidermin. An exponential regimen was attempted at the 30 L scale; 
however the attempts failed to produce high cell density cultures (Appendix 3, 
page 211). It was notable when using an exponential feed; employing a reduced 
specific growth rate in order to slow down the rapidly growing cells by limiting 
carbon source, a method often utilised to optimise antibiotic production 
(Flickinger, 1979), failed to yield high biomass. Thus, the step-up feeding 
regime was utilised for subsequent 30 L scale fermentation.    
 
Section 3.5.2 suggested a ratio of 3:1 between maltose and yeast to optimise 
cellular growth. This allows both feeds to be pumped into the culture 
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simultaneously without having to programme separate feed equations into two 
separate feed pumping setups. This eliminates the need of making adjustments 
to individual feed rates when an adjustment to the feed rate is required. 
 
Kempf et al. (1999B) initially recognised the requirement for the addition of extra 
yeast extract components in culture to optimise growth of the wild type 
S.gallinarum Tϋ3928. A subsequent study also suggested the use of a maltose 
feed when scaling-up the process (Kempf et al., 2000). Work by Valsesia et al. 
(2007) confirmed a maltose feed also led to optimal pregallidermin production 
using the modified S.gallinarum Δp. However, it was Medaglia, (2009) from the 
same research group that determined the optimal feed strategy for lantibiotic 
production involved using a dual feed system of maltose and yeast extract fed 
to the culture using an exponential regime. In contrast, the present study utilised 
a step-up feed regime, due to its ease of operation. S.gallinarum Δp 
fermentations at 30 L scale showed good reproducibility with those conducted 
at 7.5 L scale, using the same process conditions. However, it is notable that 
final pregallidermin yield was significantly lower than that achieved by Medaglia, 
(2009) at equivalent biomass concentrations; it is possible that the difference in 
feed regimes had a role in this outcome.              
 
3.7.3 Agitation  
 
The agitation rate of the fermentations closely followed the growth trends. This 
is logical as agitation rate correlates closely with mixing and mass transfer of 
various substrates and gases in culture to the growing cells (Gill et al., 2008).  
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In the current work, the bioreactors used allowed the agitation rate to be slaved 
to the cellular oxygen demand. This reduces the complexity of the fermentation 
as manually adjusting agitation rates would entail predicting and calculating 
cellular oxygen demand at various biomass concentrations, a procedure non-
conducive to rapid setup and difficult to use. This would also entail 
recalculations if unexpected changes occur in cellular growth kinetics. 
 
It is clear however that, higher rates of agitation lead to higher rates of cellular 
growth. What cannot be said conclusively from the current experimentation is 
whether manually adjusting agitation to high values from the beginning would 
result in a prolonging of exponential growth. Artificially manipulating agitation to 
high rates could possibly subject cells to high levels of shear and stress early in 
the growth phase, negatively impacting the growth rate (Ducros et al., 2009). 
Investigations into the shear and stress tolerance of S.gallinarum Δp was 
beyond the scope of this work. 
 
No previous study involving the fermentation of S.gallinarum Δp or any other 
lantibiotic producing cell strain has attempted to characterise the impact of 
agitation on cell growth. While Valsesia et al. (2007) and Medaglia, (2009) have 
mentioned agitation as important in maintaining DOT levels, no data has been 
provided to demonstrate its’ impact on fermentation. The present research has 
demonstrated that the stirrer agitation rate closely follows cellular growth and 
high agitation rates signify high growth rates. This is intuitive as previous 
studies have shown agitation as one of key parameters determining the oxygen 
mass transfer (Gill et al., 2008) and nutrient distribution to the cells (Garcia-
Ochoa et al., 2010).      
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3.7.4 OUR, CER and RQ 
The CER and OUR both mapped the cellular growth rate in the fermentations 
where off-gas analysis allowed the values to be obtained. OUR also relates to 
the volumetric oxygen transfer coefficient (Klöckner et al., 2013, Garcia-Ochoa 
et al., 2010) indicating that a higher OUR means more oxygen being transferred 
to the cells. The CER and OUR can both act as a guide to cellular respiration, 
as it is logical for actively growing and multiplying cells to demand more oxygen 
and produce more carbon dioxide. 
 
The RQ of >1 demonstrated that for S.gallinarum Δp in batch and fed-batch 
fermentation with only maltose feed, a carbohydrate source was the preferred 
substrate for respiration (Slavov et al., 2014; Arifin et al., 2014). This was in the 
absence of other nutrients necessary for cellular growth. In the dual-feed mode 
of operation, the RQ value dropped below 1, signifying a mixture of substrates 
was being used for respiration. However, this lower RQ coincided with much 
higher cellular growth and the generation of more biomass. The RQ from the 
dual-feed cultures suggests that there are certain nutrients present in the yeast-
extract, which become growth limiting if not present in adequate amounts within 
the media. 
 
The RQ appears to reaffirm the assessment by Medaglia, (2009) and Kempf et 
al. (1999B) that using just maltose feed is not sufficient for optimal growth. 
However, as no other study has attempted to analyse and characterise the 
fermentation off gas, more research is needed to gain a better understanding of 
the cellular respiration and substrate preferences.   
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3.8 Summary  
  
The aim of this chapter was to perform high cell density culture in 7.5 L STRs of 
S.gallinarum Δp reproducibly and replicate the fermentations at 30 L scale, by 
first characterising the parameters critical to PGDM production at 5 L scale. The 
results illustrate that the key parameters to consider when replicating 
fermentation and performing scale-up are: feeding regimes, aeration and 
agitation.  Ensuring these parameters map cellular exponential growth allowed 
the production of 0.7 g.L-1 of PGDM per 100 g.L-1 biomass, at 30 L scale, a 2-
fold increase on the PGDM produced in 7.5 L fed-batch fermentations. 
However, industrial scale production of the lantibiotic would require gram or 
multi-gram yields to be obtained (Islam et al., 2007), which requires further 
optimisation studies. 
 
 Analysing the different feeding strategies; the data illustrates that using dual-
feed fed-batch fermentation while focusing on the key parameters identified 
(aeration, feed-regimes, substrate-ratios, agitation) allows both scalability and 
reproducibility. It has been demonstrated that reproducibility is achievable using 
automated DOT control and impeller agitation coupled with step-up substrate-
feed and aeration regimes, a setup that reduces the complexity of the 
fermentation in comparison to exponentially adjusting the parameters.  
 
The process is also rapid, with no fermentation exceeding 20 hours. This allows 
for multiple fermentations to be run during the course of a week, increasing 
research and development efficiency in a time-limited environment. The cell 
biomass achieved was comparable to previous dual feed fed-batch studies by 
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Medaglia, (2009) at lab scale using the same organism. However, both 
Medaglia (2009) and Valsesia et al. (2007) were able to obtain significantly 
higher quantities of PGDM at lab scale in comparison to the present study. This 
appears to be due to the different feeding regimes applied, with the previous 
studies indicating exponential feed is optimal for growth. 
 
However, the successful translation of cellular growth and precursor production 
using S.gallinarum Δp from lab to pilot scale demonstrates that it is viable 
process for the production of lantibiotics. Additionally, the inexpensive media, 
rapid process completion and relatively simple operation, characteristics that 
have been deemed important for the development of platform processes in 
previous studies (Liu et al., 2010), demonstrate its potential to serve as a 
platform for large-scale and optimisation studies.     
 
In the next chapter a downstream purification process sequence will be 
developed to recover the PGDM produced in Section 3.6 at pilot scale.  
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Table 3.1 Summary of Fermentation Strategy 
 
Operation 
Feed 1* 
(g.L
-1
) 
Feed 2† 
(g.L
-1
) 
Feed 
Strategy 
DOT Control 
Strategy 
Scale Aeration 
Max 
Biomass 
(gDCWL
-1
 ) 
PGDM 
HPLC 
peak 
Batch None   NA rpm 7.5L Constant 10 No 
Batch None None NA rpm 7.5L Constant 12 No 
Batch None None NA rpm 7.5L Constant 12 No 
Fed-Batch 500 None Step-up rpm 7.5L Constant 12 No 
Fed-Batch 500 None Step-up rpm 7.5L Constant 16 No 
Fed-Batch 500 None Exponential QAir → rpm 7.5L Exponential 30 No 
Fed-Batch 500 None Step-up QAir → rpm 7.5L Linear 37 No 
Fed-Batch 500 None Step-up QAir → rpm 7.5L Exponential 28 Yes 
Fed-Batch 500 None Step-up QAir → rpm 7.5L Exponential 30 Yes 
Fed-Batch 500 None Step-up QAir → rpm 7.5L Exponential 38 Yes 
Fed-Batch 500 300 Step-up QAir → rpm 7.5L Exponential 61 Yes 
Fed-Batch 500 300 Step-up ††QAir → rpm → O2 7.5L Exponential 127 Yes 
Fed-Batch 500 300 Step-up QAir → rpm → O2 7.5L Exponential 140 Yes 
Fed-Batch 500 300 Exponential QAir → rpm → O2 30L Exponential 35 Yes 
Fed-Batch 500 300 Exponential QAir → rpm → O2 30L Exponential 45 Yes 
Fed-Batch 600 200 Step-up QAir → rpm → O2 30L Exponential 100 Yes 
 
*Maltose Feed 
†Yeast Extract Feed 
†† Qair→ rpm → O2 : represents the strategy where airflow rate (Q) is manually adjusted to 
emulate cellular growth , in order to prevent Oxygen from becoming growth limiting, agitation is 
then allowed to control DOT at the enhanced airflow rate. 
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Table 3.2 Summary of Average Fermentation Kinetics  
 
Fermentation 
Type 
Scale 
Final 
Biomass 
Final Product 
Concentration 
Yield of Biomass 
on Substrate 
(Maltose) 
Yield of 
product 
on 
Biomass 
 L g.L-1 g.L-1 g.g-1 g.g-1 
Batch 7.5 12.5 None 0.25 None 
Fed-Batch 
(Single feed) 7.5 30 0.10 0.25 0.004 
Fed-Batch 
(Dual feed) 7.5 120 0.37 0.90 0.003 
Fed-Batch 
(Dual Feed) 30 100 0.73 0.84 0.007 
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4. Downstream Process Design for 
recovery and optimisation of 
pregallidermin 
 
4.1 Introduction  
  
In Chapter 3 the parameters responsible for optimising the production of the 
novel pre-antibiotic PGDM using S.gallinarum Δp were identified. From fed-
batch fermentation, it was possible to produce a broth which at harvest 
contained 0.7 g.L-1 PGDM and 100 g.L-1 biomass. The next stage in evaluating 
options for manufacture of the novel antibiotic is the downstream purification 
processes. In order for any novel antibiotic to become usable by humans, it 
must first reach adequate purity levels using processes described in Section 
1.5.2. Additionally, for any new product to become commercially feasible the 
purification process must be cost effective (Ongey & Neubauer, 2016; Liu et al., 
2010), i.e. the desired purity should be achievable via a high yield process that 
limits the amount of product losses. 
 
In order to design a purification process, it is first necessary to understand the 
product specification required. The product is an antibiotic compound produced 
in its inactive form PGDM which possesses a leader sequence of 12 or 14 
amino acid residues (Valsesia et al., 2007) as described in section 1.3.4. In 
order to achieve the active, usable form, the PGDM must undergo trypsinization 
to cleave the leader sequence resulting in formation of the antibiotic gallidermin.  
Gallidermin with a small size (Ottenwalder et al., 1995) is an ideal candidate for 
manipulation by synthetic biology techniques in order to change its properties 
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and antimicrobial characteristics, thus allowing the creation of antibiotic libraries 
using S.gallinarum as the host organism. 
 
The design of any downstream process for these antibiotic candidates must 
consider the activation by trypsinization and the impact this will have on the 
downstream process. Figure 4.1 illustrates the various possible options for 
downstream process design. At the present time there exists no lantibiotic 
based clinical product for humans (Section 1.3.10), even after they have shown 
promise in the treatment of various bacterial infections (Valsesia, 2008). Thus 
there exists no industrial manufacturing scale process for purification of these 
compounds. A variety of purification techniques have been suggested including 
HPLC (Arias et al., 2013; Fiedler et al., 1988) and immuno-affinity 
chromatography (Suarez et al., 1997), however the cost and complexity of 
these methods means they might prove unsuitable for large scale lantibiotic 
purification. 
 
The cationic nature of these molecules (gallidermin and PGDM, Section 1.3.4) 
has resulted in a preference for ion exchange purification (Barbour et al., 2013; 
AlKhatib et al., 2014) usually along with hydrophobic interaction 
chromatography as a capture step (Barbour et al., 2013; Parente & Ricciardi, 
1999). These processes are lower cost alternatives to the higher performance 
techniques suggested previously and are already utilized at scale for the 
purification of various clinical compounds e.g. monoclonal antibodies (Liu et al., 
2010). 
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4.1.1 Aim 
 
As described in Section 1.9 the aim of this chapter is to establish a downstream 
purification sequence suitable for the large scale manufacture of the novel 
antibiotic gallidermin from PGDM. The various process options that will be 
examined were described in Fig 4.1. The specific objectives of this work are: 
 
 To examine the use of centrifugation for pilot scale solid-liquid 
separation. 
 
 To examine the use of solid-liquid adsorption/desorption processes for 
primary recovery of PGDM. 
  
 To explore the use of ion exchange chromatography for purification of 
the crude PGDM obtained from the adsorption/desorption process. 
 
 To confirm the identity of the purified PGDM and mature gallidermin 
obtained post trypsinization. 
  
 To demonstrate the operational performance of the established DSP 
sequence in terms of product recovery yield and purity at each stage 
 
As described in Section 2.5.3 analytical HPLC using a 5 μm pore size, C-18 
Nucleosil column will be used to quantify the recovery and purity of PGDM at 
each process stage and GDM post trypsinization. Here purity is defined as the 
area on the HPLC chromatogram, in mAU, of the product peaks in comparison 
to the area of all sample peaks. Confirmation of the identity of the PGDM and 
GDM will be performed by MALDI-MS as described in Section 2.5.4. 
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Figure 4.1Downstream processing options for the purification of pure gallidermin from 
the PGDM. (A) trypsinization in-situ after cell removal.(B) trypsinization of crude PGDM 
directly after initial capture from solution.(C) showing the DSP sequence for 
trypsinization after purification of PGDM.  
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4.2 Overview of Downstream Process Sequence 
 
The stated aim of this chapter is the development of a DSP sequence for the 
manufacture of PGDM at Scale. Hence the DSP sequence utilised will isolate 
and purify PGDM, which corresponds to the sequence in Figure 4.1 C. The 
polishing chromatography required to remove the cleaved leader peptide from 
gallidermin post trypsinization is not investigated, as it is beyond the scope of 
this work.   
 
4.3 Solid-Liquid separation by centrifugation 
 
Centrifugation was chosen to perform broth clarification because of the difficulty 
in using membrane filtration on broth containing yeast extract compounds. 
Culture broth that had been pre-clarified with centrifugation was still capable of 
clogging membrane filters with pore sizes of 0.2 μm, 0.4 μm and 0.7 μm. Hence 
for cell removal of culture broth containing yeast extract components at scale, 
membrane filtration proved inefficient. However, as pregallidermin is an 
extracellular product which dissolves in solution, a small mass of cells left in 
culture broth did not interfere with the adsorption of PGDM to the hydrophobic 
resin. Thus two rounds of centrifugation at 10,000 rpm for 30 minutes at pilot 
scale removed sufficient cell mass for batch adsorption requirements. 
 
When the clarified cell broth was analysed by HPLC (Section 2.5.3), no 
detectable difference was noticed in PGDM concentration. Thus PGDM 
recovery using centrifugation is almost 100%.  
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4.4 Hydrophobic Interaction: Batch Adsorption 
  
The clarified broth produced as in Section 4.3 was next used for study of PGDM 
adsorption by the hydrophobic resin Amberlite XAD-7 an acrylic ester resin, with 
a surface area for adsorption of 450 m2.g-1. The resin had already been 
previously demonstrated to adsorb pregallidermin in lab scale processes by 
Medaglia, (2009). The resin beads are porous, with an average pore diameter 
of 90 å and a pore volume of 1.14 mL.g-1. The manufacturer (Sigma-Aldrich, 
Dorset, UK) recommended XAD-1180 and XAD-7 for antibiotic recovery; 
however XAD-1180 costs twice as much per unit weight. Hence XAD-7 was 
selected as the cost effective alternative for a large scale process.  
 
The adsorption was performed in batch mode, with the XAD-7 resin simply 
mixed into the clarified fermentation broth. The effect of XAD-7 concentration on 
the adsorption of PGDM from culture broth is illustrated in Figure 4.2. Each 
gram of XAD-7 was shown to adsorb roughly 10 mg of PGDM from broth. 
However after adsorption the resin beads underwent a notable colour change to 
dark-red orange, a similar colouration to the yeast extract used in the 
fermentation media (Section 2.5.1). This would suggest that along with the 
hydrophobic absorption of PGDM, a selection of the hydrophobic culture broth 
and media components were also being adsorbed. These components would 
clearly impact the capacity of the XAD-7 resin to optimally adsorb PGDM per 
unit mass of resin, as well as impact the purity of the feed stream to purification 
processes downstream.  
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However analysis by HPLC (Section 2.5.3) determined that despite the 
adsorption of unwanted media components, all the PGDM present in broth was 
effectively removed from solution. Culture supernatant post adsorption had no 
detectable levels of PGDM. 
 
 
 
 
 
 
 
 
 
   
Figure 4.2 The adsorption profile of PGDM from clarified culture broth on Amberlite 
XAD-7. Adsorption performed as described in Section 2.3.3. A summary of the DSP 
sequence and the performance for each component process is provided in Table 4.2.  
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4.5.1 Hydrophobic Interaction: Wash 
 
  
The Amberlite XAD-7 beads adsorbed media components along with the PGDM 
in solution as clearly demonstrated by the colour change undergone by the 
beads after an adsorption carried out as described in Section 2.3.3. In order to 
achieve a high purity PGDM desorption, washing of the beads becomes 
necessary to remove the bound yeast extract to reduce the eluted impurity for 
the subsequent chromatography process.  
 
Washing the resin beads with distilled water, as described in Section 2.3.4, 
removes some of the impurities; this is visible by the colour change of the wash 
supernatant. However certain impurities such as yeast protein will have 
hydrophobic characteristics, meaning they will be more tightly bound to the 
XAD-7 resin and washing with water is not enough to remove them. In order to 
improve the removal power of the wash, solutions buffered at various pH values 
were evaluated. In general, increases in pH weaken hydrophobic interactions. 
(Hjertén, 1973) The results are illustrated in Figure 4.3, presence of impurity in 
solution was determined by OD at 600 nm, as described in Section 2.5.1. 
 
As is visible from Figure 4.3 A, a relatively basic buffer solution at pH 8 was 
most effective at desorbing the bound yeast extract impurities. The trend 
indicates that increasing pH leads to an increase in the removal of unwanted 
impurities. However HPLC analysis of the wash buffer to determine product 
losses showed the presence of PGDM at pH 8, as opposed to no losses of 
PGDM at pH 4 or 6. The PGDM eluted by the pH 8 wash solution amounted to 
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2% w/w of the total mass in the starting clarified fermentation broth. Potentially 
significant losses at manufacturing scale. 
 
The data also demonstrates that increasing the number of washes (performed 
in batch mode) will result in increased amounts of impurity removal, however 
the quantity removed diminishes for each wash cycle. The highest amount of 
impurity was always removed in the first wash cycle, with all washes beyond the 
third having a minimal impact on further impurity removal. This indicates the 
remaining impurities are very tightly bound to the resin.  Increasing the volume 
of wash buffer, from 200 mL to 500 mL per 10 g of resin, did result in an 
increase in impurity removal. However, increasing the duration of the wash by 
doubling the wash time resulted in no observable increase in impurity removal, 
with specifically increasing the duration of the 2nd wash cycle in an attempt to 
enhance impurity removal resulting in no change in OD readings at 600 nm. It 
was noted that 30 minutes proved sufficient for maximal impurity removal in that 
particular batch. 
 
 It was also noted that increasing the molarity of the pH 8 buffer solution from 
0.02 M to 0.05 M increased the removal of yeast extract impurity, however it 
also resulted in an increase in the desorption of PGDM from 2% in wash 
solution to 5% as determined by HPLC (Section 2.5.3), possibly due to an 
additional ‘salting out’ effect. Hence further increases in molarity were not 
pursued.  A summary of the buffer wash data is presented in table 4.1. The 
optimal wash conditions based on the data is a 0.02 M buffer at pH 6. 
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4.5.2 Hydrophobic Interaction: Desorption 
 
Desorption of the bound PGDM was performed with a solution of Methanol and 
acidified water (0.005 M sulphuric acid). The acidified water is added to 
enhance the solubility and stability of PGDM in the elution buffer, as low pH has 
been indicated to do this for Type A lantibiotics (Rollema et al., 1995). A 
comparison of desorption performed with 100% methanol and 60% 
Methanol/40% acidified water is illustrated in figure 4.3 (B). As is demonstrated 
a 60% MeOH solution resulted in substantially higher PGDM obtained as 
opposed to 100%. This is attributable to the minimal solubility of PGDM in 
methanol (40 mg.L-1) as opposed to water (>3g L-1). It is noteworthy, that the 
recovered PGDM at 60% methanol represented 57 % of the total PGDM in 
clarified culture broth as determined by HPLC (Section 2.5.3). Thus the PGDM 
desorption was optimal at 60/40 % (v/v) Methanol/5 mM H2SO4. 
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A 
 
 
B 
 
 
 
 
Figure 4.3 Washing and desorption of PGDM from Amberlite XAD-7 resin with A) 
representing the yeast extract impurities removed by each successive wash and B) the 
PGDM captured in solution when eluted with 100% methanol and 60% methanol. Wash 
and desorption performed as described in Section 2.3.4. A summary of the DSP 
sequence and the performance for each component process is provided in Table 4.2. 
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Table 4.1 Summary of wash variation data 
 
 
Impact of varying wash conditions on impurity removal 
Wash condition Variation Impact PGDM Losses 
Duration Increase No change None 
Volume Increase Marginal Increase None 
pH Increase Increase Yes 
Number of washes Increase No improvement after 3 washes None 
Molarity Increase Increase Yes 
Methanol Content Increase Increase Yes 
 
 
 
4.6 Ion Exchange Chromatography 
 
The PGDM solution from the batch adsorption/desorption process described in 
Sections 4.4 and 4.5.2 provided the feed stream for the subsequent 
chromatographic separation. This is intended to be the high resolution step in 
the purification sequence, enhancing the purity of the recovered PGDM. An XK-
16 column (diameter 16 mm) was packed with the strong cation exchange resin 
SP HP (SP sepharose high performance) as described in Section 2.3.5. The 
column was first equilibrated using buffer A (0.02M acetate buffer at pH 4.5, 
common for both equilibration and feed loading) with the PGDM feed stream 
then loaded onto the column.  
 
Figure 4.4(A) demonstrates the ion exchange chromatograms at various 
dilutions of the feed material. Elution was performed by increasing buffer B 
gradient from 0 % to 15 % (Section 2.3.5), with the two variants of PGDM 
referred to as PGDM 1 and PGDM 2, based on the length of their leader 
sequences (Figure 4.5), eluting at 12.5 % buffer B and 9.5 % buffer B 
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respectively.  The identity of the PGDM peaks was confirmed by analytical 
HPLC as described in Section 2.5.3, followed by MALDI-MS as described in 
Section 2.5.4. 
  
 It is visible from Figure 4.4 B that a higher dilution, results in a smaller volume 
of unwanted yeast extract capture; the first peak in the chromatogram is the 
yeast extract component peak and the size diminishes with increasing feed 
dilution. This would imply higher product purity when the PGDM peaks are 
captured by fractionating the PGDM product stream. However, yeast extract 
components were still present in the PGDM fractions at 20 dilutions, but PGDM 
purity increased from 28.5 % without any dilution to 72 % with 20 dilutions as 
determined by HPLC (Section 2.5.3). The PGDM variants were recovered for 
further processing by capturing the eluent fraction from 250 mL to 350 mL at 20 
dilutions. 
 
The removal of all yeast extract components proved extremely challenging 
using the SP HP resin, this is clearly demonstrated by the final yeast extract 
component peak eluting well after the two PGDM variants at a Buffer B gradient 
of 15 %. The implication being that some impurities from the fermentation broth 
possess a strong positive charge, causing them to bind very strongly with the 
resin, thus in order for the process to achieve very high purity, it might be 
necessary to determine a method to remove these components from the overall 
production process. 
 
The chromatograms of feed loading in Figure 4.4 B demonstrate the break-
through curves of the PGDM feed, i.e. the amount of PGDM feed being loaded 
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onto the column that is not attaching to the resin and flowing straight through. 
PGDM possesses a net positive charge, as described by Medaglia (2009) 
hence it is expected to attach strongly with the resin, allowing media 
components possessing an opposite charge to flow through. However as yeast 
extract is a complex mixture of autolysed yeast components, it is expected that 
certain charged yeast extract components will attach to the resin. As is 
demonstrated by Figure 4.4 A the pure undiluted feed stream onto the column 
will result in very high material breakthrough, 550 maU as opposed to less than 
50 maU  when the feed is diluted 20 times ( 1volume feed: 19 volumes buffer).  
 
The high breakthrough in the load phase implies that most of the feed stream 
including product and media components is flowing through unattached, 
resulting in lower productivity and process yield; cation exchange of the 
undiluted feed stream resulted in a process yield of only 20% PGDM as 
opposed to about 50% yield with 20 dilutions as determined by HPLC (Section 
2.5.3). It is noteworthy that the undiluted feed stream had to be loaded as an 
injection into the mobile phase, which also implies smaller volumes have to be 
processed in a given cycle. Injecting larger volumes of PGDM feed results in 
higher breakthroughs resulting in high product wastage. The pressure drop 
across the column created by large impurity molecules saturating the top of the 
matrix could potentially compromise column packing integrity. 
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Figure 4.4 Chromatograms for ion exchange of pregallidermin product. A) elution 
profiles of the PGDM solution at 20 dilutions, 10 dilutions and no dilution. B) load 
profiles of the PGDM solution at 20 dilutions, 10 dilutions and no dilution (raw solution 
injection).  Ion exchange chromatography performed as described in Section 2.3.5. A 
summary of the DSP sequence and the performance for each component process is 
provided in Table 4.2. 
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4.7 Salt removal from eluted product stream  
 
 
The eluted PGDM in buffer B (2 M NaCL dissolved in 0.02M acetate buffer at 
pH 4.5) contained high concentrations of NaCl, requiring removal prior to further 
processing and trypsinization. Salt removal was performed by using the same 
batch adsorption/desorption process as described in Section 4.4 and Section 
4.5, with only a single wash step utilised. The batch process resulted in an 
increase in purity from 72 % to 80 % and the step yield increased to 76 % as 
opposed to 57 % in the original batch process using the cell free supernatant. 
The methanol fraction in the desorption eluent was evaporated in-vacuo and the 
remaining solution was lyophilised to obtain the powdered PGDM. 
 
It is however noteworthy that the desorption solution had to be modified, as the 
original desorption involved the use of 5 mM H2SO4. When lyophilized with the 
original desorption solution containing 5 mM H2SO4, the gradual removal of 
water left behind an increasingly concentrated acid which it is assumed 
denatured the PGDM, resulting in a black, discoloured powder. Thus in order to 
prevent this and provide unaltered PGDM for tryptic digestion, desorption from 
XAD-7 during salt removal was performed with a solution of 60 % (v/v) MeOH / 
40 % MilliQ water. 
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4.8 Trypsinisation of pregallidermin to produce 
mature gallidermin 
 
Once PGDM was obtained in powdered form after lyophilisation, it was weighed 
and re-dissolved in distilled water for trypsinization. Trypsinization was 
performed in pH 7 phosphate buffer as described in Section 2.4.The 
trypsinization cleaves off the PGDM leader sequence, leaving behind mature 
gallidermin. Every 1 g of PGDM produced 0.6 g of mature gallidermin when 
trypsinised, a step yield of 60 %. The identity of PGDM and gallidermin was 
confirmed by HPLC (Section 2.5.3) and MALDI-MS (Section 2.5.4) as described 
in the following section. 
 
4.9 Identification of pregallidermin and 
gallidermin 
 
 
In order to confirm the presence of both PGDM and gallidermin, off-line HPLC 
analysis was performed as described in Section 4.6 analysis of the ion 
exchange chromatograms. However the retention time from HPLC 
chromatograms confirms identity only in relation to the retention time of 
commercial standards, and provides no other physico-chemical evidence to 
confirm identity. A combination of the HPLC chromatogram with the molecular 
mass of the compound in question provides much stronger evidence for positive 
identification. Thus the mass of the product compounds pre and post 
trypsinization along with their HPLC chromatograms were used to positively 
identify PGDM and gallidermin in solution. 
 
Figure 4.5 shows the chromatogram and mass spectrum of the product fraction 
obtained from the Ion exchange chromatography stage shown in Figure 4.4. 
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The mass spectrum confirms the presence of the two variants of PGDM 
detected by Valsesia et al. (2007). It is also notable that S.gallinarum Δp 
appears to have a much higher preference for the production of PGDM variant 1 
as opposed to PGDM variant 2, a fact confirmed by Medaglia (2009). The peaks 
on the chromatogram left unidentified are thought to be various buffer solution 
and cell culture broth components eluted along with the PGDM. 
 
Figure 4.6 A shows the HPLC chromatogram and 4.6 B the mass spectrum of 
the PGDM sample in Figure 4.5, post trypsinisation. The presence of the 
gallidermin peak at 9.1 minutes is notable, which can also be confirmed by the 
mass spectrum at 2166.5 m/z (relative mass of ions). The data would also 
suggest that PGDM 2 is cleaved in preference to PGDM 1; however that may 
just be observable due to the difference in concentration between variants, 
resulting in PGDM 2 being completely utilized quicker. 
 
The data does however confirm the production of the novel antibiotic PGDM by 
S.gallinarum Δp, which is then trypsinised to gallidermin, as demonstrated by 
the presence of both in solution compared to the complete absence of 
Gallidermin from figure 4.5 B. 
 
In order to confirm the identity of the gallidermin produced by trypsinisation from 
the PGDM variants, the mass spectrum of a sample where the PGDM had been 
completely trypsinised was compared to a sample of commercially available 
Gallidermin (Enzo Life Sciences, East Farmingdale, NY, USA). The mass 
spectra in Figure 4.7 determined using MALDI-TOF (Section 2.5.4); indicate 
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identical masses for both samples at 2168 m/z (molecular mass of Gallidermin 
is calculated at 2165 g.M-1).   
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 Time (min) 
  
PGDM 1 Mass 3408 Da  AKESNDSGAEPR- Gallidermin  
  
 PGDM 2 Mass 3621 Da  VNAKESNDSGAEPR- Gallidermin 
 
B 
    
 
 
Figure 4.5 Identification of PGDM. A) HPLC chromatogram of the PGDM product solution 
obtained from Ion Exchange chromatography show the retention times 8.4 min and 8.9 min for 
variants PGDM 1 and PGDM 2 respectively. B) Mass-spectrum of the same product solution 
using MALDI-MS, the spectrum shows the relative abundance of ions (%) relative to the mass of 
ions (m/z). The molecular masses obtained correspond to values obtained by Valsesia et al. 
(2007). 
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Figure 4.6 The trypsinization of PGDM to produce gallidermin. A) HPLC chromatogram of the 
PGDM product solution 6 min after the introduction of Porcine Trypsin, the presence of 
Gallidermin with a retention time of 9.1 minutes is notable, indicating the conversion of PGDM to 
active Gallidermin. B) Mass Spectrum of the same sample, confirming the presence of 
Gallidermin (mass: 2166) along with PGDM variant 1. The Maldi-MS spectrum shows the 
abundance of the ions (%) relative to the mass of ions (m/z). 
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Figure 4.7 MALDI-TOF mass spectrum of Gallidermin) Gallidermin (2168.1) obtained from the 
near-total trypsinization of PGDM product solution, note the presence of small traces of PGDM 
variant 1 (3411.2). B) commercially produced gallidermin, from Enzo Life Sciences. The Maldi-
MS spectrum shows the abundance of the ions (%) relative to the mass of ions (m/z). 
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4.10 Assessment of overall downstream 
process performance 
 
 
Having examined the selection and performance of potential downstream 
processing steps in Section 4.3 to 4.8, the whole process sequence was 
performed on a batch of PGDM produced as described in Section 3.6. The 
culture broth was harvested at 15 h, when PGDM concentration was 0.7 g.L-1 
(Figure 3.10 A). Table 4.1 shows a purification table summarising the recovery 
yield and purity of PGDM/GDM at each stage and for the overall process. The 
PGDM was quantified at each process stage using HPLC analysis as described 
in Section 2.5.3. The purity for each process stage was calculated using 
Equation 2.5. 
 
The DSP sequence utilised for PGDM purification and the activation of GDM 
was initially proposed by Medaglia, (2009), in their work on S.gallinarum Δp. 
However, it was noted in that study that the sequence needed to be tested with 
an actual purification run in order to determine step yields and increases in 
purity. Table 4.2 illustrates the results of using the sequence at pilot scale. 
Overall process yield from the sequence is 13.5%, while the active GDM 
obtained after trypsinization had a purity of 70%. Previous studies have 
reported lab-scale methods to obtain GDM purities of above 90% (Allgaier et al., 
1991); however there are no reports of pilot-scale studies involving the 
purification of a lantibiotic precursor. The reduction in purity of GDM post 
trypsinization noted in Table 4.2 is accountable to the presence of both trypsin 
and the cleaved PGDM leader sequence.  
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It is also noted that the maximum purity obtained for PGDM was 80%. This can 
be accounted to the presence of some residual media components. The yeast 
extract based fermentation media is complex and the use of an optimised 
defined medium would improve the purification process allowing greater PGDM 
purity to be achieved (Medaglia, 2009).    
 
 
 
 
 
 
 
Table 4.2 Purification table summarising PGDM step yield and purity for the whole downstream 
process sequence  
 
 
Process  
Total Mass of 
PGDM (g) 
Overall 
Yield (%) 
Step Yield 
(%) 
Concentration 
(g.L
-1
) 
Purity (%) 
Fermentation 14 100 100 0.7 0.56 
Centrigufation 14 100 100 0.7 0.56 
HI* 8 57 57 0.4 28 
IEX Chrom. † 4.1 29 51 0.2 72 
HI 3.1 22 76 0.15 80 
Lyophilization 3.1 22 100 0.15 80 
Trypsinization 1.9 13.5 60 0.09** 70 
Total Process 1.9 13.5 NA 0.09** 70 
 
*Hydrophobic Interaction 
†Ion exchange Chromatography 
**Galliderimin 
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4.10.1 Solid-Liquid separation by centrifugation 
 
Centrifugation proved capable of removing adequate cell mass to allow the 
operation of the subsequent hydrophobic interaction resin adsorption/desorption 
stage. The fermentation broth was spun at 10,000 rpm, the literature shows 
ranges for centrifugation from 9,000g to 16,000g (Barbour et al., 2013; Valsesia 
et al., 2008). However, it seems that a process temperature of 4°C is consistent 
to every study. This is possibly in order to reduce potential lantibiotic 
degradation from occurring at higher temperatures in the culture media. 
Centrifugation was performed for 30 minutes, longer than for previous studies 
as pilot-scale volumes of fermentation broth were being clarified.    
 
HPLC analysis found no detectable difference in PGDM concentration pre and 
post centrifugation; a product yield of 100%. This is most likely because the 
PGDM is extra cellular and dissolves in the solution, hence the removal of cells 
does not impact its presence in solution. Additionally due to the subsequent 
adsorption/desorption step happening in batch mode, the presence of a small 
number of cells is expected to have a negligible effect on adsorption efficiency.  
 
Centrifugation has been used frequently as a method to obtain cell-free 
supernatant with dissolved lantibiotics (Souza et al., 2017; Zhou et al., 2016; 
Barbour et al., 2013). There are also reports in literature of other methods such 
as cross flow filtration (Arias et al., 2013) However, centrifugation may prove 
beneficial in a manufacturing scale process by being a lower cost alternative to 
clarification by membrane filtration. It is also a process that allows high 
throughput of product solution, which could potentially reduce the processing 
times of product batches at manufacturing scale.  
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4.10.2 Hydrophobic Interaction  
 
 
The use of batch adsorption as an initial capture step is beneficial due to its 
relatively simple operation in comparison to column separation procedures. 
There are also economic benefits to utilizing mixing tanks and resin beads, as 
opposed to the capital investment required at industrial scale to install a large 
scale column rig. The resins used are in-expensive in relation to 
chromatography resins. Additionally due to the robustness of resin beads such 
as Amberlite XAD-7, the same resins can be used multiple times. 
 
The resin adsorption process is also beneficial due to its ability to adsorb the 
PGDM from a feed stream that is fairly impure; it contains all the components of 
the fermentation minus the cells removed by centrifugation. In comparison a 
column separation step for initial capture, would require a purer feed stream in 
order for the resins to last longer. This aids in the processing of large volumes 
of culture broth quickly, which can subsequently be desorbed into smaller 
volumes of buffer for further processing by column separation techniques, 
something which could prove useful for manufacturing at large scale, where 
thousands of litres of culture broth needs to be processed in a single batch 
(Garcia-Ochoa et al., 2010).  
 
However, desorption of the captured product from the resin beads resulted in a 
process yield of only 57 % and a product purity of 28 %. This is attributable to 
the complex medium, composed of yeast extract proteins. Yeast proteins are 
also adsorbed onto the resin along with the product, with many yeast 
compounds much larger than the PGDM molecule (2000 Da). It is reasoned that 
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the reduced yield may be due to the larger yeast extract compounds blocking 
the resin pores by attaching strongly under the conditions required for PGDM 
desorption, along with some of the PGDM attaching irreversibly to the resin 
beads. This is indicated by the increase in step yield achieved by the secondary 
batch adsorption for salt removal (Section 4.7), where the much purer product 
stream from the Ion Exchange chromatography resulted in step yield increasing 
to 76 %. However, the interaction of medium components to resin beads is 
beyond the scope of this work to determine.   
 
The use of resin based product capture finds common use in literature involving 
the purification of lantibiotics. The preferred are all of the ‘Amberlite’ XAD 
series, with XAD-16 and XAD-1180 used frequently (Arias et al., 2013; Barbour 
et al., 2013; Krismer et al., 2012; Medaglia, 2009). However, when Valsesia et 
al. (2007) originally created the S.gallinarum Δp cell strain, XAD-7 was used for 
initial product capture. Thus, for the present work, XAD-7 was utilised. 
Additionally, XAD-7 is a cheap resin, a characteristic suitable for a material to 
be used in platform processes. 
 
4.10.3 Ion Exchange Chromatography 
 
Ion exchange chromatography is a suitable high resolution purification step due 
to the PGDM possessing a net positive charge (Section 1.3.4). The strong 
cation exchange resin SP HP (high performance) by GE Healthcare (Little 
Chalfont, UK) is used in a capture and elute mode, to allow all non-charged and 
negative charged particles to flow through. The product purity increases to 72 
%, from an initial 28 % after the batch adsorption. However, purity grades of 
above 90 % have been reported in the literature (Medaglia, 2009; Allgaier et al., 
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1991) and hence there is substantial room for improvement. It is suggested 
again that the purity achievable is impacted by the feed stream containing 
undefined yeast extract components, which proved difficult to remove and elute 
simultaneously with the PGDM under the gradient elution conditions (Figure 4.4 
A).   
 
A potential solution to achieve purer product fractions could be allowing a 
shallower gradient, giving the impurities a larger amount of time to elute off. 
However in a manufacturing environment increasing process times might not 
always be suitable as it leads to reduced chromatography cycle efficiency and 
productivity. Another possibility is the use of higher dilution levels for the 
product solution beyond 20 times to ensure lower feed solution breakthrough, 
however at large scale that could lead to problems with handling large 
quantities of buffer and also increase the process time. However, there remains 
much scope for further optimization work to determine suitable conditions to 
enhance PGDM purity.  
 
The process yield also leaves room for further improvement, with the step yield 
at 51 % as shown in Table 4.2. The ion exchange data indicates that increasing 
the product dilution reduces the feed breakthrough (Figure 4.4A), thus 
increasing the amount of PGDM capture. However there is a limit to the amount 
of dilutions that are feasible at manufacturing scale as this could substantially 
affect plant productivity and process efficiency. An alternative could be using 
multiple column rigs; however that leads to large increases in capital and 
operational costs. Thus in order to optimise the yield and purity of the Ion 
exchange process, a relatively pure feed stream could provide advantages, 
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something that becomes difficult when using complex media composed of 
undefined yeast extract components. It is intuitive that reducing the 
concentration of impurity would allow more PGDM to bind, as opposed to 
saturating the column with media components and allowing PGDM to 
breakthrough. 
 
Ion exchange chromatography has been used frequently in studies that involve 
lantibiotic purification (Zhou et al., 2016; Zhou et al., 2015; Barbour et al., 2013). 
This is due to the cationic nature of the lantibiotics that have been most 
extensively studied. Work by Medaglia, (2009) demonstrated that PGDM was 
also a cationic peptide, although possessing less positive charge than the wild-
type gallidermin. This provided the reasoning behind the selection of the cation 
exchange resin for the process in this study.  
 
Medaglia, (2009) indicated that at lab scale, the purity of PGDM after cation 
exchange was 86%, whereas the present work achieved  product purity of 70% 
using a pilot scale process (Table 4.2). This difference in purity can be 
accounted to Medaglia’s use of a defined medium resulting in fewer complex 
yeast extract components in the purification feed stream. 
 
4.11 Discussion and Summary  
 
 
The aim of this chapter was to establish a downstream purification sequence 
suitable for the large scale manufacture of the lantibiotic gallidermin from 
PGDM. The DSP utilised to achieve this is summarised in Figure 4.8. The 
process outlined to achieve this aim uses centrifugation for the removal of the 
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producer cells from fermentation broth. Centrifugation proved suitable to rapidly 
provide material of a sufficient clarity to allow the subsequent hydrophobic 
interaction process. No PGDM losses were detected by HPLC after broth 
clarification (Table 4.2); meaning centrifugation provides a cheap, scalable and 
high throughput process option, characteristics that are suited to manufacturing 
scale production. 
 
The hydrophobic interaction adsorption/desorption process provided the primary 
product capture step of the DSP sequence. Although rapid, cheap and scalable, 
the product yield of 57 % and purity of 28 % has room for improvement (Table 
4.2). The use of a complex medium for cellular growth was suggested as a 
reason for the lower product recovery and purity, meaning improvements in 
yield and purity would be possible by using a defined media, as demonstrated 
by Medaglia, (2009) and optimising the removal of media impurities from the 
resin during the wash stages. 
 
Ion exchange chromatography was able to increase the purity of the desorbed 
PGDM 2.5 fold to 72 % (Table 4.2). However PGDM recovery was low at 51 %, 
which illustrated room for process optimisation. Although the process was rapid, 
the scalability of ion exchange chromatography is questionable without a 
process input stream of higher purity. The DSP was able to produce PGDM 
which was successfully trypsinised to gallidermin. The identities of the products 
were confirmed initially by HPLC, followed by Mass Spectrometry (Section 4.9).    
 
 As demonstrated in Table 4.2, the process provides a DSP platform that can 
produce material of a sufficient quality to allow trypsinization of the PGDM, 
allowing the mature gallidermin to be obtained. This is done rapidly; each 
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process step in the sequence was concluded in less than 24 hours using low 
complexity processes. However the results shown in Table 4.2 underline the 
importance of optimising individual processes to achieve high total process yield 
and purity.  
 
All processes utilised in this DSP sequence have been used in previous studies 
for the purification of other lantibiotic compounds. Although the complete 
sequence may differ between studies e.g. Arias et al. (2013) utilised a cross-
filtration step rather than centrifugation for cell removal, there is a high degree 
of similarity (Alkhatib et al., 2014; Barbour et al., 2013; Arias et al., 2013; 
Medaglia, 2009).  
 
Although no study has been conducted on pilot scale DSP sequences for 
lantibiotics, there are lab-scale sequences that utilise HPLC as a final 
purification step (Zhou et al., 2016; Zhou et al., 2015). Replicating these at pilot 
and large scale may prove costly and unsuitable for commercial operations. 
 
It is notable that PGDM yield and purity is not very high, however platform 
processes are meant to rapidly and cheaply provide usable quantities of 
material for clinical, further developmental and optimisation studies and may be 
non-optimal in terms of yield, process economics and throughput (Liu et al., 
2010). Thus, the existing process may not translate to commercial production 
without further optimisation work. The present study has demonstrated that the 
identified DSP sequence is a viable method of PGDM capture and purification. 
Lantibiotics have similar biosynthesis pathways (Medaglia, 2009) hence, the 
process may be generic enough to be utilised with other molecules. 
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Figure 4.8 Summary of the final overall process used for the production of PGDM, including the 
finalised DSP sequence that was used to achieve the PGDM yields and purity outlined in Table 
4.2 
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5. Microscale Methods for Rapid 
Analysis 
5.1 Introduction  
 
The development of the DSP sequence for pregallidermin manufacture, 
described in Chapter 4, facilitates the commencement of process optimisation 
studies. The major cost drivers in the manufacture of modern biotech 
compounds are the downstream purification processes utilized and the number 
of steps required to meet regulatory requirements (Marr et al., 2006; Kelley, 
2006). Purification technologies such as chromatography involve both high set-
up costs along with expensive consumables such as the resins utilized (Arauz 
et al., 2009). In the development of novel lantibiotic candidates (Section 1.3.10), 
once a compound is identified with the required antimicrobial profile, 
optimization studies to identify suitable process parameters for purification at 
the manufacturing scale are required. These can be both time consuming and 
costly. Conducting optimization studies at pilot-scale also requires product 
quantities that are uneconomical to produce with non-optimized processes; an 
approach that diverts resources from the development of other potential drug 
candidates. 
 
Microscale processing techniques offer a potential solution in reducing both cost 
and time required for performing optimization studies on the chosen candidate 
(Voulgaris et al., 2016; Micheletti and Lye, 2006). The use of microscale 
techniques allows the generation of quantitative process data in parallel with 
initial pilot scale production runs, as the required quantity of material for each 
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microscale investigation is in milligrams or less. In terms of downstream 
processing operations microscale methods already exist for a number of unit 
operations. These include depth filtration (Jackson et al., 2006), centrifugation 
(Hutchinson et al., 2006), adsorption (Lye and Woodley, 1999), liquid-liquid 
extraction and chromatography. In the case of lantibiotic downstream process 
synthesis there remains a requirement for microscale methods to acquire the 
relevant physic-chemical property data.  
 
5.1.1 Aims 
 
Hence the aim of this chapter is to use microscale analysis techniques to 
develop a comprehensive set of data on the PGDM product physico-chemical 
characteristics. This would enable informed process design choices that would 
impact the DSP operations, enabling the optimization of the downstream 
processes in pursuit of higher product recovery and purity. The specific 
objectives of this chapter are: 
 
 To develop microscale optimization studies for the hydrophobic 
interaction based capture of PGDM from culture broth by Amberlite XAD-
7. It is employed as the primary capture step as shown in Table 4.2; with 
a step yield of 57% and purity of 28%. Improvements at this stage of the 
process would allow for improvements in all subsequent steps.  
 
 To demonstrate a substantial improvement in yield and purity of the 
primary capture step at microscale, which will inform the redesign of the 
follow-on DSP sequences.  
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 To develop microscale methods to enable the rapid acquisition relevant 
physico-chemical data. 
 
 It will be suggested that the microscale analytical methods aid design of the 
manufacturing process for the production of novel antibiotics by proving their 
usefulness in the collection of data that would enable a comprehensive analysis 
of the suitability of the candidate antibiotic to existing DSP processes.  
 
As described in Section 2.5.3 Analytical HPLC will be used to determine the 
purity and quantity of the antibiotics pregallidermin and gallidermin. For this 
work, purity is calculated using Equation 2.5 in Section 2.5.3. 
 
5.2 Overview of the microscale methods 
 
The microscale methods development aims to inform process design, hence 
these optimisation studies will focus on the primary capture step; PGDM 
capture by adsorption/desorption. Thus all the methods developed aim to gather 
process data that could enhance the yield and purity of PGDM obtained by the 
XAD-7 Adsorption/Desorption process. A ‘one-factor-at-a-time’ optimisation 
strategy  was used to develop the methods, as each set of experiments gave 
rise to data that needed answering with a follow on sequence of experiments 
(Sequential Analysis). The results from the optimisation experiments are 
presented as contour plots.    
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5.3 Impact of pH on impurity removal 
 
 
The primary capture step suggested for a PGDM manufacturing process is 
hydrophobic interaction chromatography, as previously shown in Section 4.4, 
hydrophobic interaction allows for the complete adsorption of PGDM onto the 
resin Amberlite XAD-7 from clarified fermentation broth. Upon elution this allows 
a recovery of 57% (w/w) PGDM at 28% purity, a 50 fold increase compared to 
the culture broth (Table 4.2). It is however worthwhile to investigate the scope 
for optimization of the primary PGDM capture, with factors such as pH variation 
influencing PGDM uptake from broth (Yang et al., 1992). 
 
  
Microscale experiments were conducted to investigate the interaction of multiple 
parameters on product recovery and impurity removal. Broth pH was adjusted 
from acidic at pH 5 to more alkaline at pH 9 to determine the impact on the 
adsorption of impurities along with the PGDM product. Once the adsorption 
phase was complete (Section 2.7.1), the resin beads were washed with wash 
buffers at pH ranging from 5 to 8 in an attempt to determine a set of conditions 
that resulted in the highest amount of impurity removal as determined by HPLC.  
 
Figure 5.1 A) shows the impurity removal efficiency using wash buffers at 
various pH values. The data indicates that adsorption at higher pH ranges 
(alkaline) results in higher impurity removal from the resin when combined with 
a basic wash at pH 8. The least impurity removal occurred when batch 
adsorption was performed under acidic conditions and followed up with an 
acidic wash at pH 5. However the highest amount of impurity removal occurred 
when batch absorption occurred at pH 6, with a wash buffer at pH 8 (40,000 
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mAU of impurities detected in wash).  This would suggest that post-adsorption 
resin washes be performed with alkaline wash buffers to achieve higher purity 
PGDM. 
 
When elution was performed with a buffer of 60% (v/v) Methanol/40% (v/v) 
5mM H2SO4, the highest PGDM recovery was achieved when the broth was 
adjusted to an acidic pH along with a resin wash at acidic pH (Figure 5.1 B). 
The highest PGDM yield of over 80 mg/L was obtained when broth was 
adjusted to pH 5 with the resin washed at pH 5. Increasing the broth pH for 
batch adsorption negatively impacted PGDM recovery as did increasing the pH 
of the resin wash for impurity removal. 
 
Similarly to product yield, Figure 5.1 C shows the highest PGDM purity of 15% 
was achieved under acidic broth/wash conditions. This was contrary to the 
expectation that the highest impurity removal during the wash would result in 
the highest purity product. In contrast to the removal of broth impurity bound to 
the XAD-7 resin, alkaline pH resin washes resulted in reduced product purity. It 
is also notable that none of the purity values achieved for the microscale 
experiments could emulate the 28% PGDM purity achieved at the pilot scale 
process. This may be due to the degradation of the PGDM under the 
broth/wash conditions being used, reducing the amount of PGDM in comparison 
to impurities, or at such small scales some PGDM may be tightly bound to the 
beads.  
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Figure 5.1 Contour plots of microscale XAD-7 adsorption/desorption data at different broth pH 
values for adsorption and wash pH values for elution: (A) the amount of impurity removal, the 
colour bands represent the sum of all impurity peak areas in mAU on an HPLC chromatogram; 
(B) the concentration of eluted PGDM with colour bands representing the eluted PGDM in mg.L
-
1
 and (C) the purity of the eluted PGDM with the colour bands displaying the percentage purity 
(%) of the PGDM. Microscale method performed as described in Section 2.7.3 
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5.4 Stability of PGDM and Gallidermin 
 
5.4.1 pH 
 
The purity and yield results from the microscale wash experiments were 
unexpected. The PGDM recovery in batch adsorption at microscale was a 
maximum 95 mg out of a broth product concentration of 400 mg.L-1, a yield 
closer to 25 %, as opposed to 57 % achieved at pilot scale. A potential reason 
for the low product recovery could be the impact on PGDM stability of varying 
pH levels. Prior to the microscale elution in section 5.3, the resin was subjected 
to 3 wash cycles of a minimum 8 hours. With the additional time taken to 
perform HPLC analysis on multiple samples, (each HPLC run being completed 
in 18 minutes) the PGDM wash exposed to the wash buffer for a minimum 12 
hours for each wash. Thus it is proposed that low yields and purity might be due 
to product degradation. 
 
Figure 5.2 compares the microscale stability data of pure PGDM and 
gallidermin buffered at pH 6, 7 and 8 at 25 °C. Each experiment was perfomed 
at 100 μL scale and required just 1 mg of PGDM in total. As is visible, 
increasing pH results in increased degradation for both PGDM and gallidermin, 
however gallidermin (Figure 5.2 B) degrades at a higher rate as compared to 
PGDM. In the case of stability at pH 8, gallidermin was found to degrade 5 
times faster than PGDM. This result corresponds to studies on the stability of 
Nisin, another Class I lantibiotic, which displayed maximal stability at low pH 
values (Rollema et al., 1995). 
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It is worth noting, however that the stability experiments were conducted with 
pure antibiotic product, as opposed to the PGDM in culture broth. The culture 
broth contains undefined components from yeast extract and potentially cellular 
components and enzymes released by S.gallinarum Δp that were not removed 
by centrifugation. Varying the pH on these cellular components may impact the 
stability of PGDM, possibly accelerating degradation. Indeed it is found that 
when PGDM is left in un-clarified culture broth post fermentation, it begins to 
degrade (Medaglia, 2009). 
 
Later studies by Arias et al. (2013) on a Type B lantibiotic and Barbour et al. 
(2013) on a novel potentially Type A (the structural grouping was under 
investigation and not made completely clear)  lantibiotic demonstrated that they 
were stable at high temperatures between a pH range of 2 to 9 and 2 to 10 
respectively. Those results are very different from what has been observed in 
the present study, providing further evidence that the structural variety of 
lantibiotics may lead to significant differences in their physico-chemical 
properties (van Heel et al., 2013).    
  
5.4.2 Ionic Strength 
The impact of varying ionic strength was investigated by performing microscale 
experiments with pure gallidermin and PGDM buffered at pH 7, in microwells 
shaken at 1200 rpm and maintained at 37 °C. Ionic strength of the buffer was 
varied from 0.02 M to 0.06 M. No change was observed in the rate of 
degradation for both PGDM and GDM by variation of the buffer ionic strength. 
This suggests that using a wash buffer at high ionic strength should remove 
maximal impurity without negatively impacting the PGDM recovery.  
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Figure 5.2 The Stability of PGDM and GDM under varying pH. (A) PGDM and (B) GDM in 
microwells buffered at pH 6, 7 and 8 over a 24 hour time span, maintained at 25°C and shaken 
at 1200 rpm. Microscale studies performed as described in Section 2.6.2. Error bars represent 
standard error.     
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5.4.3 Temperature 
 
Temperature is known to have an impact on lantibiotic stability (Rollema et al., 
1995), especially at extremes of pH. It is therefore important to consider the 
impact of temperature on lantibiotic stability over a range of conditions. The 
microscale method described in Section 5.4.1 to examine the influence of pH on 
lantibiotic stability was also used to investigate the effect of temperature on 
stability.  
  
The adsorption of PGDM onto Amberlite XAD-7 in Section 5.3 was carried out 
overnight at 25 °C and 1200 rpm from broth buffered at the various pH values. 
The subsequent resin washes were also performed at 25 °C for 8 hours. 
However it is notable that between washes, when replacing buffer or waiting for 
the sample to be analysed by HPLC (Section 2.5.3) on the equipment tray, the 
samples may have been exposed to higher ambient lab temperatures for a 
period of a few hours. These process ‘waiting’ times could be magnified at the 
manufacturing scale, where thousands of litres of product solutions may require 
holding at certain conditions between process steps. 
 
Thus, it becomes relevant from a process efficiency viewpoint that the amount 
of product loss by degradation is minimized due to these process ‘gaps’. An 
investigation into the impact of increasing temperature is shown in figure 5.3. 
Both PGDM and gallidermin are shown to be increasingly unstable with an 
increase in temperature. It is notable that gallidermin degrades quicker than 
PGDM, with degradation at 37 ºC five times faster for gallidermin in comparison 
to PGDM. Stability for the lantibiotic products is higher at 25 ºC, however it is 
again notable that gallidermin degrades 2 times faster than PGDM. As in the 
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case of pH, it is suggested that certain undefined components of the complex 
media and cell-culture broth could exacerbate product degradation further. 
 
The stability data suggests that when designing a manufacturing process for 
PGDM based modified antibiotics, it would be prudent to keep the antibiotic in 
its inactive form for as long as possible during the process to minimise losses 
associated with active gallidermin instability. The enhanced stability of PGDM, if 
a generic feature of lantibiotic precursor peptides, could support a wider 
adoption of this approach to lantibiotic purification and production. 
 
No previous studies have been conducted on the physico-chemical properties 
of pregallidermin, to the knowledge of this author. A search of the wider 
literature did not reveal any comprehensive studies on the physico chemical 
properties of gallidermin either. Lantibiotics have often been referred to as 
attractive compounds based on their stability against proteases, heat and 
oxidation, as well as their antimicrobial activity (Dischinger et al., 2014). Studies 
by Arias et al. (2013) on a novel type B lantibiotic, Amylolysin, showed it to be 
stable between temperature ranges of 25 to 100 degrees Celsius and a pH 
range of 2 to 9. A separate lantibiotic, Salivaricin 9 also retained biological 
stability at temperatures of 90 to 100 degrees Celsius for a pH range of 2 to 10 
(Barbour et al., 2013). The current results are contrary to these studies, as both 
PGDM and GDM start degrading, with GDM degrading significantly, at 
physiological temperature and pH.        
 
However, earlier studies by Rollema et al. (1995) on the stability and solubility 
of Nisin, showed trends consistent to those elucidated in the present study. 
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Nisin was shown to have low stability at physiological pH and temperature, 
while the stability was a little greater at pH 7 and 20°C. Equivalent data for Nisin 
precursors is not available. This suggests that the physico-chemical properties 
are related to lantibiotic structure and synthesis pathway, as both Nisin and 
Gallidermin are type A (I) lantibiotics. Additionally, it suggests that similar 
production processes and DSP sequences might be applicable to lantibiotics 
belonging within the same structural grouping. 
 
It is also notable that while the properties for GDM showed consistency with 
Nisin, PGDM showed enhanced stability at physiological pH for both 
temperatures. This information could be useful when making process choices 
e.g. the data suggests that any DSP sequences at high temperatures should be 
performed prior to the proteolytic cleavage of PGDM leader peptide.    
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Figure 5.3 The Stability of PGDM and GDM under changing temperature. (A) PGDM and (B) 
pure GDM in microwells at 25 °C and 37 °C, buffered at pH 7 over a 24 hour time span and 
shaken at 1200 rpm. Microscale studies performed as described in Section 2.6.2. Error bars 
represent standard error.      
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5.5 Impact of Methanol and co-solvent ionic 
strength on elution 
  
 
The protocol used for PGDM elution from XAD-7, as described in section 2.3.6, 
was based on work by Medaglia (2009) where a 60/40 % (v/v) methanol to 
acidified water elution buffer is suggested. Different authors have suggested 
various compositions for the elution buffer with some using up to 90 % methanol 
(Kellner et al., 1988).  However, as demonstrated in the overall PGDM 
purification table in Chapter 4 (Table 4.2), with a yield of 57 % and purity of 28 
%, there is scope for optimisation. It is worth investigating the optimal elution 
conditions for PGDM adsorbed to the XAD-7 resin, which could potentially 
increase primary capture efficiency, improving overall process yield. A DoE 
sequential analysis approach was adopted for these experiments. 
 
Figure 5.4 displays the effect of varying the methanol fraction of the elution 
buffer while increasing the ionic strength of the acidified water on PGDM elution 
from XAD-7 under uniform broth pH and wash conditions. Figure 5.4 A) 
demonstrates the impact on product purity, with a high methanol content of 70 
to 80% seemingly the most suitable to optimise PGDM purity. The ionic strength 
of the acidified water (H2SO4 based) does not apparently have as substantial an 
impact on purity as methanol content, which is understandable as a lower pH 
promotes PGDM solubility and stability (Rollema et al., 1995) rather than having 
any impact on the removal of culture broth impurities.  
 
In comparison, ionic strength of the acidified water plays a larger role in PGDM 
recovery (figure 5.4 B), with higher ionic strength promoting desorption of 
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PGDM from the resin by promoting solubility and in turn enhancing the 
hydrophilic characteristics of the product.  
 
Thus, the highest product yields are obtained with a high methanol fraction and 
higher ionic strength of the acid fraction, with the highest PGDM elution 
occurring at 80 % methanol and 2.5 mM H2SO4.In terms of product recovery, 
this translates to 0.37 g.L-1 out of a process broth concentration of 0.5 g.L-1, a 
primary product recovery greater than 70 %. In comparison, Medaglia, (2009) 
found the optimal elution buffer for use with Amberlite XAD-1180 to be 
composed of 60% methanol, which resulted in a PGDM recovery of 90%. This 
difference in recovery indicates selecting the most suitable resin to be used in 
the DSP sequence is crucial to ensure process optimisation and that a single 
resin may not be suitable or all lantibiotic variants.    
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Figure 5.4: Contour plots of microscale XAD7 product elution data at different values for elution 
buffer methanol content and ionic strength of H2SO4 in the acidified water fraction. (A) Showing 
the impact on PGDM product purity. The coloured bands represent the percentage purity (%) of 
the recovered PGDM product in comparison to the all eluted components. (B) Illustrates the 
impact on product recovery with the coloured bands representing the concentration of 
recovered PGDM in g.L
-1
. Microscale method performed as described in Section 2.7.2 
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5.6 Impact of Methanol and ionic strength on 
wash impurity removal 
 
  
The data from Figure 5.4 suggests that PGDM is adsorbs strongly to XAD-7 and 
requires a high fraction of methanol in the elution buffer to be recovered from 
the resin. Hence in pursuit of optimal removal of cell culture impurities adsorbed 
along with product, it is worth investigating the impact of including methanol in 
the resin wash buffer. It is proposed that if methanol is included, the wash buffer 
might enable the removal of culture broth impurities that possess a slight 
hydrophobic nature and will not otherwise be removed by the alkalinity of the 
basic wash buffer. 
 
Figure 5.5 A) suggests that the maximum culture broth impurity is removed from 
the resin when the methanol fraction of wash buffers is 10 % (v/v) and the buffer 
ionic strength is increased. Maximum culture broth impurity of 26800 mAU (as 
determined by HPLC analysis of wash fraction) was removed using a wash that 
contained 10 % methanol and had a buffer ionic strength of 0.02 M, with high 
impurity removal at 0.06 M also noted. The general trend displayed was 
increasing impurity removal with an increasing methanol fraction in the wash 
buffer. 
 
Similarly figure 5.5 B) shows maximum PGDM purity obtained with high 
methanol content and a high buffer ionic strength, which is logical considering 
the highest impurity was also removed under these wash conditions. This 
seems to be confirmed by the comparatively low purity of the PGDM eluted from 
XAD-7 after wash buffers containing 0 % methanol. It is again notable that the 
Haroon D.S. Khan  Chapter 5 
 
187 
 
ionic strength of the wash buffer seemingly has a lower impact on purity in 
comparison to methanol content. 
  
However, conversely, as shown in Figure 5.5 C) a buffer wash with increasing 
methanol content resulted in lower PGDM yield. The highest PGDM elution was 
recorded after the resin was washed with 0.02 M buffer which included no 
methanol. This outcome is logical as the methanol would have removed small 
amounts of PGDM from the resin; however the methanol concentration does not 
reach the threshold where all PGDM gets eluted during the wash. 
 
There are no studies in the literature that examine the impact of the wash buffer 
on desorption of media impurities. To the knowledge of the author, the present 
study is the first that examines this relationship in the interests of DSP 
sequence optimization for lantibiotic production. Previous work by Medaglia, 
(2009), Kellner et al. (1988) and Kempf et al. (1999) has made use of Amberlite 
resin adsorption/desorption for product capture, however none of them have 
characterised the resin wash stage. Medaglia, (2009) does not even use a wash 
step between steps, eluting the PGDM from resin straight after adsorption.       
   
However, it is notable that Medaglia, (2009) does perform optimisation studies 
on the elution buffer, which indicates that at low methanol concentrations, a 
majority of the PGDM remains adsorbed to the resin. This is consistent with the 
results of the current study, where a wash buffer with a 10% methanol fraction 
does not elute a majority of the PGDM.  
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Figure 5.5 Contour plots of microscale XAD-7 adsorption/desorption data on the impact of 
increasing the ionic strength of the wash buffer and including methanol. A) impurity removal 
from the XAD-7 resin beads, with the coloured bands representing the sum of impurities 
removed in mAU as determined by HPLC, B) the purity of PGDM product eluted after the 
Methanol/high ionic strength buffer wash, the coloured bands represent percentage purity (%). 
C) the PGDM product yield upon elution after resin wash with the Methanol/high ionic strength 
buffer, the coloured bands represent PGDM concentration in g.L
-1
. Microscale method 
performed as described in 2.7.1 
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5.7 Selection of optimised downstream process 
conditions 
 
5.7.1 Impact of pH on antibiotic recovery and 
processing 
  
The variation of pH during various stages of the adsorption/desorption primary 
capture process was found to have a significant impact on PGDM recovery and 
purity as described in Section 5.3. In general, it appears that adjusting broth to 
an acidic pH results in the highest recovery of PGDM, as opposed to an alkaline 
environment. This is similar to work by Yang et al. (1992) who managed to 
adsorb maximum lantibiotic product onto the producer cells in acidic 
environments. Alkaline pH was found to negatively impact recovery, possibly 
due to a reduction in the amount of PGDM adsorbing to the resin. 
 
However the recovery of PGDM could also depend on product stability at 
different pH values. In particular it was noted that alkaline conditions greatly 
increased the product degradation rate as compared to neutral or acidic 
conditions; which displayed the highest lantibiotic stability (Rollema et al., 
1995). Thus it is possible that the reduced PGDM recovery when culture broth 
pH is adjusted to above 7 could be attributable to product losses from 
degradation in solution along with reduced adsorption onto the resin beads.  
 
In contrast to the negative impact of alkaline conditions on PGDM adsorption, 
high pH values were most effective in removing fermentation impurities 
adsorbed to the resin during the resin wash before PGDM elution (Section 5.3). 
Increasing wash buffer pH resulted in increasing impurity removal, however the 
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highest amount of impurity removal occurred when the culture broth was 
adjusted to pH 6 pre-adsorption and a pH 8 buffer was used to perform the 
resin washes. This could be due to higher amounts of broth components 
adsorbing onto the resin beads at pH 6 as opposed to alkaline culture broths, 
and subsequently more impurities being removed with the pH 8 washes.  
 
The use of alkaline pH washes, while enhancing adsorbed impurity removal, 
negatively impacted the purity of the recovered PGDM. The highest product 
purities were obtained where fermentation broth was acidic and the wash 
buffers were acidic as well. This result could potentially be caused by the 
product losses due to degradation under alkaline conditions, with a lower 
concentration of recovered product reducing the purity in comparison to other 
eluted components. 
 
The data generated by the microscale experiments in Figure 5.1 show that the 
optimal production process will operate with a pH range for adsorption and 
wash buffers that represent a trade-off between product purity and recovery. 
Priority at the primary capture stage should be product recovery; hence 
adjusting broth to pH 6 and performing resin washes with a buffer around pH 7 
is suggested to achieve optimal results. However, other operating parameters 
such as processing time, that impact PGDM stability also need to be considered 
prior to finalizing operational parameters. 
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5.7.2 Impact of increasing methanol content and 
buffer ionic strength on resin wash and 
product elution efficiency 
  
Originally, PGDM elution from the XAD-7 resin was performed using a 60/40 % 
(v/v) methanol to 5 mM sulphuric acid solution. However, microscale 
investigation revealed that increasing the methanol content results in increased 
PGDM elution from resin (Figure 5.4). This is logical as PGDM adsorbs based 
on a hydrophobic interaction, thus reducing the water content of the elution 
buffer would promote the increased desorption of the lantibiotic. However, due 
to the low solubility of PGDM in methanol, 40 mg.L-1, as opposed to > 4 g.L-1 in 
water (Medaglia, 2009), the elution cannot be performed with pure methanol, as 
precipitation of the saturated PGDM would block the resin pores. The 
microscale data also indicates that increasing the methanol fraction of the 
elution buffer leads to higher overall product purity (Figure 5.4). This is probably 
caused by the increased efficiency of PGDM elution at higher methanol content 
in comparison to the total culture broth impurities adsorbed. Indeed it is 
expected that under uniform broth pH, wash pH, temperature, process time and 
agitation conditions, the amount of total impurity and product adsorbed by the 
XAD-7 resin would be constant for a unit mass of resin. Hence logically, 
increased purity levels would be attributable to higher product recovery. 
 
The finding that efficient PGDM elution from the XAD-7 resin requires high 
methanol is consistent with prior work by Kellner et al. (1988) and Medaglia, 
(2009). It suggests that low amounts of methanol (up to 10 % (v/v)) could be 
incorporated in the resin wash buffer to increase the purity of eluted antibiotic. 
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The methanol washes were shown to remove higher amounts of broth 
impurities, as well as resulting in the elution of a higher purity product, however 
the overall lantibiotic recovery was higher without the use of methanol in wash 
buffer (Figure 5.5). This is because, along with the removal of higher amounts 
of impurity, the methanol content of the wash buffer managed to elute small 
amounts of PGDM from the resin as well. However, the product losses when 
using a methanol based wash were limited to 18 % of total when compared with 
no methanol wash, while increasing purity by 10 %.  
 
The ionic strength of the wash buffer was not as significant in impurity removal 
as pH. However it was observed that increasing the ionic strength of a wash 
buffer that contained no methanol reduced the purity and recovery of PGDM. 
This outcome was unexpected as stability studies had shown no noticeable 
change in the rate of lantibiotic degradation when using higher ionic strength 
buffers. However one possible explanation for the reduced PGDM recovery is 
that using  a higher concentration of the salts necessary to create the buffer 
result in a ‘salting-out’ of a small amount of the PGDM. Indeed one of the 
methods suggested for the primary capture of lantibiotics by certain authors is 
an ammonium sulphate precipitation (Furmanek et al., 1999; Jack et al., 1995; 
Holtsmark et al., 2006; Georgalaki et al., 2002). 
 
In comparison to the wash buffer, increasing the ionic strength of the elution 
buffer (Methanol/ acidified water) had no impact on PGDM purity. It did however 
impact product recovery, with higher ionic strength of the acidified water 
increasing the amount of PGDM eluted from the resin. This is logical as 
increasing acid content would reduce the pH of the water, which has been 
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shown to promote lantibiotic solubility and stability (Rollema et al., 1995), 
allowing a larger mass of the lantibiotic to dissolve in a given volume of water, 
while promoting the hydrophilic nature would enable more product to elute. 
 
5.7.3 Potential as a platform for informing process 
design 
 
The application of the data obtained from the microscale analysis is not just 
limited to DSP e.g. the GDM stability is shown to be very sensitive to 
temperature increases, with the antibiotic product degrading rapidly at 37 ºC, 
information which is useful when scheduling fermentation runs and determining 
how quickly broth refrigeration would be required. The data obtained would 
suggest that the PGDM not be activated to GDM in the fermentation broth 
(maintained at 37 ºC), in order to prevent unnecessary product losses. 
 
The information enables the optimisation of the hydrophobic adsorption/ 
desorption in this work. The initial DSP described in Section 4.2, included a 
process with adsorption at neutral pH (required for optimal growth of 
S.gallinarum Δp), washing with a 0.02 M buffer at pH 8; and desorbed with a 
60/40 % (v/v) methanol/ 5 mM H2SO4 elution buffer. This resulted in an overall 
PGDM yield of 57 % and purity of 28 % as indicated in Table 4.2. 
 
Based on the results presented in Section 5.3 to 5.6, data from the established 
microscale methods indicates that adsorption from culture broth would be best 
at pH 6, followed by a resin wash with a 0.04 M buffer at pH 7 containing 10% 
methanol (v/v) followed by elution with 75/25% (v/v) methanol/2.5mM H2SO4 . 
This would result in a product recovery of 70% and purity of roughly 80%.  
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These optimisation studies enabled the redesign of the downstream purification 
process to eliminate ion exchange chromatography as a secondary purification 
step and increase overall process yield to 42% from the original 13%, a 3-fold 
increase (Table 5.2). The original DSP sequence in Table 5.1 is provided for 
comparison. 
 
It has been recommended that the microscale methods become an integral part 
of the manufacturing platform for novel antibiotics, owing to the substantial cost 
and time which can potentially be saved by early acquisition of optimal process 
parameters (Ongey & Neubauer, 2016). Additionally, they provide the ability to 
continuously improve a manufacturing process when faced with variations in 
production processes; such as changes in fermentation media (Jackson et al., 
2006), changes in process parameters or the use of novel strains (Smanski et 
al., 2016; Sandiford, 2014) due to relocating production or producing alternative 
compounds.  
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Table 5.1 Purification table summarizing the PGDM step yield and purity for the whole 
downstream process sequence 
 
Process 
Total Mass 
of 
PGDM(g) 
Overall 
Yield (%) 
Step 
Yield (%) 
Concentration 
(g.L-1) 
Purity 
(%) 
Fermentation 14 100 100 0.7 0.56* 
Centrigufation 14 100 100 0.7 0.56 
HI† 8 57 57 0.4 28 
IEX 4.1 29 51 0.2 72 
HI 3.1 22 76 0.15 80 
Lyophilization 3.1 22 100 0.15 80 
Trypsinization 1.9 13.5 60 0.09 70** 
Total Process 1.9 13.5 NA 0.09 70 
 
*purity as a percentage of all dissolved components in cell culture 
**reduction in purity due to presence of cleaved leader sequence which requires removal 
†Hydrophobic Interaction  
 
 
 
 
Table 5.2 Purification table summarizing the step yield and purity for the redesigned 
downstream process sequence 
 
Process  
Total Mass 
of 
PGDM(g) 
Overall Yield 
(%) 
Step Yield 
(%) 
Concentration 
(g.L-1) 
Purity 
(%) 
Fermentation 14 100 100 0.7 0.56* 
Centrigufation 14 100 100 0.7 0.56 
HI† 9.8 70 70 0.49 80 
Lyophilization 9.8 70 100 0.49 80 
Trypsinization 5.9 42 60 0.3 
   
70** 
Total 
Process 
5.9 42 NA 0.3 
70 
 
*purity as a percentage of all dissolved components in cell culture 
**reduction in purity due to presence of cleaved leader sequence which requires removal 
†Hydrophobic Interaction  
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5.8 Summary 
 
The aim of this chapter was to establish microscale methods to determine 
certain physico-chemical properties for the novel antibiotic pregallidermin, which 
would enable optimisation of the selected product purification process and 
enable informed decisions on the future design of DSP sequences for large 
scale product manufacture. 
 
The initial objective was to establish a series of microscale methods to enable 
the rapid analysis of product physico-chemical properties; this would aid in the 
optimisation of downstream processes, as evident by the determination of the 
optimal parameters for primary capture by Hydrophobic interaction. Parameters 
were determined where the primary recovery of the PGDM could be increased 
from 57% of total produced to >70% and purity increased from 28% to > 80%. 
(Table 5.1 and Table 5.2) 
 
The product data obtained was also useful in redesigning the determined DSP 
sequence. Based on the optimized primary capture, it became logical to 
redesign the DSP to remove the ion exchange chromatography. This would 
reduce the capital investment required and the consumables cost by resizing 
the column needed to process a feed-stream containing fewer impurities. 
 
The microscale methods were shown to additionally provide product data that 
could be used to make production plant design and process scheduling 
decisions, such as the GDM stability data, which suggests that fermentation 
broth which contains activated GDM may require refrigeration, something that 
may have to be factored into the purchase of the bioreactors and building of the 
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liquid storage areas. The sensitivity of PGDM to alkaline conditions suggested 
that resin washes during the batch adsorption/desorption may need to be 
performed rapidly, as prolonged exposure to high pH buffers could lead to 
product losses.  
 
Thus, it is suggested that the microscale methods be included as a tool to 
inform the design and operation of the lantibiotic manufacturing platform. 
Microscale methods have previously demonstrated their utility in elucidating 
process data that can inform process decisions at scale (Voulgaris et al., 2016; 
Sandiford, 2014). Due to their utility in process design and optimisation, it is 
strongly recommended that they become an integral part of bioprocess 
development for novel lantibiotics. This recommendation is supported by 
evidence from the wider bioprocess industries, where they have gained 
widespread usage and acceptance (Ongey & Neubauer, 2016; Micheletti & Lye, 
2006).  
 
The microscale studies were performed using the ‘one factor at a time’ (OFAT) 
method, the most commonly used bioprocess optimization technique (Ducros et 
al., 2009). However, it is notable that OFAT is time consuming, especially when 
several factors need to be analysed. Additionally, OFAT ignores possible 
interactions between factors, which are important when determining the optimal 
process operating conditions.  An alternative approach could be the use of the 
‘Design of Experiments’ (DOE) methodology, a combinatorial optimization 
method that can look at multiple variables at a time and reduces the number of 
experiments needed to elucidate optimal conditions (Smanski et al., 2016). The 
current OFAT based work acts as a useful screening study in preparation for a 
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full DOE. Indeed, a combination of DOE with high through-put studies based on 
microscale methods is used widely throughout industry to shorten process 
development times (Li et al., 2010).
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6. Conclusions and future work 
 
6.1 Conclusion and novel findings 
  
 
This research aimed to develop and analyse processes for the production of a 
novel modified peptide antibiotic, pregallidermin, at scale. Characterisation of 
the process parameters would be done to allow the reproduction of results 
between process runs, in view of outlining a potential generic platform process.  
This was followed up with the creation of microscale methods that would allow 
the rapid analysis of the production process, enabling informed decisions to be 
made about process design and optimisation. As described in Chapters 3-5 this 
aim has been largely achieved by demonstrating that a viable process for the 
production of pregallidermin at pilot scale has been developed. 
 
Although some initial work has been reported on attempting to develop 
production processes for the wild type antibiotic, gallidermin (Section 1.5.1), the 
auto-toxicity displayed by the molecule to the producing organism resulted in 
low titres, < 300mg.L-1 that would be impractical for a commercial manufacturing 
process. Thus the use of a novel genetically modified precursor, pregallidermin, 
was examined in this work. Preliminary studies carried out at ETH Zurich 
indicated that this has a considerably lower auto-toxicity, potentially allowing 
higher product yields (Valsesia et al., 2007).However, this requires an additional 
trypsination step be included in the downstream process sequence, in order to 
remove the leader peptide and form mature, biologically active lantibiotic. At 
present there is no published work on the development and analysis of a 
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manufacturing process feasible for the large scale production and purification of 
the precursor lantibiotic, pregallidermin. The current lack of information is what 
this thesis set out to address. 
 
The main conclusions and novel findings of this work are: 
 
 A procedure for the pilot scale (30L) fed-batch fermentation of 
S.gallinarum Δp was established that enabled production of up to 0.7 g.L-
1 of pregallidermin (Figure 3.10). This was based on research at the 7.5 L 
bioreactor scale (Table 3.1) that attempted to define parameters that are 
critical to reproducibly achieve high cell density and product yield 
fermentations. The work also demonstrated the importance of 
maintaining those parameters at similar levels (aeration, feed rate, and 
culture agitation rate) in scaling up the process. The main conclusions 
from this work are that in order to achieve high PGDM titres fed-batch 
cultures are required in which it is necessary to feed both Maltose and 
Yeast-extract (Figure 3.8) while maintaining a dynamic process 
environment by changing key process parameters in response to the 
cellular growth behaviour. The best fermentation biomass yields were 
obtained when bioreactor DOT control involved initial increase of the 
aeration rate before increases in agitation rate (Section 3.7.1). However, 
yields of pregallidermin were lower than those achieved by Medaglia, 
(2009) using an exponential substrate feed regime, demonstrating that 
the process can be optimised further. 
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This is the first time that the lantibiotic precursor, pregallidermin, has 
been produced at pilot scale using the modified S.gallinarum Δp.   
 
 A DSP sequence capable of processing pilot-scale quantities (30L) of 
fermentation broth containing the novel antibiotic PGDM was developed 
(Section 4.2). The process utilises hydrophobic interaction between the 
pregallidermin and the acrylic Amberlite XAD-7 resin as the primary 
capture method recovering 57 % of PGDM at a product purity of 28% 
(Table 4.2). This is followed by an ion exchange chromatography as the 
high resolution purification step with a 51 % product recovery and 
increase in purity to 72 % (Section 4.6), the yeast-extract culture broth 
components proved the most difficult to remove. The sequence is 
demonstrated to achieve material suitable for activation to gallidermin by 
trypsinization (Section 4.8). The identity of the product was verified by 
using HPLC and MALDI-MS (Figure 4.6), with findings consistent with 
identification studies by Valsesia et al. (2007) and Medaglia, (2009). The 
main conclusions from this work are that the outlined DSP sequence is 
scalable, with high throughput processes such as centrifugation, resin 
adsorption/desorption and ion exchange chromatography demonstrably 
capable of producing PGDM to a purity level sufficient for trypsinization 
and final processing (Table 4.2). The developed sequence could thus 
provide a generic template for the DSP sequence in the large scale 
manufacture of lantibiotics from the same structural grouping and 
biosynthesis pathway as gallidermin 
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Based on the extensive review of literature, this work is the first time that 
pilot scale DSP operations have been attempted for the purification of a 
lantibiotic precursor.   
 
 The development of microscale methods to determine the physico-
chemical properties of pregallidermin and generate process data on 
pregallidermin interaction in specific process environments such as the 
impact of pH on stability (Section 5.4.1), which demonstrated results 
consistent with previous studies on the Type A (1) lantibiotic Nisin 
(Rollema et al., 1995). It was demonstrated that the data was useful to 
rapidly analyse the suitability of the production process, which allowed 
the optimisation of purification processes and also informed the redesign 
of the DSP sequence (Section 5.7.3). The main conclusions from this 
work are that microscale methods are extremely useful in the rapid 
generation of process data through high throughput experimentation and 
reduced material requirements i.e. < 1g of product (Section 5.4.1), 
allowing optimisation studies to be conducted concurrently with 
developmental studies, saving the expense of pilot scale optimisation 
studies. The generated data allows informed process design choices, as 
demonstrated by the redesign of the pilot scale DSP sequence for PGDM 
to improve overall yield (Table 5.2). Thus, the microscale methods are 
recommended as a generic tool for rapid analysis and optimisation of the 
lantibiotic manufacturing processes 
 
The present study was the first to attempt the combination of 
fermentation, DSP and microscale methods into a platform process to 
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inform process design of lantibiotic precursor manufacture. Additionally, it 
was also the first study to examine the impact on lantibiotic yield and 
purity of optimising the resin wash steps during primary product capture. 
 
Overall this thesis resulted in the development of a scalable production process 
for modified lantibiotic compounds that could potentially serve as a platform 
process for the manufacture of novel lantibiotics. The process when combined 
with suitable lantibiotic modification and fermentation development studies, 
could potentially enhance the existing antibiotic pipeline, increasing the 
likelihood of a lantibiotic based clinical product being developed. The results 
also present a case, for the integrated platform (fermentation, DSP sequence 
and microscale methods), to be used as a tool for performing rapid analysis on 
other candidate lantibiotics, to find those most commercially feasible by 
increasing the throughput of pilot scale studies.  
 
6.2 Future Work 
 
  
The platform process identified has scope for further improvement in order to 
make the process data generated for a lantibiotic candidate more 
comprehensive. There is also scope for additional research on variations to the 
process that will solve some of the difficulties encountered during process 
development and the microscale methods. Work suggested to improve the 
production platform and microscale analysis methods is as follows: 
 
 The replacement of yeast-extract in the fermentation media with defined 
components. A defined medium that optimises lantibiotic production by 
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enabling the accurate calculation of yield coefficient. Additionally, a 
defined medium would enhance recovery and purity by reducing the 
selection of suitable DSP processes, aiding in removing many of the 
unknown components from yeast extract. 
 
 The testing of a variety of hydrophobic resins to identify the optimal resin 
for PGDM adsorption. XAD-7 was utilised because of its relatively low 
cost and easy availability in the lab, however it is possible a different 
resin would show increased adsorption/desorption efficiency, increasing 
the cost effectiveness of a manufacturing process. 
 
 Optimization studies on the ion exchange chromatography step for 
maximum recovery of lantibiotic, including operational parameters and 
type of resin. The redesign of the DSP has eliminated the need for ion 
exchange in the purification of PGDM; however ion exchange 
chromatography would still be required post trypsinization as a polishing 
step to remove the cleaved leader sequence to obtain the active 
lantibiotic. 
 
 Automation of the microscale methods on a robotic microscale liquid 
handling system would improve accuracy by removing human error in 
liquid handling. It would also reduce the time taken to setup and conduct 
the experiments, increasing the speed of data gathering. 
 
 The scalability of the platform should be tested by attempting a 100L 
S.gallinarum Δp fermentation and running the same DSP sequence. This 
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would confirm whether the parameters of feed-rate, agitation and broth 
aeration are important at all scales, establishing the generic nature of the 
process and its applicability to all structurally similar lantibiotics. 
 
 Perform the process with different precursor lantibiotics in order to test if 
precursor manufacture is a generic solution to overcome product auto-
toxicity. 
 
 Perform microscale analysis of different modified lantibiotic variants e.g. 
structural mutants of Nisin. Evaluate if the developed methods allow 
physico chemical data to be obtained for individual structural 
modifications and determine if the developed DSP sequence is 
sufficiently generic to purify novel lantibiotics. 
 
 Perform microscale optimisation using a full DOE. Elucidate optimal 
process conditions from a multivariable, combinatorial analysis and run 
the outlined DSP sequence to purify pregallidermin. Compare the results 
of the DOE optimised process with the existing results. 
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7.  Outlook and Practical Applications† 
 
7.1 Outlook 
  
The increasing number of bacteria developing resistance, to existing antibiotic 
compounds, has been identified as a problem that will have a major negative 
impact on global health systems (Walsh, 2014). Antibiotics that were used as 
the standard treatment for bacterial infections now no longer work. A report by 
The Economist (2014), points out that in the USA, standard antibiotics used to 
treat wound infections fail to work half the time. The report outlines a similar 
situation in China, where a standard antibiotic used to prevent lung infections 
fails to work 1/3rd of the time. 
 
The drying up of the antibiotic pipeline has multiple reasons, including the 
failure to discover any new classes of antibiotics since 1987 (World Economic 
Forum, 2013) and the low monetary returns for pharmaceutical companies that 
have invested in antibiotic development (The Economist, 2012). This means 
new antibiotic discoveries are becoming time pressured, with the costs to treat 
antibiotic resistance set to increase dramatically and medical procedures facing 
disruption (Gallagher, 2014). In order to mitigate the actualization of these 
harmful outcomes, it is necessary to enhance the antibiotic product pipeline. 
 
This research attempts to expedite the development of novel antibiotics by 
providing a powerful tool capable of rapidly acquiring process data, analysis of 
which can determine the commercial viability of a drug candidate by 
determining scalability. The increasing cost of novel antibiotic development, in 
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some cases greater than $500 million (Charles and Grayson, 2004) becomes a 
huge hindrance to the product pipeline, with large pharmaceutical companies 
opting to devote resources to the pursuit of higher profitability sectors e.g. 
oncology. If the platform is improved to make the data collection more 
comprehensive (Chapter 6.2), it could greatly reduce the cost of 
commercialisation, by indicating non-viable candidates early in the development 
phase. Furthermore, it is suggested that in combination with a high-throughput 
antibiotic modification platform and a rapid antibiotic screening process 
(Sandiford, 2014), the outlined platform could potentially enable the 
identification of a library of lantibiotics capable of treating existing drug-resistant 
infections that show the most commercial viability. 
 
 7.2 Practical Implementation 
 
 
The rapid analysis platform developed is outlined in Figure 7.1. It illustrates how 
the pilot scale antibiotic manufacture generates sufficient material to conduct 
the rapid microscale analyses, generating a feedback cycle which allows the 
production process to be optimised during process developmental studies. This 
would save time and cut the costs of having to perform multiple pilot scale runs 
for testing a large number of artificially created antibiotics. 
 
It is also noteworthy that the comprehensive bioprocess and product physico-
chemical data generated by the tandem microscale analysis could be used to 
inform large scale manufacturing process design, plus initial antibiotic 
development and modification. As an example, in Chapter 5 of the thesis it was 
discovered that the lantibiotic pregallidermin is most stable under acidic 
conditions; however impurity removal during the purification process is highest 
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under alkaline conditions. This information could be used to modify the antibiotic 
further to allow higher stability under alkaline conditions, optimising the product 
to the chosen DSP sequence. These possibilities are illustrated in figure 7.2. 
 
There are also practical aspects to be considered when implementing 
microscale rapid analysis at industrial scale, such as instrument maintenance. 
Working with small quantities of product and liquid volumes means slight 
variations due to human error or uncalibrated equipment could be magnified in 
the results. Hence, SOP’s would need to be created for equipment 
maintenance, cleaning procedures, contamination prevention and standard 
techniques for data analysis. 
 
The technology finds most application in bringing novel antibiotics to market, 
specifically the lantibiotics (Type A1) which have demonstrated high therapeutic 
potential against multi-resistant infections, and have similar physical properties 
and biosynthesis pathways. However, the platform could be applicable to other 
novel pharmaceutical or industrial compounds (such as enzymes) developed 
using synthetic biology processes and produced by cell culture. The platform 
could serve as a generic test-bed for commercial viability testing of engineered 
biological products from similar types of bacterial cells.  
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Figure 7.1: Flowsheet representing the platform lantibiotic production process with integrated 
microscale methods for process optimization and rapid product analysis 
 
 
 
 
 
Figure 7.2: How the rapid manufacturing and analysis platform (from figure 7.1) can become 
part of a complete antibiotic design and manufacturing process, with the microscale methods 
generating process and product data that can optimize manufacture by providing feedback to 
both process and antibiotic development. 
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Appendix 
 
Appendix 1: Full list of Chemicals used 
 
Acetic Acid 
Acetonitrile 
Amberlite XAD-7 HP 
Ammonium Hydroxide 
D+ Maltose  
Ethanol 
Kanamycin Sulphate 
Methanol 
Milli Q water 
Phosphoric Acid 
Polypropylene Glycol (PPG) 
Sodium Acetate 
Sodium Chloride 
Sodium Dibasic 
Sodium Hydroxide 
Sodium Monobasic 
SP HP Resin 
Sulphuric Acid 
Tetracycline 
Trypsin (Porcine) 
Yeast Extract 
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Appendix 2: Calibration Curves 
 
 
Callibration curve determined by comparing gallidermin concentration against 
peak area. An example of a Chromatogram to determine peak area is given 
below where peak at time 9.1 is pure gallidermin. 
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Appendix 3: 30 L STR fermentation: automated dual feed 
fed-batch 
 
 
 
 
 
 
 
The above figure illustrates the results of S.gallinarum Δp fermentation at 30 L 
scale when using an exponential feed strategy on the dual 500 g.L-1 and 300 
g.L-1 substrate feed (feed data not shown). The exponential feed profile was 
calculated using a reduced specific growth rate in an attempt to prolong the 
cellular growth phase by slowing the growth rate. 
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Appendix 4: Contour Plot Data 
 
 
Molarity/MeoH Conc. 0.02/0 
  
Peak Area 
721.12 
  450.50 
  319.34 
  485.69 
  370.58 
  391.07 
  450.55 
  193.77 
  256.01 
  203.51 
    
    
    
  PGDM 1 Peak Area 486.69 
  PGDM 2 Peak Area 199.79 
  Total Area 4528.64 
  Total PGDM 686.49 
  PGDM Purity 15.16 
  PGDM Conc. 0.11 
  Average Purity 15.17 
  Averag Conc. 0.11 
  Molarity/MeoH Conc. 0.02/0 
  
Peak Area 
723.84 
  454.50 
  316.41 
  484.47 
  381.98 
  383.93 
  464.71 
  185.82 
  267.30 
  203.86 
    
    
    
  PGDM 1 Peak Area 482.82 
  PGDM 2 Peak Area 209.25 
  Total Area 4558.89 
  Total PGDM 692.07 
  PGDM Purity 15.18 
  PGDM Conc. 0.11 
     
Table representing data necessary to calculate an individual contour point on 
contour plots. PGDM purity is calculated using Equation 2.5 and PGDM 
concentration using a conversion based on the calibration curve (Section 2.5.3).
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